INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

36th Annual Meeting and Scientific Sessions
APRIL 27-30, 2016

ISHLT Academies
APRIL 26 and APRIL 30

WASHINGTON DC, USA
CONVENING AT MARRIOTT WARDMAN PARK
Join us for a non-CME lunch symposium

Friday, April 29, 2016
12:00 NOON Registration & Buffet Lunch
12:30 - 2:00 PM Interactive Session

Controversies in PAH:
Experts Explore Combination Therapy

MARRIOTT WARDMAN PARK HOTEL
Maryland Suite, Lobby Level
2660 Woodley Road, NW, Washington, DC

FACULTY

MARDI GOMBERG-MAITLAND, MD
Associate Professor of Medicine, University of Chicago
Director, Pulmonary Hypertension Program
Chicago, IL

RAYMOND BENZA, MD
Professor of Medicine at Temple University
Chair of Cardiometabolic Research, Allegheny General Hospital
Pittsburgh, PA

THENAPPAN THENAPPAN, MD
Assistant Professor, University of Minnesota Cardiology
University of Minnesota Medical Center
Fairview, MN

Join us for a non-CME lunch symposium featuring leading experts in PAH in an interactive and engaging discussion-based format. The faculty will explore the latest developments in PAH, including combination therapy and recent clinical trial data. The program will also feature an interactive patient scenario and allow for audience participation.

To Register For This Program
www.Gilead-lunch.com

This is an independent event and is not an official part of the ISHLT Annual Meeting and Scientific Sessions.

A non-CME educational program sponsored by Gilead Sciences, Inc.

Please be mindful and observe any restrictions mandated by your employer or state related to meals or gifts. In accordance with company policy and the PhRMA Code on Interactions with Health Care Professionals, attendance at this educational program is limited to U.S. health care professionals. Accordingly, attendance by a guest is not appropriate and cannot be accommodated.

GILEAD

© 2016 Gilead Sciences, Inc. All rights reserved. URB99214 April 2016

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.
CONTENTS

2016 FINAL PROGRAM

Annual Meeting General Information 3
About ISHLT 4
2015-2016 Board of Directors 6
Scientific Program Committee 8
Abstract Reviewers 10
Continuing Medical Education Information 19
Commercial Support 22 & 24
Annual Meeting Highlights 26
Marriott Wardman Park Floor Plans 35
Acronyms 39
Annual Meeting Time Table Schedule 40
Annual Meeting Daily Schedule 50
2016 Scientific Sessions Program 83
  Wednesday, April 27 84
  Thursday, April 28 113
  Friday, April 29 142
  Saturday, April 30 179
2016 Scientific Sessions Posters 198
Corporate Events and Industry Theaters 251
ISHLT 2016 Exhibitors 255
Exhibit Hall Floor Plan 257
Future Annual Meetings 278
ANNUAL MEETING

General Information

Meeting Location
The ISHLT 36th Annual Meeting and Scientific Sessions will be held at the Marriott Wardman Park Hotel, Washington, DC.

ISHLT Academy: Core Competencies in Heart Failure and Cardiac Transplant Medicine
April 26, 2016

ISHLT Academy: Master Class in Pulmonary Transplantation
April 26, 2016

ISHLT Academy: Core Competencies in Mechanical Circulatory Support
April 26, 2016

ISHLT Academy: Master Class in Mechanical Circulatory Support
April 30, 2016

ISHLT 36th Annual Meeting and Scientific Sessions
April 27-30, 2016

Convening at the Marriott Wardman Park Hotel, Washington, DC, USA
THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.
THE PURPOSES OF THE SOCIETY ARE:

• To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.

• To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

• To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

• To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

• To establish and maintain an international registry for heart and lung transplantation.

• To award research grants and establish endowments for the study of these disciplines.
Officers
Duane Davis, MD, MBA, President
Maryl R. Johnson, MD, President-Elect
Hermann Reichenspurner, MD, PhD, Past-President
Stuart C. Sweet, MD, PhD, Secretary-Treasurer

Directors
Carla C. Baan, PhD, Director
Christian Benden, MD, Director
Lara Danziger-Isakov, MD, MPH, Director
Tobias Deuse, MD, PhD, Director
Andrew J. Fisher, FRCP, PhD, Director
Daniel J. Goldstein, MD, Director
Daniel R. Goldstein, MD, Director
Peter M. Hopkins, FRACP, Director
Myung H. Park, MD, Director
Michael G. Petty, PhD, RN, CNS, Director
Jeffrey J. Teuteberg, MD, Director

Ex Officio Board Members
Mandeep R. Mehra, MD, Editor-in-Chief Journal of Heart and Lung Transplantation
Josef Stehlik, MD, MPH, Transplant Registry Medical Director
Christopher H. Wigfield, MD FRCS (C/Th), Medical Director of Educational Affairs
Amanda W. Rowe, ISHLT Executive Director
Staff

Amanda W. Rowe
Executive Director

Phyllis Glenn
Director of Membership Services

Lisa Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

Susie Newton
Communications Manager

Megan Barrett
Communications Assistant

14673 Midway Road, Suite 200
Addison, TX  75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org
SYMPOSIUM PLANNING COMMITTEE

- Andrew J. Fisher, FRCP, PhD, Newcastle upon Tyne, UK, 2016 Program Chair
- Duane Davis, MD, MBA, Orlando, FL, USA, ISHLT President
- Andreas O. Zuckermann, MD, Vienna, Austria, 2015 Program Chair
- Jeffrey J. Teuteberg, MD, Pittsburgh, PA, USA 2017 Program Chair

- David A. Baran, MD, Newark, NJ, USA
- Christian Benden, MD, Zurich, Switzerland
- Andrew J. Boyle, MD, Atlanta, GA, USA
- Stephen C. Clark, FRCS, Newcastle upon Tyne, UK
- Hannah Copeland, MD, Indianapolis, IN, USA
- Lara Danziger-Isakov, MD, MPH, Cincinnati, OH, USA
- Sabina M. De Geest, RN, PhD, Basel, Switzerland
- Goran Dellgren, MD, PhD, Goteborg, Sweden
- Shashank S. Desai, MD, Falls Church, VA, USA
- Kumud K. Dhital, MD, PhD, Sydney, Australia
- Stephan Ensminger, MD, DPhil, Bad Oeynhausen, Germany
- Christopher R. Ensor, PharmD, BCPS-CV, Pittsburgh, PA, USA
- Benjamin H. Freed, MD, Chicago, IL, USA
- Andrew E. Gelman, PhD, St. Louis, MO, USA
- Patricia Ging, PharmD, Dublin, Ireland
- Christopher S. Hayward, MD, Sydney, Australia
- Peter M. Hopkins, FRACP, Brisbane, Australia
- Jonathan N. Johnson, MD, Rochester, MN, USA
- Annemarie Kaan, MCN, RN, Vancouver, Canada
- Mary E. Keebler, MD, Nashville, TN, USA
- Kiran K. Khush, MD, Stanford, CA, USA
Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada
Laveena Chhatwani, MD, Stanford University, Stanford, CA
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada
Jose M. Cifrian, MD, Hospital University Marques Valdecilla, Santander, Spain
Tamara E. Claridge, PharmD, Hospital of the University of Pennsylvania, Philadelphia, PA
Joseph C. Cleveland, Jr, MD, University of Colorado School of Medicine, Aurora, CO
Adam B. Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA
Erin Coglanese, MD, Loyola University Medical Center, Maywood, IL
Rebecca J. Cogswell, MD, University of Minnesota, Minneapolis, MN
Monica M. Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI
Pamela S. Combs, PhD, RN, Seton Medical Center, Austin, TX
Jennifer L. Cook, MD, University of Arizona Sarver Heart Center, Tucson, AZ
Jennifer Cowger, MD, St Vincent Heart Center, Indianapolis, IN
Rachel M. Crackett, MSc, Freeman Hospital, Newcastle upon Tyne, UK
Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain
Michiel Dalinghaus, MD, PhD, Erasmus Medical Center, Rotterdam, The Netherlands
Mani A. Daneshmand, MD, Duke University Medical Center, Durham, NC
Teresa De Marco, MD, FACC, University of California at San Francisco, San Francisco, CA
Fabio De Robertis, MD, Harefield Hospital, Harefield, UK
Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Eugene C. DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA
Tobias Deuse, MD, PhD, University of California at San Francisco, San Francisco, CA
Gundeep S. Dhillon, MD, Stanford University, Stanford, CA
Joshua M. Diamond, MD, University of Pennsylvania, Philadelphia, PA
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada
Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium
Debra A. Dodd, MD, Vanderbilt Children’s Hospital, Nashville, TN
Stavros G. Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT
ABSTRACT

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada
Debi H. Dumas-Hicks, RN, BS, CCTC, CCTN, Ochsner Medical Center, New Orleans, LA
Jean-Paul Duong-Van-Huyen, MD, PhD, Hospital Necker, Paris, France
Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA
Jerry D. Estep, MD, The Methodist Hospital, Houston, TX
Roger W. Evans, PhD, UNRTP, Transplant Professionals.com, LLC, Rochester, MN
Katherine Y. Fan, MD, Grantham Hospital, Aberdeen, Hong Kong
Maryjane A. Farr, MD, Columbia University Medical Center, New York, NY
Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH
Brian Feingold, MD, MS, Children’s Hospital of Pittsburgh, Pittsburgh, PA
Mark E. Fenton, MD, FRCPC, Royal University Hospital, Saskatoon, SK, Canada
Katrina Ford, BPharm, Great Ormond Street Hospital, London, UK
Jennifer L. Franzwa, MSN, RN, CCTC, University of Iowa Hospitals and Clinics, Iowa City, IA
Darren H. Freed, MD, PhD, FRCSC, University of Alberta Hospital, Edmonton, AB, Canada
Jason S. Fritz, MD, FCCP, University of Pennsylvania, Philadelphia, PA
Laura K. Frye, MD, University of Pennsylvania, Philadelphia, PA
Louise M. Fuller, PT, Alfred Hospital, Melbourne, VIC, Australia
Rochelle M. Gellatly, PharmD, Alfred Hospital, Melbourne, VIC, Australia
Helen Gibbs, RN, Auckland City Hospital, Auckland, New Zealand
Claudia G. Gidea, MD, Barnabas Health, New York, NY
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, NSW, Australia
Martin J. Goddard, FRCS, MRCPa, Papworth Hospital, Cambridge, UK
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY
Mardi Gomberg-Maitland, MD, University of Chicago Medical Center, Chicago, IL
Jose Gonzalez-Costello, MD, Hospital Universitari de Bellvitge, Barcelona, Spain
Francisco Gonzalez-Vilchez, MD, PhD, Hospital Marques de Valdecilla, Santander, Spain
Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany
Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL
John R. Greenland, MD, PhD, University of California at San Francisco, San Francisco, CA
ABSTRACT

Erika D. Lease, MD, University of Washington, Seattle, WA
David J. Lederer, MD, Columbia University Medical Center, New York, NY
Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland
Choon Pin Lim, MBBS, National Heart Center, Singapore, Singapore
Ugolino Livi, MD, S. Maria della Misericordia General Hospital, Udine, Italy
Gabriel Loor, MD, University of Minnesota, Minneapolis, MN
Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH
Lars Lund, MD, PhD, Karolinska University Hospital, Stockholm, Sweden
Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada
Peter Macdonald, MD, PhD, St. Vincent’s Hospital, Sydney, Australia
Claudius Mahr, DO, University of Washington, Seattle, WA
George B. Mallory, MD, Texas Children’s Hospital, Houston, TX
Monique Malouf, FRACP, St. Vincent’s Hospital, Sydney, NSW, Australia
Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN
Pradeep P. A. Mammen, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX
Charles C. Marboe, MD, Columbia University, New York, NY
Bradley A. Maron, MD, Brigham and Women’s Hospital, Boston, MA
Stanley I. Martin, MD, Geisinger Health System, Danville, PA
Oliver Mauthner, PhD, University of Basel, Basel, Switzerland
John McDyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Dana P. McGlothlin, MD, Kaiser San Francisco, San Francisco, CA
Tanya J. McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand
Tina Melicoff, MD, Baylor College of Medicine, Houston, TX
Sonia Mirabet, MD, Hospital Sant Pau, Barcelona, Spain
Nader Moazami, MD, Cleveland Clinic, Cleveland, OH
Paul J. Mohacsi, MD, University Hospital, Bern, Switzerland
Thomas Moller, MD, PhD, Oslo University Hospital, Oslo, Norway
Joshua J. Mooney, Stanford University, Stanford, CA
Michiel Johan Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany
Michael S. Mulligan, MD, University of Washington School of Medicine, Seattle, WA
Jayan Nagendran, MD, University of Alberta, Edmonton, AB, Canada
Takeshi Nakatani, MD, PhD, National Cerebral & Cardiovascular Center, Osaka, JAPAN
Sanem Nalbantgil, MD, Ege University, Izmir, Turkey
Tomohiro Nishinaka, MD, Tokyo Women’s Medical University, Tokyo, Japan
Robert F. Padera, MD, PhD, Brigham & Women’s Hospital, Boston, MA
Francis D. Pagani, MD, PhD, University of Michigan Health, Ann Arbor, MI
Maryse Palaridy, MD, University of Michigan, Ann Arbor, MI
Kruti A. Pandya, MD, UCLA, Los Angeles, CA
Chetan B Patel, MD, Duke University Medical Center, Durham, NC
Caroline M. Patterson, MD, Papworth Hospital, Cambridge, UK
Simon Pech, MD, University Heart Center Hamburg, Hamburg, Germany
Michael Pham, MD, MPH, Stanford University, Palo Alto, CA
Daniela Pini, MD, Istituto Clinico Humanitas, Milan, Italy
Sean P. Pinney, MD, Mt Sinai Medical Center, New York, NY
Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France
Evgenij V. Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany
Ioana R. Preston, MD, Tufts Medical Center, Boston, MA
Yuriy Pya, MD, National Research Cardiac Surgery Center, Astana, Kazakhstan
Axel Rahmel, MD, German Procurement Organization DSO, Frankfurt, Germany
Keshava Rajagopal, MD, PhD, University of Texas Health Science Center at Houston, Houston, TX
J. Eduardo Rame, MD, Pennsylvania Heart & Vascular Center, Philadelphia, PA
Danny Ramzy, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA
Aaron M. Ranasinghe, MD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Yazhini Ravi, MD, Baylor Scott & White Memorial Hospital, Temple, TX
Leigh C. Reardon, MD, UCLA, Los Angeles, CA
Anja C. Roden, MD, Mayo Clinic, Rochester, MN
Joseph W. Rossano, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA
Dmitry Rozenberg, MD, University of Toronto, Toronto, ON, Canada
Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD
John J. Ryan, MD, FACC, FAHA, University of Utah, Salt Lake City, UT
Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia
Christopher T. Salerno, MD, St. Vincent’s Heart Center, Indianapolis, IN
Murat Sargin, MD, Siyami Ersek Hospital, Istanbul, Turkey
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Stephan Schubert, MD, German Heart Center, Berlin, Germany
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Martin Schweiger, MD, Children’s Hospital, Zurich, Switzerland
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany
Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain
Ashish S. Shah, MD, Johns Hopkins Hospital, Baltimore, MD
Keyur B. Shah, MD, Virginia Commonwealth University, Richmond, VA
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA
Pali Shah, MD, Johns Hopkins University, Baltimore, MD
Esther Shao, MD, Maine Health Cardiology, Portland, ME
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA
Scott C. Silvestry, MD, Washington University School of Medicine, St. Louis, MO
Andre R. Simon, MD, PhD, Harefield Hospital, London, UK
Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA
Kathleen Simpson, MD, Washington University St. Louis, St. Louis, MO
Tajinder P. Singh, MD, MSc, Boston Children’s Hospital, Boston, MA
Cumara C. Sivathasan, MBBS, FRCS, National Heart Centre, Singapore, Singapore
Mark S. Slaughter, MD, University CT Surgical Associates, Louisville, KY
George G. Sokos, DO, Allegheny General Hospital, Pittsburgh, PA
Amparo Sole, MD, PhD, Hospital Universitario la Fe Unidad de Trasplante Pulmonar, Valencia, Spain
Melinda Solomon, MD, FRCP, Hospital for Sick Children, Toronto, ON, Canada
Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
Ajay V. Srivastava, MD, Stanford University, San Jose, CA
William E. Stansfield, MD, Toronto General Hospital, Toronto, ON, Canada
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT
Emily Stimpson, MSN, CCTC, Cedars-Sinai Medical Center, Los Angeles, CA
Valentina Stosor, MD, Northwestern University/Feinberg School of Medicine, Chicago, IL
Martin Stueber, MD, Spectrum Health Hospital, Grand Rapids, MI
Zsolt Szepfalusi, MD, Medical University of Vienna, Vienna, Austria
Carmela D. Tan, MD, Cleveland Clinic, Cleveland, Ohio
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN
Adriana Torres, MD, Fundacion Cardioinfantil, Bogota, Colombia
Christopher Towe, MD, Cincinnati Children’s Hospital, Cincinnati, OH
Wayne M. Tsuang, MD, Cleveland Clinic, Cleveland, OH
Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC
Marian Urban, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Nir Uriel, MD, University of Chicago, Chicago, IL
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada
Jean-Luc Vachiery, MD, Erasme University Hospital ULB, Brussels, Belgium
Victor H. Van Berkel, MD, PhD, University of Louisville Physicians, Louisville, KY
Rebecca R. Vanderpool, PhD, University of Pittsburgh, Pittsburgh, PA
Rhea A. Varughese, MD, Alberta Health Services, Edmonton, AB, Canada
Rajammyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, UK
Geert M. Verleden, MD, PhD, University Hospital Gathuisberg, Leuven, Belgium
Stijn Verleden, PhD, KU Leuven, Leuven, Belgium
Erik A. M. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands
Gary A. Visner, DO, Boston Children’s Hospital, Boston, MA
C Dario Vizza, MD, University of Rome, Rome, Italy
I-Wen Wang, MD, PhD, Methodist Hospital, Indianapolis, IN
Katherine Watkins, PharmD, University of California, San Francisco, San Francisco, CA
Robert G. Weintraub, FRACP, FACC, Royal Children’s Hospital, Melbourne, Australia
Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, VIC, Australia
George M. Wieselthaler, MD, University of California at San Francisco, San Francisco, CA
Keith M. Wille, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL
Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria
ACCME Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement
ISHLT designates this live activity for a maximum of 30 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation
The ABTC Board of Governors has granted a total of 30 Category 1 Continuing Education Points for Transplant Certification (CEPTC) to the International Society for Heart & Lung Transplantation’s ISHLT 36th Annual Meeting and Scientific Sessions.

ACPE Accreditation
PHARMACISTS
Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 13.0 contact hours. Full attendance is required. No partial contact hours will be awarded for partial attendance. Unique Activity Numbers: 0453-9999-16-029-L04-P through 0453-9999-16-047-L04-P.

ANCC Accreditation
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This course is co-provided by Amedco and the International Society for Heart and Lung Transplantation (ISHLT). Maximum of 30.00 contact hours.
Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Educational Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.
Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management and patient management for the treatment of patients suffering from end-stage heart and lung disease.

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications and psychosocial management strategies for patients with end-stage heart and lung failure.

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.
The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the:

36th Annual Meeting and Scientific Sessions

**ACTELION PHARMACEUTICALS**

**GILEAD SCIENCES**
The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2016:
Tier 1
ACTELION PHARMACEUTICALS

Tier 2
BAYER HEALTHCARE
GILEAD SCIENCES
HEARTWARE
ST. JUDE
UNITED THERAPEUTICS

Tier 3
CAREDX
LUNG BIOENGINEERING
TRANSMEDICS
ANNUAL MEETING
HIGHLIGHTS
Basic Science and Translational Research

The 2016 ISHLT Annual Meeting will include a range of sessions covering basic science and translational research topics in heart and lung failure and transplantation. These carefully crafted symposia will feature internationally recognized leaders in the field. The aim of each session will be to bring together in one room basic scientists as well as clinicians and clinical researchers who wish to explore the given topics. The pre-meeting symposium entitled “Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation” will include talks given by experts in biobanking, omics data analysis, big data modeling and multi-center study design. Speakers will also explore the potential clinical applications of the resulting datasets. “Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?” will be an exciting state-of-the-art set of lectures by world-renowned pioneers in tissue engineering, cell therapy and tolerance induction presented in the context of heart and lung failure and transplantation. A sunrise symposium will offer a more basic coverage of transplant immunology and biology: “Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology.” This will be an opportunity for all ISHLT members to brush up on their basic science knowledge and also review the clinical relevance of underlying mechanisms of allograft rejection and injury. In addition to these three core symposia, other talks focused on basic and translational research have been incorporated into other sessions in order to create a well-rounded high-quality program for the ISHLT conference attendees.
Heart Failure and Transplantation
The ISHLT 2016 in Washington DC will bring dynamic and thought provoking symposia in heart failure and transplantation for clinicians, surgeons and allied health professionals. **Timing Support in Cardiogenic Shock: When to Move Forward** will confront us with the difficult question of when is the best time to intervene in an emergent situation? Then we will challenge our current paradigm with **Rethinking Valvular Heart Disease in Heart Failure** from percutaneous intervention to surgical interventions. We will also explore how to select the best donor and optimize the current donor shortage with the session, **Donor Selection: Strategies to Improve Organ Utilization.** A comprehensive discussion on how to diagnose and manage right heart failure will be included in **When Right Is Wrong: Management of the Dying Right Ventricle.** We will look at post-transplant surgical challenges with a session on **Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective** that will discuss topics such as technical considerations in adult congenital heart transplantation, surgical management of primary graft dysfunction and surgical options for late graft failure. We will tackle post heart transplant – Immunology with a **Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR** from the most update diagnoses to the best treatments. We will continue with immunology to immunosuppression with **Controversies in Heart Transplantation: How Low Can You Go? – Tailoring Immunosuppression.**

Infectious Diseases
ISHLT 2016 will offer wide-ranging insight into topics of vital importance to infection in thoracic organ transplantation and MCSD, with symposia of interest both to the diehard Transplant Infectious Diseases provider as well as to other clinicians and scientists with interest in Infectious Diseases. We lead off with **The Future is Here: Emerging Issues in Infectious Disease,** a whirlwind tour of challenging topics including Mycobacterium abscessus, RSV, Scedosporium and other emerging fungi, Clostridium difficile and those troublesome resistant Gram-negative organisms. Next up is a comprehensive look at CMV in **It’s All in the Translation: CMV from Bedside to Bench and Back,** which will examine the
impact of CMV on the heart and lung allograft, the anti-CMV immune response and review our current antiviral armamentarium and preview new tools on the horizon. We end the day with a not-to-be-missed session entitled Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infections with an update on UNOS data on donor derived infections and a review of the European perspective, a look at the donor with possible encephalitis, nucleic acid based testing for HIV, Hepatitis C and Hepatitis B and new opportunities ahead for HIV-positive organs. Grab some coffee for our Sunrise Symposium on The Fly in the Ointment: Nosocomial Infections, a novel look at antimicrobial stewardship, infection prevention and outbreaks in the transplant center, with a special look at patients with open chest or ECMO. But that’s not all – our colleagues in MCS are presenting Achilles Heel: Infectious Complications in MCS, our friends in Pharmacy will review the lifecycle of Hepatitis C patient with heart failure, specialists from the Pediatrics community will discuss Child’s Play: Infectious Risk After Transplant During Everyday Life and from Lung Transplantation, a session on infection in the elderly lung transplant recipient.

**Lung Failure And Transplantation**

This year there will be numerous stimulating sessions with four Pre-meeting Symposia and two Sunrise Symposia dedicated to lung transplantation. Current Innovations and Future of EVLP will explore the future of EVLP with respect to lung repair using cell or gene based therapies and drug or molecular interventions. Advanced techniques of ex-vivo perfusion using portable systems and dual artery cannulation techniques will be discussed. EVLP as a platform to reduce infection and possible allo responsiveness will be summarized. Multiorgan Transplantation for Lung Recipients: When is Two Better than One? will summarize key recommendations pertaining to heart-lung, lung-liver and lung-kidney transplantation. Furthermore, the ethics and equity debate of multi organ transplantation shall be outlined as well as issues of possible immunological allograft protection. The Biology of Aging and Lung Transplantation will cover issues of immunosenescence, impact of telomerase mutations, measures of frailty and other challenges in the elderly recipient including infection and immunosuppressive regimens. Our persistent nemesis CLAD will be reviewed in Endotypes of CLAD and Novel Treatment
Strategies. The symposium will include a presentation on the historical basis for CLAD phenotypes and review of current clinical, radiological and pathological criteria. Contemporary medical and surgical treatment practices for patients as directed by phenotype will be outlined, along with future perspectives with regards to CLAD prevention. Thoracic Organ Transplantation and Malignancy, will review key issues including relevance to lung transplant candidate selection and overview of current cancer screening guidelines. Lung Transplant Benefit is More Than Just Survival will question the outcome of survival as the only relevant measure of success with lung transplantation. The session will assess contemporary assessment tools of health related quality of life, functioning and disability and their relevance to measuring important patient outcomes, as well as the impact of neuro cognitive changes post lung transplant.

Mechanical Circulatory Support
We are looking forward to the 2016 Annual Meeting and expect the MCS content will stimulate the broad interests of the MCS community and actively represent the variety of subspecialties which contribute to the advancement of the field. The challenges of managing anticoagulation and antiplatelet therapy, the use of platelet functional assays and the approach to high-risk patients will be addressed in Anticoagulation and MCS: Can We Do Better? The ISHLT is very pleased to introduce the first joint ISHLT/ICCAC symposium, Joined at the Heart – International Perspectives on MCS Issues, which has leaders from both societies exploring the factors which allow multidisciplinary teams to achieve excellent results across a wide array of practice environments. Achilles Heel: Infectious Complications in MCS will have representatives from both MCS and infectious disease review the diagnosis, therapy, prevention and long-term consequences of infections in patients with MCS. We will tackle several controversial issues such as transplantation versus DT in the elderly, mechanical support in less sick patients and the use of minimally invasive implant techniques in Great Debates in MCS. The debates will be case-based and will provide both an informative and entertaining review of these contentious topics. The MCS community recognizes the importance of patient selection and management on outcomes and the incidence of adverse events, but device engineering also plays a critical role. In MCS Chal-
lenges and Engineering Solutions, we will review the role of shear stress, the impact of pump miniaturization, the use of physiologic controls and available engineering options to improve outcomes and reduce adverse events. These engineering principles will be presented in the context of their clinical applications and in a manner that is accessible to the practicing MCS care provider. Clear as Mud: Assessing the Right Ventricle will address the always challenging issues of preoperative assessment of RV function, intraoperative treatment strategies and the approach to treatment of chronic RV failure.

Nursing, Health Science, Allied Health

This year, we are showcasing how art and evidence can inspire innovation in several areas of clinical care. An attractive program has been created through the collaboration of several different specialties including three diverse symposia in the areas of genomics, selection of marginal donors and ECMO. Genomics: What do I Have to Know and How Will It Affect My Practice? will provide all attendees with the basics of this new field and provides examples of how genomics will impact clinical transplant care in the future. The ethical reflection on this field and a discussion of nursing competencies will complete this session. In Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates, treatment decisions for marginal transplant and mechanical support candidates will be tackled in three debates developed around difficult issues that clinicians face every day. Should we, or should we not list this patient? What is the evidence base? Which ethical reflections influence our decisions? An interactive response system and a panel discussion will maximize the involvement of the audience. Ambulatory ECMO in Adults: We Like to Move It, Move It addresses the issue at the forefront of critical care practice: ambulation in adult ECMO patients. What are the risks and benefits? What is required to implement such a practice in your program? Which team members should be involved? In addition, there will be nursing, health sciences and allied health content being presented in other symposia. This “cross-pollination” will serve to make this year’s ISHLT conference richer and more relevant.
Pathology
This year's pathology satellite symposium takes aim at “chronic rejection” in the heart. Controversy and confusion surrounding this topic stem from varying definitions of what “chronic” means as well as whether the observed changes in the allograft are truly rejection. Speakers in this session will address the myocardial alterations (beyond CAV) seen after years of repetitive rejection episodes, novel mechanisms of CAV development, the role of complement and other mechanisms in potentiating late graft damage, a morphologic comparison to analogues of chronic rejection in other organs and a review of animal models of late graft loss.

Pediatrics
We all recognize that there are major variations in pediatric heart failure and transplant management, and so this year’s pediatric symposia will spotlight major controversies in these fields. VADs in Patients with Congenital Heart Disease will focus on the big questions in this difficult group of patients, both pediatric and adult. Child’s Play after Pediatric Thoracic Transplant will examine the prevailing dogma after heart and lung transplantation in children, addressing whether isolation is necessary, which pets are allowed, what limits can be placed on travel, which water and food sources are safe and current vaccination practices for endemic diseases. Controversies in Pediatric Heart Failure will focus squarely on the heart failure community, engaging the audience with discussions of novel pharmaceutical agents in pediatric heart failure and how to prevent sudden death in the pediatric heart failure patient. We will continue the important discussion from last year's meeting on making palliative care part of the plan for every patient and conclude with a presentation on the new ISHLT pediatric heart failure registry – will it result in useable data, or just make more work?
Pharmacy And Pharmacology

The 2016 ISHLT Annual Meeting will showcase clinical care and research initiatives through a diverse program of informative sessions. Two Pharmacy and Pharmacology sessions, which focus on drug therapy, lend applicability across all disciplines represented by the ISHLT membership. Join us in the return of the ever-popular lifecycle journey series, with a look at a Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016. An enduring case will be presented, interspersed with a best practice based discussion at pre-defined, key “journey intervals.” In this session, we focus on how the new hepatitis treatments have altered management at all stages of this lifecycle; pay particular consideration to the controversial areas of listing these patients for transplant; evaluate the tricky issue of immunosuppression; malignancy post-transplantation; and finally when to consider palliation? This is certain to be a lively session giving challenging insights into this developing area of practice, definitely not to be missed! The sunrise symposium on Saturday, Precision Medicine in Transplantation: Drug Levels and Beyond, involve a bench-to-bedside exploration of pharmacogenetics and the impact on drug metabolism and predicting adverse effects. We then approach the problem from the other angle as we consider therapeutic gene modulation, learning from the field of cystic fibrosis.

Pulmonary Hypertension

Pulmonary hypertension is truly at the forefront of the 2016 ISHLT Scientific Sessions with a total of seven provocative symposia! Areas covered will include pulmonary hypertension related to chronic thromboembolic disease, parenchymal lung disease, left heart disease and congenital heart disease. Sessions will also detail important issues in lung transplantation related to pulmonary hypertension, the use of combination therapy in pulmonary artery hypertension and a translational symposium on emerging biology of pulmonary hypertension and the right heart. The two joint sessions with the European Society of Cardiology (ESC) and the Pulmonary Vascular Research Institute (PVRI) in particular are not to be missed.
THE MARRIOTT
WARDMAN PARK

L1 EXHIBITION LEVEL
Atrium
Exhibit Hall A
Exhibit Halls B & C
Washington 1
Washington 2
Washington 3
Washington 5

L2 LOBBY LEVEL
Capitol Boardroom
Convention Registration
Delaware Suite
Maryland Suite
Park Tower 8206
Park Tower 8212
Park Tower 8216
Park Tower 8217
Salon 1
Salons 2-3
Virginia Suite

L3 MEZZANINE LEVEL
Balcony A
Balcony B
Harding
Hoover
Jackson
Madison
Taft
Taylor
Thurgood Marshall North
Thurgood Marshall East
Thurgood Marshall South and West
Wilson
To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

- **BSI**: BASIC SCIENCE
- **CASE**: JUNIOR FACULTY CLINICAL CASE REPORTS
- **EEP**: ECONOMICS, ETHICS, PUBLIC POLICY
- **HF**: HEART FAILURE – ADULT
- **HTX**: HEART TRANSPLANTATION – ADULT
- **ID**: INFECTION DISEASES
- **LBCS**: LATE BREAKING CLINICAL SCIENCE
- **LF**: LUNG FAILURE – ADULT
- **LTX**: LUNG TRANSPLANTATION – ADULT
- **MCS**: MECHANICAL CIRCULATORY SUPPORT – ADULT
- **NHSAH**: NURSING, HEALTH SCIENCE AND ALLIED HEALTH
- **PATH**: PATHOLOGY
- **PEDS**: PEDIATRICS
- **PHARM**: PHARMACY AND PHARMACOLOGY
- **PH**: PULMONARY HYPERTENSION
ANNUAL MEETING
TIME TABLE SCHEDULE
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 AM</td>
<td>Board of Directors Meeting 8am - 2pm</td>
</tr>
<tr>
<td>8:30</td>
<td>ISHLT Core Competencies in Heart Failure and Cardiac Transplant Medicine 8:00am - 6pm</td>
</tr>
<tr>
<td>9 AM</td>
<td>ISHLT Master’s Course in Pulmonary Hypertension 8:00am - 6pm</td>
</tr>
<tr>
<td>9:30</td>
<td>ISHLT Core Competencies in Mechanical Circulatory Support 8:00am - 6pm</td>
</tr>
<tr>
<td>9:30</td>
<td>ISHLT G&amp;A Tx Registry 6pm - 8pm</td>
</tr>
<tr>
<td>10 AM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>10:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>11 AM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>11:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>12 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>12:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>1 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>1:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>2 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>2:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>3 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>3:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>4 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>4:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>5 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>5:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>6 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>6:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>7 PM</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
<tr>
<td>7:30</td>
<td>ISHLT Comm Mtg 6pm - 8pm</td>
</tr>
</tbody>
</table>

**TUESDAY · APRIL 26**

**LEVEL:** Mezzanine Lobby

**ROOM:** THURGOOD MARSHALL NORTH

**LEVEL:** Mezzanine Lobby

**ROOM:** THURGOOD MARSHALL EAST

**LEVEL:** Mezzanine Lobby

**ROOM:** THURGOOD MARSHALL S & W
<table>
<thead>
<tr>
<th>LEVEL:</th>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Exhibition</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Mezzanine</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
<tr>
<td>Lobby</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>LEVEL:</th>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 AM</td>
<td>8 AM</td>
<td>Lobby</td>
</tr>
<tr>
<td>8:30</td>
<td>8:30</td>
<td>Lobby</td>
</tr>
<tr>
<td>9 AM</td>
<td>9 AM</td>
<td>Lobby</td>
</tr>
<tr>
<td>9:30</td>
<td>9:30</td>
<td>Lobby</td>
</tr>
<tr>
<td>10 AM</td>
<td>10 AM</td>
<td>Lobby</td>
</tr>
<tr>
<td>10:15</td>
<td>10:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>10:45</td>
<td>10:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>11:15</td>
<td>11:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>11:45</td>
<td>11:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>12:15</td>
<td>12:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>12:45</td>
<td>12:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>1:15</td>
<td>1:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>1:45</td>
<td>1:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>2:15</td>
<td>2:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>2:45</td>
<td>2:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>3:15</td>
<td>3:15</td>
<td>Lobby</td>
</tr>
<tr>
<td>3:45</td>
<td>3:45</td>
<td>Lobby</td>
</tr>
<tr>
<td>4:00</td>
<td>4:00</td>
<td>Lobby</td>
</tr>
<tr>
<td>4:30</td>
<td>4:30</td>
<td>Lobby</td>
</tr>
<tr>
<td>5:00</td>
<td>5:00</td>
<td>Lobby</td>
</tr>
<tr>
<td>5:30</td>
<td>5:30</td>
<td>Lobby</td>
</tr>
<tr>
<td>6:00</td>
<td>6:00</td>
<td>Lobby</td>
</tr>
<tr>
<td>7 PM</td>
<td>7 PM</td>
<td>Lobby</td>
</tr>
<tr>
<td>8 PM</td>
<td>8 PM</td>
<td>Lobby</td>
</tr>
<tr>
<td>9 PM</td>
<td>9 PM</td>
<td>Lobby</td>
</tr>
</tbody>
</table>

**SYMPOSIUM 1:** Anticoagulation and MCS
**SYMPOSIUM 2:** Controversies in Heart Tx
**SYMPOSIUM 3:** Current Innovations and Future of EVLP
**SYMPOSIUM 4:** Under Pressure: PH/ILD
**SYMPOSIUM 5:** Making It Work: Heart Tx Challenges Surgical
**SYMPOSIUM 6:** Back to the Future: Cell Therapy
**SYMPOSIUM 7:** Future is Here: Emerging Issues in ID

**SYMPOSIUM 8:** Joint ISHLT/ICCAC MCS Donor Heart Selection
**SYMPOSIUM 9:** Strategies to Improve Organ Utilization
**SYMPOSIUM 10:** Multi-Organ Tx for Lung Recipients
**SYMPOSIUM 11:** CMV from Bench to Bedside
**SYMPOSIUM 12:** Child’s Play: Infectious Risk after Tx

**SYMPOSIUM 13:** Joint ISHLT/ESC PH
**SYMPOSIUM 14:** Genomics

**SYMPOSIUM 15:** Achilles Heal: Infectious Complications in MCS
**SYMPOSIUM 16:** When Right is Wrong! Mgt of Dying RV
**SYMPOSIUM 17:** Biology of Aging and Lung Tx
**SYMPOSIUM 18:** Current Issues in CTEPH
**SYMPOSIUM 19:** Debating Treatment Decisions for Marginal Psychosocial Candidates
**SYMPOSIUM 20:** Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Tx

**SYMPOSIUM 21:** Unraveling “Chronic Rejection” in Heart Tx

**SYMPOSIUM 22:** Great Debates in MCS
**SYMPOSIUM 23:** Update on AMR in Cardiac Tx
**SYMPOSIUM 24:** Endotypes of CLAD and Novel Treatment Strategies
**SYMPOSIUM 25:** Inflammation and Altered Metabolism in PH
**SYMPOSIUM 26:** Minimizing Risk Maximizing Benefit with Donor Derived Infection
**SYMPOSIUM 27:** VAD in Patients with Congenital Heart Disease
**SYMPOSIUM 28:** Journey of Hep C Heart Failure Patient

**SYMPOSIUM 29:** Joint ISHLT/ICCAC AHSAH Council Mtg
**SYMPOSIUM 30:** 12:15pm - 1:45pm

**SYMPOSIUM 31:** NHAH Council Mtg
**SYMPOSIUM 32:** 12:15pm - 1:45pm

**SYMPOSIUM 33:** ICCAC Annual Mtg
**SYMPOSIUM 34:** 7pm - 10pm
<table>
<thead>
<tr>
<th>TIME</th>
<th>LEVEL</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Mezzanine</td>
<td>Hall A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hall B &amp; C</td>
</tr>
<tr>
<td>8 AM</td>
<td>Mezzanine</td>
<td>Wilson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taft</td>
</tr>
<tr>
<td>8:30</td>
<td>Mezzanine</td>
<td>Hall A</td>
</tr>
<tr>
<td>9 AM</td>
<td></td>
<td>Hall B &amp; C</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>Wilson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taft</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>Hall A</td>
</tr>
<tr>
<td>10 AM</td>
<td></td>
<td>Hall B &amp; C</td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td>Wilson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taft</td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td>Hall A</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td>Hall B &amp; C</td>
</tr>
<tr>
<td>11 AM</td>
<td></td>
<td>Wilson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taft</td>
</tr>
<tr>
<td>11 AM</td>
<td></td>
<td>Hall A</td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td>Hall B &amp; C</td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td>Wilson</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taft</td>
</tr>
</tbody>
</table>

**POSTER SESSION 1**

- **PHARM Council Mtg**
  - 12:15pm - 1:45pm
- **IMACS Reg Comm Mtg**
  - 12:15pm - 1:45pm
- **CDI Reg Comm Mtg**
  - 12:15pm - 1:45pm
- **Jr Faculty Mentor Lunch**
  - 12:15 - 1:45pm
- **Grant Opening Reception**
  - 6pm - 7pm

- **Remove/Re-number POSTER SESSION 1**

---

**LEVEL: Exhibition**

**LEVEL: Exhibition Mezzanine**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
<th>Session 4</th>
<th>Session 5</th>
<th>Session 6</th>
<th>Session 7</th>
<th>Session 8</th>
<th>Session 9</th>
<th>Session 10</th>
<th>Session 11</th>
<th>Session 12</th>
<th>Session 13</th>
<th>Session 14</th>
<th>Session 15</th>
<th>Session 16</th>
<th>Session 17</th>
<th>Session 18</th>
<th>Session 19</th>
<th>Session 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 AM</td>
<td>OPENING PLENARY</td>
<td>CONCURRENT 1</td>
<td>CONCURRENT 2</td>
<td>CONCURRENT 3</td>
<td>CONCURRENT 4</td>
<td>CONCURRENT 5</td>
<td>CONCURRENT 6</td>
<td>CONCURRENT 7</td>
<td>CONCURRENT 8</td>
<td>CONCURRENT 9</td>
<td>CONCURRENT 10</td>
<td>CONCURRENT 11</td>
<td>CONCURRENT 12</td>
<td>CONCURRENT 13</td>
<td>CONCURRENT 14</td>
<td>CONCURRENT 15</td>
<td>CONCURRENT 16</td>
<td>CONCURRENT 17</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 AM</td>
<td>CONCURRENT 1</td>
<td>CONCURRENT 2</td>
<td>CONCURRENT 3</td>
<td>CONCURRENT 4</td>
<td>CONCURRENT 5</td>
<td>CONCURRENT 6</td>
<td>CONCURRENT 7</td>
<td>CONCURRENT 8</td>
<td>CONCURRENT 9</td>
<td>CONCURRENT 10</td>
<td>CONCURRENT 11</td>
<td>CONCURRENT 12</td>
<td>CONCURRENT 13</td>
<td>CONCURRENT 14</td>
<td>CONCURRENT 15</td>
<td>CONCURRENT 16</td>
<td>CONCURRENT 17</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 AM</td>
<td>CONCURRENT 1</td>
<td>CONCURRENT 2</td>
<td>CONCURRENT 3</td>
<td>CONCURRENT 4</td>
<td>CONCURRENT 5</td>
<td>CONCURRENT 6</td>
<td>CONCURRENT 7</td>
<td>CONCURRENT 8</td>
<td>CONCURRENT 9</td>
<td>CONCURRENT 10</td>
<td>CONCURRENT 11</td>
<td>CONCURRENT 12</td>
<td>CONCURRENT 13</td>
<td>CONCURRENT 14</td>
<td>CONCURRENT 15</td>
<td>CONCURRENT 16</td>
<td>CONCURRENT 17</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 PM</td>
<td>CONCURRENT 1</td>
<td>CONCURRENT 2</td>
<td>CONCURRENT 3</td>
<td>CONCURRENT 4</td>
<td>CONCURRENT 5</td>
<td>CONCURRENT 6</td>
<td>CONCURRENT 7</td>
<td>CONCURRENT 8</td>
<td>CONCURRENT 9</td>
<td>CONCURRENT 10</td>
<td>CONCURRENT 11</td>
<td>CONCURRENT 12</td>
<td>CONCURRENT 13</td>
<td>CONCURRENT 14</td>
<td>CONCURRENT 15</td>
<td>CONCURRENT 16</td>
<td>CONCURRENT 17</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 PM</td>
<td>CONCURRENT 1</td>
<td>CONCURRENT 2</td>
<td>CONCURRENT 3</td>
<td>CONCURRENT 4</td>
<td>CONCURRENT 5</td>
<td>CONCURRENT 6</td>
<td>CONCURRENT 7</td>
<td>CONCURRENT 8</td>
<td>CONCURRENT 9</td>
<td>CONCURRENT 10</td>
<td>CONCURRENT 11</td>
<td>CONCURRENT 12</td>
<td>CONCURRENT 13</td>
<td>CONCURRENT 14</td>
<td>CONCURRENT 15</td>
<td>CONCURRENT 16</td>
<td>CONCURRENT 17</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
</tr>
<tr>
<td>2:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 AM</td>
<td>Junior Faculty/Trainees Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 AM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 AM</td>
<td>Exhibiton Hall Open</td>
<td>Poster Mount</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Poster Hall Open</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td>Exhibit Hall Open</td>
<td>Poster Mount</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 AM</td>
<td>Poster Hall Open</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 AM</td>
<td>Exhibit Hall Open</td>
<td>Poster Mount</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td>PATH Council Mtg</td>
<td>Mezzanine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 AM</td>
<td><strong>Lobby</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 AM</td>
<td><strong>MEZZANINE LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 AM</td>
<td><strong>LEVEL 1 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td><strong>LEVEL 2 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td><strong>LEVEL 3 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td><strong>LEVEL 4 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td><strong>LEVEL 5 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td><strong>LEVEL 6 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 AM</td>
<td><strong>LEVEL 7 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>LEVEL 8 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 AM</td>
<td><strong>LEVEL 9 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>LEVEL 10 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 PM</td>
<td><strong>LEVEL 11 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td><strong>LEVEL 12 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 PM</td>
<td><strong>LEVEL 13 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td><strong>LEVEL 14 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 PM</td>
<td><strong>LEVEL 15 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td><strong>LEVEL 16 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 PM</td>
<td><strong>LEVEL 17 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td><strong>LEVEL 18 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 PM</td>
<td><strong>LEVEL 19 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td><strong>LEVEL 20 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 PM</td>
<td><strong>LEVEL 21 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td><strong>LEVEL 22 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td><strong>LEVEL 23 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30</td>
<td><strong>LEVEL 24 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td><strong>LEVEL 25 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 PM</td>
<td><strong>LEVEL 26 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td><strong>LEVEL 27 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td><strong>LEVEL 28 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td><strong>LEVEL 29 LOBBY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**SUNRISE SYMPOSIUM 1**
- Pimp My Pump: Novel Designs & Mgmt
- GI Bleeding after MCS
- MCS Design & Mgmt
- Selection

**SUNRISE SYMPOSIUM 2**
- Choosing a Gift Donor
- What’s the Dark Side of Heart TX Ltx
- Living with CAH

**SUNRISE SYMPOSIUM 3**
- What’s the New in Primary Prevention
- Dr. Out There
- Protect from Anti-Body

**PLENARY**
- President’s Cocktail Reception – Smithsonian National Museum of Natural History, 8pm - 9:30pm

---

**CONCURRENT 1**
- Pimp My Pump: Novel Designs & Mgmt
- GI Bleeding after MCS
- MCS Design & Mgmt
- Selection

**CONCURRENT 2**
- Choosing a Gift Donor
- What’s the Dark Side of Heart TX Ltx
- Living with CAH

**CONCURRENT 3**
- What’s the New in Primary Prevention
- Dr. Out There
- Protect from Anti-Body

---

**MINI ORALS 1**
- How Much Is Too Much?
- Too Thick or Too Thin?
- Is It Really a Wonderful Life?

**MINI ORALS 2**
- Assessing Risk Prior to MCS
- Assessing Anticoagulation

**MINI ORALS 3**
- Life Post Heart TX, Prob.

---

**MINI ORALS 4**
- Assessing Risk Prior to MCS
- Assessing Anticoagulation

**MINI ORALS 5**
- Life Post Heart TX, Prob.
<table>
<thead>
<tr>
<th>LEVEL:</th>
<th>ROOM:</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Level 4</th>
<th>Level 5</th>
<th>Level 6</th>
<th>Level 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Exhibition</td>
<td>Washington 1</td>
<td>EXHIBIT HALL A</td>
<td>EXHIBIT HALL B &amp; C</td>
<td>Mezzanine</td>
<td>Mezzanine</td>
<td>Mezzanine</td>
<td>Mezzanine</td>
</tr>
<tr>
<td>8 AM</td>
<td>8 AM</td>
<td>9 AM</td>
<td>10 AM</td>
<td>10:30</td>
<td>11 AM</td>
<td>11:30</td>
<td>12 PM</td>
<td>12:30</td>
</tr>
<tr>
<td>12 PM</td>
<td>12 PM</td>
<td>1 PM</td>
<td>1:30</td>
<td>2 PM</td>
<td>SYMPOSIUM 31</td>
<td>2:30</td>
<td>3 PM</td>
<td>3:30</td>
</tr>
<tr>
<td>3:30</td>
<td>4 PM</td>
<td>4:30</td>
<td>5 PM</td>
<td>5:30</td>
<td>6 PM</td>
<td>6:30</td>
<td>7 PM</td>
<td>8 PM</td>
</tr>
<tr>
<td>8 PM</td>
<td>8:30</td>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Poster Mount**
7am - 10am

**Exhibit Hall Open**
10am - 4pm

**Poster Hall Open**
10am - 7pm

**IMACS User Mtg**
12pm - 2pm

**ISHLT/AST Lung Tx**
12pm - 2pm

**Benefit Mtg**
12pm - 2pm

**ID Council Mtg**
12pm - 2pm

**R&DB Comm Mtg**
12pm - 2pm

**SYMPOSIUM 3**
Performing Under Pressure: LTx in PH & PAH
6pm - 7pm

**POSTER SESSION 3**
6pm - 7pm

**President's Cocktail Reception – Smithsonian National Museum of Natural History**, 8pm - 9:30pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Registration</td>
</tr>
<tr>
<td>8:30</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>9 AM</td>
<td>Session 1: Essentials of Heart Failure Management</td>
</tr>
<tr>
<td>9:30</td>
<td>Break</td>
</tr>
<tr>
<td>10:15</td>
<td>Session 2: Heart Failure Diagnosis and Management</td>
</tr>
<tr>
<td>11:15</td>
<td>Break</td>
</tr>
<tr>
<td>12 PM</td>
<td>Session 3: Advances in Heart Failure Treatment</td>
</tr>
<tr>
<td>1:30</td>
<td>Break</td>
</tr>
<tr>
<td>2 PM</td>
<td>Session 4: Heart Failure Prevention and Microcirculatory Dysfunction</td>
</tr>
<tr>
<td>3:30</td>
<td>Break</td>
</tr>
<tr>
<td>4 PM</td>
<td>Session 5: Heart Failure Outcomes and Treatment</td>
</tr>
<tr>
<td>5:30</td>
<td>Break</td>
</tr>
<tr>
<td>6:30</td>
<td>Session 6: Heart Failure Management and Outcomes</td>
</tr>
</tbody>
</table>

*LEVEL: Concourse Lobby
*ROOM: Lobby

---

**Saturday - April 30**

**LEVEL: Mezzanine Lobby
ROOM: Exhibition Lobby**

---

**LEVEL: Conference Room Levels
ROOM: Marathon Meeting Room**
<table>
<thead>
<tr>
<th>LEVEL:</th>
<th>ROOM:</th>
<th>Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mezzanine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MADISON AB</td>
<td>7 AM</td>
<td>SPEAKER READY ROOM 7am - 5pm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mezzanine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HARDING</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30</td>
<td>Committee/Council Reports 7:45am - 9:45am</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exhibition</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WASHINGTON FOYER</td>
<td>7 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 PM</td>
<td></td>
</tr>
</tbody>
</table>
All meetings and activities will take place at the Marriott Wardman Park Hotel in Washington, DC, USA, unless otherwise specified. All papers will be presented in English. Please check the ISHLT website (www.ishlt.org) for updates.

This Final Program reflects the latest session schedule and room assignments.

8:00 AM - 10:00 PM
Exhibit Hall Build
(Exhibit Hall A)

9:00 AM - 5:00 PM
ISHLT Strategic Planning Meeting
(Delaware Suite)

6:00 PM - 9:00 PM
Academy Registration Open
(Convention Registration)

Speaker Ready Room Open
(Madison)
6:00 AM - 7:00 PM
Speaker Ready Room Open
(Madison)

7:00 AM - 3:00 PM
Academy Registration Open
(Convention Registration)

8:00 AM - 2:00 PM
ISHLT Board of Directors Meeting
(Harding)

8:00 AM - 6:00 PM
ISHLT Academy:
Core Competencies in Heart Failure and Cardiac Transplant Medicine
(Thurgood Marshall North)

ISHLT Academy:
Core Competencies in Mechanical Circulatory Support
(Thurgood Marshall East)

ISHLT Academy:
Master Class in Pulmonary Transplantation
(Thurgood Marshall South & West)

9:00 AM - 11:00 AM
Airway Guidelines Writing Group Meeting
(Balcony B)

12:00 PM - 2:00 PM
I2C2 Asia Meeting
(Balcony A)
2:00 PM - 6:00 PM
ISHLT Board/Committee/Council Leadership Orientation
(Hoover)

2:00 PM - 7:00 PM
Registration Open
(Convention Registration)

5:00 PM - 7:00 PM
Press Office Open
(Park Tower 8219)

6:00 PM - 8:00 PM
I2C2 Committee Meeting
(Balcony A)
Education Committee Meeting
(Balcony B)
Grants & Awards Committee Meeting
(Park Tower 8212)
International Transplant Registry Committee Meeting
(Park Tower 8217)
Standards and Guidelines Committee Meeting
(Park Tower 8216)

6:00 AM - 7:00 PM
Speaker Ready Room Open
(Madison)

7:00 AM - 7:00 PM
Registration Open
(Convention Registration)
Wednesday · April 27

7:00 AM - 10:00 AM
Exhibitor Set-Up  
(Exhibit Hall A)
Poster Session 1 Mount  
(Exhibit Hall B & C)

8:00 AM - 10:00 AM
Pre-Meeting Symposium 01:  
Anticoagulation and MCS: Can We Do Better?  
(Salons 2-3)  
(MCS, HF, PHARM)

Pre-Meeting Symposium 02:  
Controversies in Heart Transplantation: Past, Present and Future  
(Thurgood Marshall)  
(HTX, HF, ID, NHSAH, PATH, PEDS, PHARM)

Pre-Meeting Symposium 03:  
Current Innovations and Future of EVLP  
(Salon 1)  
(LTX, LF, MCS)

Pre-Meeting Symposium 04:  
Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease  
(Maryland Suite)  
(PH, HF, LF, LTX)

Pre-Meeting Symposium 05:  
Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective  
(Virginia Suite)  
(HTX, HF, MCS, NHSAH, PEDS)
Pre-Meeting Symposium 06:  
*Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?*  
(Delaware Suite)  
(ALL)

Pre-Meeting Symposium 07:  
*The Future is Here: Emerging Issues in Infectious Disease*  
(Washington Ballroom 2)  
(ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM)

9:00 AM - 10:30 AM  
*Smithsonian Curators Meeting*  
(Capitol Boardroom)

9:00 AM - 7:00 PM  
*Press Office Open*  
(Park Tower 8219)

10:00 AM - 7:00 PM  
*Exhibit Hall Open*  
(Exhibit Hall A)  
*Poster Hall Open*  
(Exhibit Hall B & C)

10:00 AM - 10:15 AM  
*Coffee Break*  
(Exhibit Hall A)  
*View Posters*  
(Exhibit Hall B & C)

10:15 AM - 12:15 PM  
Pre-Meeting Symposium 08:  
*Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart - International Perspectives on MCS Issues*  
(Salons 2-3)  
(MCS, HF, HTX, NHSAH)
Pre-Meeting Symposium 09:
Donor Heart Selection: Strategies to Improve Organ Utilization
(Thurgood Marshall)
(HTX, LTX, MCS, NHSAH, PEDS)

Pre-Meeting Symposium 10:
Joint ISHLT/ESC Symposium: Left, Right and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)
(Salon 1)
(PH, ALL)

Pre-Meeting Symposium 11:
Multiorgan Transplantation for Lung Recipients: When is Two Better than One?
(Maryland Suite)
(LTX, HTX)

Pre-Meeting Symposium 12:
It’s All in the Translation: CMV from Bedside to Bench and Back Again
(Virginia Suite)
(ALL)

Pre-Meeting Symposium 13:
Child’s Play: Infectious Risk After Transplant During Everyday Life
(Delaware Suite)
(PEDS, HTX, ID, LTX, NHSAH, PHARM)

Pre-Meeting Symposium 14:
Genomics: What Do I Have to Know and How Will It Affect My Practice?
(Washington Ballroom 2)
(NHSAH, BSI, HF, HTX, LTX)
12:15 PM - 1:45 PM

**Lunch Break**

*Junior Faculty and Mentor Lunch Meeting*
  (Wilson)

*IMACS Registry Committee Meeting*
  (Taft)

*Basic Science and Translational Research Scientific Council Meeting*
  (Hoover)

*Nursing, Health Sciences and Allied Health Scientific Council Meeting*
  (Washington Ballroom 2)

*Pharmacy and Pharmacology Scientific Council Meeting*
  (Harding)

*DCD Registry Committee Meeting*
  (Taylor)

*US Heart Allocation Proposal Working Group Meetings (ISHLT/UNOS)*
  (Balcony B, Jackson, Jefferson)

1:45 PM - 3:45 PM

**Pre-Meeting Symposium 15:**

*Achilles Heel: Infectious Complications in MCS*
  (Salons 2-3)
  *(MCS, HTX, ID, NHSAH, PHARM)*

**Pre-Meeting Symposium 16:**

*When Right is Wrong! Management of the Dying Right Ventricle*
  (Thurgood Marshall)
  *(ALL)*

**Pre-Meeting Symposium 17:**

*The Biology of Aging and Lung Transplantation*
  (Salon 1)
  *(LTX, ID, LF, MCS, NHSAH, PH)*
Pre-Meeting Symposium 18:  
Proximal, Distal, Balloons and Scalpels: Current Issues in CTEPH  
(Maryland Suite)  
(PH, HF, LF, PEDS)

Pre-Meeting Symposium 19:  
Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates  
(Virginia Suite)  
(NHSAH, HF, HTX, LTX, MCS)

Pre-Meeting Symposium 20:  
Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation  
(Delaware Suite)  
(ALL)

Pre-Meeting Symposium 21:  
Unraveling “Chronic Rejection” in the Heart  
(Washington Ballroom 2)  
(PATH, BSI, HF, HTX, LTX, PEDS)

3:45 PM - 4:00 PM  
Coffee Break  
(Exhibit Hall A)

View Posters  
(Exhibit Hall B & C)

4:00 PM - 6:00 PM  
Pre-Meeting Symposium 22:  
Great Debates in MCS  
(Salons 2-3)  
(MCS, HF, HTX, NHSAH)
Pre-Meeting Symposium 23:
A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR
(Thurgood Marshall)
-HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM

Pre-Meeting Symposium 24:
Endotypes of CLAD and Novel Treatment Strategies
(Salon 1)
-LTX, BSI, PATH, PEDS

Pre-Meeting Symposium 25:
Inflammation and Altered Metabolism in Pulmonary Hypertension
(Maryland Suite)
-PH, ALL

Pre-Meeting Symposium 26:
Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection
(Virginia Suite)
-ALL

Pre-Meeting Symposium 27:
VAD in Patients with Congenital Heart Disease
(Delaware Suite)
-PEDS, HF, HTX, MCS, NHSAH, PH

Pre-Meeting Symposium 28:
Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016
(Washington Ballroom 2)
-PHARM, HF, HTX, ID, MCS, NHSAH
6:00 PM - 7:00 PM
Exhibit Hall Grand Opening Reception
(Exhibit Hall A)

Poster Session 1
(Exhibit Hall B & C)
(ALL)

EUROMACS Meeting
(Park Tower 8205)

6:00 PM - 9:00 PM
Pulmonary AMR Working Group Meeting
(Park Tower 8216)

7:00 PM – 7:30 PM
Poster Session 1 Removal
(Exhibit Hall B & C)

7:00 PM - 10:00 PM
ICCAC Annual Meeting
(Virginia Suite)
7:00 AM - 7:00 PM
Registration Open
(Convention Registration)

Speaker Ready Room Open
(Madison)

7:00 AM - 10:00 AM
Poster Session 2 Mount
(Exhibit Hall B & C)

7:00 AM - 8:00 AM
Junior Faculty and Trainees Council Meeting
(Harding)

7:00 AM - 10:00 AM
UNOS Heart Allocation Policy Discussions
(Delaware)

8:00 AM - 10:00 AM
Opening Plenary Session:
Transplantation: Where Does the Science End and the Art Begin?
(Salon 1-3)
(ALL)

9:00 AM - 7:00 PM
Press Office Open
(Park Tower 8219)

10:00 AM - 7:00 PM
Exhibit Hall Open
(Exhibit Hall A)

Poster Hall Open
(Exhibit Hall B & C)

10:00 AM - 10:30 AM
Coffee Break
(Exhibit Hall A)

View Posters
(Exhibit Hall B & C)
10:30 AM - 12:00 PM

Concurrent Session 01:
Too Much of a Bad Thing?
Complications after Mechanical Support
(Salon 1-3)
(MCS, HF, ID, NHSAH)

Concurrent Session 02:
On the Road to Recovery:
Treating Chronic Heart Failure with Mechanical Support
(Thurgood Marshall)
(MCS, BSI, HF, LBCS)

Concurrent Session 03:
Donor Organ Allocation and Management – What’s Hot and New?
(Maryland Suite)
(LTX, BSI, EEP, ID, LBCS, NHSAH, PEDS, PHARM)

Concurrent Session 04:
Keep It Down: New Insights on Immunosuppression
(Virginia Suite)
(HTX, ID, LBCS, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 05:
Improving Heart Failure Outcomes with Pills, Procedures and Sex
(Delaware Suite)
(HF, MCS, NHSAH, PHARM)

Concurrent Session 06:
Pediatric Heart Transplant Outcomes
(Washington Ballroom 2)
(PEDS, HTX, NHSAH)
12:00 PM - 1:00 PM

IPLTC Meeting
(Park Tower 8212)

12:00 PM - 2:00 PM

Lunch Break

ID Symposium Working Group Meeting
(Park Tower 8205)

JHLT Editorial Board Lunch Meeting
(Wilson)

Mechanical Circulatory Support Scientific Council Meeting
(Delaware Suite)

Pathology Scientific Council Meeting
(Harding)

Pulmonary Hypertension Scientific Council Meeting
(Washington Ballroom 1)

Pulmonary Transplantation Scientific Council Meeting
(Washington Ballroom 2)

2:00 PM - 3:30 PM

Concurrent Session 07:
It’s Tough to Make Predictions, Especially About the Future: Outcomes in MCS
(Salons 2-3)
(MCS, HTX, NHSAH)

Concurrent Session 08:
Quality Over Quantity?
Quality of Life in MCS
(Thurgood Marshall)
(MCS, EEP, NHSAH)
Concurrent Session 09:  
*Rolling the Dice: Risk Prediction in Cardiac Transplantation*  
[Salon 1]  
[HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM]

Concurrent Session 10:  
*The Frailty Construct and Body Composition – Impact on Lung Transplant Outcomes*  
[Maryland Suite]  
[LTX, NHSAH, PEDS, PHARM]

Concurrent Session 11:  
*The Heartbreak of Rejection: All Against the Graft*  
[Virginia Suite]  
[HTX, BSI, NHSAH, PATH, PEDS, PHARM]

Concurrent Session 12:  
*Pediatric Lung Transplantation*  
[Delaware Suite]  
[PEDS, LTX]

Concurrent Session 13:  
*Philip K. Caves Award Candidate Presentations*  
[Washington Ballroom 2]  
[ALL]

Symposium 29:  
*Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH*  
[Washington Ballroom 1]  
[PH, BSI, LF, LTX, NHSAH, PHARM]
3:30 PM - 4:00 PM

Coffee Break
[Exhibit Hall A]

View Posters
[Exhibit Hall B & C]

2017 Symposium Planning Committee Meeting
(Harding)

4:00 PM - 5:30 PM

Concurrent Session 14:

*Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS*
[Salons 2-3]
[MCS, HF]

Concurrent Session 15:

*Let’s Be Specific: Donor Specific Antibodies – Challenges Ahead*
[Thurgood Marshall]
[HTX, BSI, ID, MCS, PATH, PEDS, PHARM]

Concurrent Session 16:

*Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction*
[Salon 1]
[LTX, BSI, LBCS, PEDS, PHARM]

Concurrent Session 17:

*Pediatric Mechanical Circulatory Support*
[Maryland Suite]
[PEDS, MCS]

Concurrent Session 18:

*Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance*
[Virginia Suite]
[BSI, HTX, LTX]
Concurrent Session 19:  
**Improving Outcomes: Body and Soul**  
(Delaware Suite)  
(NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH)

Concurrent Session 20:  
**Condemnatory or Commendatory Effects of Thoracic Transplantation**  
(Washington Ballroom 2)  
(EEP, HF, HTX, LTX, MCS, NHSAH)

5:30 PM - 6:00 PM  
**Coffee Break**  
(Exhibit Hall A)  
**View Posters**  
(Exhibit Hall B & C)

6:00 PM - 7:00 PM  
**Mini Oral 01:**  
*Science, Surgery and Shock in MCS*  
(Thurgood Marshall)  
(MCS, BSI, HTX, NHSAH)

**Mini Oral 02:**  
*Donor Dilemmas in Heart Transplantation*  
(Salon 1)  
(HTX, ID, NHSAH, PATH, PEDS, PHARM)

**Mini Oral 03:**  
*Candidate and Recipient Management in Heart Transplantation*  
(Maryland Suite)  
(HTX, ID, NHSAH, PATH, PEDS, PHARM)
Mini Oral 04:  
Donor and Recipient Management in Lung Transplantation  
(Virginia Suite)  
(LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM)

Mini Oral 05:  
Pediatrics: Organ Support and Transplantation  
(Delaware Suite)  
(PEDS, LBCS, HTX)

Mini Oral 06:  
Pharmacy & Pharmacology and Mechanical Circulatory Support  
(Washington Ballroom 2)  
(PHARM, HTX, ID, LTX, MCS)

Wine & Cheese Reception  
(Exhibit Hall A)

Poster Session 2  
(Exhibit Hall B & C)  
(ALL)

Past Presidents Council Meeting  
(Harding)

7:00 PM – 7:30 PM  
Poster Session 2 Removal  
(Exhibit Hall B & C)

7:00 PM - 9:00 PM  
AMR Inflammatory Burden Multicenter Study  
(Park Tower 8216)
6:00 AM - 7:00 PM
Speaker Ready Room Open
(Madison)

7:00 AM - 7:00 PM
Registration Open
(Convention Registration)

7:00 AM - 10:00 AM
Poster Session 3 Mount
(Exhibit Hall B & C)

7:00 AM - 8:00 AM
Sunrise Symposium 01:
MCS Challenges and Engineering Solutions
(Thurgood Marshall)
(MCS, HF, HTX, NHSAH)

Sunrise Symposium 02:
Timing Support in Cardiogenic Shock: When to Move Forward
(Salon 1)
(ALL)

Sunrise Symposium 03:
Thoracic Organ Transplantation and Malignancy
(Maryland Suite)
(LTX, HF, HTX, LF, NHSAH, PEDS, PHARM)

Sunrise Symposium 04:
Let’s Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease
(Virginia Suite)
(PH, LTX, NHSAH, PEDS)
Sunrise Symposium 05:
*Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology*
[Delaware Suite]
[ALL]

Sunrise Symposium 06:
*The Fly in the Ointment: Nosocomial Infections*
[Washington Ballroom 2]
[ID, ALL]

8:00 AM - 10:00 AM
***Plenary Session:***
*Where is the Future for Innovation?*
[Salons 2-3]
[ALL]

9:00 AM - 7:00 PM
***Press Office Open***
[Park Tower 8219]

10:00 AM - 4:00 PM
***Exhibit Hall Open***
[Exhibit Hall A]

10:00 AM - 7:00 PM
***Poster Hall Open***
[Exhibit Hall B & C]

10:00 AM – 10:30 AM
***Annual Business Meeting***
[Salons 2-3]

Coffee Break
[Exhibit Hall A]

View Posters
[Exhibit Hall B & C]
10:30 AM - 12:00 PM

Concurrent Session 21:
*Pimp My Pump: Novel MCS Design and Management*  
(Salons 2-3)  
(MCS, HF, NHSAH)

Concurrent Session 22:
*What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS*  
(Thurgood Marshall)  
(MCS, HF, NHSAH, PHARM)

Concurrent Session 23:
*Choosing a Gift: Donor Selection*  
(Salon 1)  
(HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 24:
*What’s New in Primary Graft Dysfunction Post Lung Transplantation*  
(Virginia Suite)  
(LTX, BSI, ID, LBCS, NHSAH, PEDS, PHARM)

Concurrent Session 25:
*Beyond Adherence: What’s New Out There?*  
(Delaware Suite)  
(NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

Concurrent Session 26:
*Mechanisms of AMR: Can We Protect The Body From The Anti-Body?*  
(Washington Ballroom 2)  
(BSI, HTX, LTX, MCS, PEDS)
Symposium 30:
JHLT at ISHLT: The Year in a Capsule
(Maryland Suite)
(ALL)

11:00 AM - 12:00 PM
Registries and Databases Committee Meeting
(Taft)

12:00 PM - 12:30 PM
Lung Quality of Life Workforce Meeting
(Wilson)

12:00 PM - 2:00 PM
Lunch Break

Heart Failure and Transplantation Scientific Council Meeting
(Delaware Suite)

Infectious Diseases Scientific Council Meeting
(Hoover)

Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting
(Washington Ballroom 2)

IMACS Users Group Meeting
(Harding)

Lung Transplant Benefits Guidelines Working Group
(Wilson)

12:15 PM - 1:30 PM
Women in Transplantation Networking Meeting
(Salon 1)

1:00 PM - 2:00 PM
I2C2 Latin American Meeting
(Balcony A)

Pulmonary AMR Working Group Meeting
(McKinley)
Concurrent Session 27:
*Are Two Pumps Better Than One? RV Failure and MCS*
(Salons 2-3)
(MCS, HF, NHSAH, PH)

Concurrent Session 28:
*Pump Thrombosis: What’s Hot with the Clot*
(Thurgood Marshall)
(MCS, HF, NHSAH)

Concurrent Session 29:
*The Dark Side of Heart Transplant: Living With CAV*
(Salon 1)
(HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 30:
*What You Need to Know About Donors and Early Outcome Following Lung Transplantation*
(Maryland Suite)
(LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 31:
*Pediatric Early Post Transplant Problems*
(Virginia Suite)
(PEDS, HTX, MCS)

Concurrent Session 32:
*Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring and Treatment*
(Delaware Suite)
(ID, HTX, LTX, MCS, NHSAH)
Concurrent Session 33:
“A Bipartisan Effort:” Antibodies and Complement in Heart and Lung Allografts
(Washington Ballroom 2)
(PATH, BSI, HF, HTX, LTX, PEDS)

Symposium 31:
Performing Under Pressure: Lung Transplantation in PH and PAH
(Washington Ballroom 1)
(PH, ALL)

3:30 PM – 4:00 PM
Coffee Break
[Exhibit Hall A]

View Posters
[Exhibit Hall B & C]

4:00 PM - 5:30 PM
Concurrent Session 34:
How Much is Too Much? Assessing Risk Prior to MCS
(Salons 2-3)
(MCS, HTX, NHSAH)

Concurrent Session 35:
Too Thick or Too Thin? Assessing Anticoagulation in MCS
(Thurgood Marshall)
(MCS, HF, NHSAH, PHARM)

Concurrent Session 36:
Is It Really A Wonderful Life? Problems Post Heart Transplant
(Salon 1)
(HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)
Concurrent Session 37:
Prognostic Variables Associated with CLAD Onset and Progression
(Maryland Suite)
(LTX, BSI, ID, NHSAH, PEDS, PHARM)

Concurrent Session 38:
New Insights in Pulmonary Hypertension
(Virginia Suite)
(PH, BSI, HF, HTX, LTX, MCS, PEDS, PHARM)

Concurrent Session 39:
Junior Faculty and Trainee Council's Clinical Case Dilemmas: The Best of the Best
(Delaware Suite)
(ALL)

Concurrent Session 40:
Too Much of a Good Thing: Balancing Benefit and Medication Complexity
(Washington Ballroom 2)
(PHARM, HTX, ID, LTX, MCS, NHSAH)

5:30 PM – 6:00 PM
Coffee Break
(Exhibit Hall A)

View Posters
(Exhibit Hall B & C)

5:30 PM – 6:30 PM
NHSAH Psychosocial Guidelines Writing Group
(Park Tower 8216)
6:00 PM - 7:00 PM

Mini Oral 07:  
Patient Management and Outcomes in MCS  
(Thurgood Marshall)  
(MCS, HF, NHSAH)

Mini Oral 08:  
Technology, Physiology and Complications in MCS  
(Salon 1)  
(MCS, HTX, NHSAH)

Mini Oral 09:  
Risk Factors and Lung Transplant Outcomes  
(Maryland Suite)  
(LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM)

Mini Oral 10:  
Heart Transplantation and Heart Failure  
(Virginia Suite)  
(HTX, BSI, LTX, NHSAH, PATH, PEDS, PHARM)

Mini Oral 11:  
Models in Transplantation: From Mouse to Rat to Pig to Human  
(Delaware Suite)  
(BSI, HTX, LTX, MCS)

Mini Oral 12:  
Applied Health Research and Pulmonary Hypertension  
(Washington Ballroom 2)  
(NHSAH, EEP, HTX, LTX, MCS, PEDS)
Wine & Cheese Reception
(Exhibit Hall A)

Poster Session 3
(Exhibit Hall B & C)
(ALL)

7:00 PM – 7:30 PM
Poster Session 3 Removal
(Exhibit Hall B & C)

8:00 PM - 9:30 PM
President’s Cocktail Reception
(Smithsonian National Museum of Natural History)
7:00 AM - 5:00 PM
Speaker Ready Room Open
(Madison)

7:00 AM - 11:00 AM
Registration Open
(Convention Registration)

7:00 AM - 8:00 AM
Sunrise Symposium 07:
Clear as Mud: Assessing the Right Ventricle
(Thurgood Marshall)
(MCS, ALL)

Sunrise Symposium 08:
Rethinking Valvular Disease in Heart Failure
(Maryland Suite)
(HF, HTX, MCS, NHSAH, PEDS, PH)

Sunrise Symposium 09:
Lung Transplant Benefit is More Than Just Survival
(Virginia Suite)
(LTX, ALL)

Sunrise Symposium 10:
Ambulatory ECMO in Adults: We Like to Move It, Move It
(Delaware Suite)
(NHSAH, HF, HTX, LTX, MCS)

Sunrise Symposium 11:
Controversies in Pediatric Heart Failure
(Washington Ballroom 2)
(PEDS, HF, HTX, NHSAH, PHARM)
Sunrise Symposium 12:  
*Precision Medicine in Transplantation: Drug Levels and Beyond*  
(Washington Ballroom 1)  
(ALL)

7:45 AM - 9:45 PM  
*Committee/Council Reports to Board*  
(Harding)

8:00 AM - 9:30 AM  
**Concurrent Session 41:**  
*You Get Out What You Put In: Assessing Risk in Mechanical Support*  
(Thurgood Marshall)  
(MCS, HTX, NHSAH)

**Concurrent Session 42:**  
*Difficult Decisions in Mechanical Support*  
(Maryland Suite)  
(MCS, HTX, NHSAH)

**Concurrent Session 43:**  
*Paying the Tolls: Effects of Bridge to Transplant*  
(Virginia Suite)  
(HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

**Concurrent Session 44:**  
*Lung Transplantation – Advanced Diagnostics!*  
(Delaware Suite)  
(LTX, BSI, NHSAH, PATH, PEDS, PHARM)
Concurrent Session 45:  
**Pediatric Heart Failure**  
(Washington Ballroom 2)  
(PEDS, HF, HTX)

Concurrent Session 46:  
**From ‘Jeans’ to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics**  
(Washington Ballroom 1)  
(BSI, HF, HTX, LTX, MCS)

9:30 AM – 9:45 AM  
**Coffee Break**  
(Convention Registration)

9:45 AM - 11:45 AM  
**Plenary Session:**  
*Pushing New Scientific Frontiers: It’s In Our Heritage*  
(Thurgood Marshall)  
(ALL)

11:45 AM – 12:00 PM  
**Coffee Break**  
(Convention Registration)
Concurrent Session 47: 
Medicines or Machines? The Failing Right Ventricle in MCS  
(Thurgood Marshall)  
(MCS, HF, NHSAH, PH)

Concurrent Session 48:  
Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient  
(Maryland Suite)  
(MCS, HTX, NHSAH)

Concurrent Session 49:  
My Heart Is Broken: Primary Graft Dysfunction and Early Problems  
(Virginia Suite)  
(HTX, BSI, ID, MCS, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 50:  
Recipient Factors and Outcome After Lung Transplantation – Are We Getting It Right?  
(Delaware Suite)  
(LTX, BSI, ID, NHSAH, PATH, PHARM)

Concurrent Session 51:  
Heart Failure Risk Prediction: From Molecules to Mechanism  
(Washington Ballroom 2)  
(HF, BSI, HTX, NHSAH)

Concurrent Session 52:  
Factors Determining Outcomes in Pulmonary Hypertension  
(Washington Ballroom 1)  
(PH, BSI, HF, LTX, PEDS, PH, PHARM)
12:00 PM - 6:00 PM
ISHLT Board of Directors Meeting
(Harding)

12:00 PM - 3:00 PM
Academy Registration Open
(Washington Foyer)

1:45 PM - 6:30 PM
ISHLT Academy: Master Class in Mechanical Circulatory Support
(Washington Ballroom 1 & 2)
2016 SCIENTIFIC SESSIONS PROGRAM
8:00 AM - 10:00 AM

Pre-Meeting Symposium 01:  

**Anticoagulation and MCS: Can We Do Better?**  
(Salons 2-3)  
(MCS, HF, PHARM)

CHAIRS: Michael A Shullo, PharmD and Sanem Nalbantgil, MD

8:00 AM  
**Too Thick or Too Thin?**  
*Bleeding and Thrombosis in MCS*  
Ulrich Jorde, MD, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

8:15 AM  
Q & A

8:20 AM  
**Pre-operative Genetic Screening for Coagulation Abnormalities and Impact on Post-operative Management**  
Douglas L. Jennings, PharmD, New York-Presbyterian Hospital, New York, NY, USA

8:35 AM  
Q & A

8:40 AM  
**Who Should Be Monitoring INR and How?**  
Anna L Meyer, MD, Leipzig Heart Center, Leipzig, Germany

8:55 AM  
Q & A

9:00 AM  
**Heparin Monitoring: Xa vs. aPTT**  
Christopher S. Hayward, MD, St. Vincent's Hospital, Sydney, Australia

9:15 AM  
Q & A

9:20 AM  
**Is There a Role for Antiplatelet Monitoring in MCS?**  
Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

9:35 AM  
Q & A

9:40 AM  
**Alternative Approaches to Recurrent Bleeding – Octreotide, Hormonal Therapy, Etc.**  
Nir Uriel, MD, University of Chicago, Chicago, IL, USA

9:55 AM  
Q & A
8:00 AM - 10:00 AM

Pre-Meeting Symposium 02:

Controversies in Heart Transplantation: Past, Present and Future

[Thurgood Marshall]

(HTX, HF, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Savitri E Fedson, MD and Eulalia Roig, MD

8:00 AM  
Back to Basics: Pharmacology & Pharmacodynamics of Immunosuppressants
Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

8:20 AM  
Putting it Together: Approaches to Immune Monitoring
Michael Pham, MD, Stanford University, Palo Alto, CA, USA

8:40 AM  
DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (PRO)
Stuart D Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

8:55 AM  
DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (CON)
Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

9:10 AM  
DEBATE REBUTTAL (PRO)
Stuart D. Russell, MD

9:15 AM  
DEBATE REBUTTAL (CON)
Howard Eisen, MD

9:20 AM  
The Future of Heart Transplant Immunosuppression: Something’s Old, Something’s New, Something’s Borrowed, Somebody’s Blue
David A Baran, MD, Newark Beth Israel, Newark, NJ, USA

9:40 AM  
PANEL DISCUSSION
Pre-Meeting Symposium 03:

Current Innovations and Future of EVLP
(Salon 1)
(LTX, LF, MCS)

CHAIRS: Christopher H. Wigfield, MD, FRCS and Jasleen Kukreja, MD, MPH

8:00 AM | The Future of Lung Repair - Drug and Molecular Interventions during EVLP
Christine L Lau, MD, University of Virginia, Charlottesville, VA, USA

8:15 AM | Q & A

8:20 AM | The Future of Lung Repair - Cell and Gene Interventions during EVLP
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

8:35 AM | Q & A

8:40 AM | The Future of Lung Preservation Techniques
Gregor Warnecke, MD, FRCSC, Hannover Medical School, Hannover, Germany

8:55 AM | Q & A

9:00 AM | EVLP as a Platform to Reduce Infection
John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

9:15 AM | Q & A

9:20 AM | Is Reduced Allo Responsiveness after EVLP a Reality? - Long Term Follow Up
Goran Dellgren, MD, PhD, Salgrenska University Hospital, Göteborg, Sweden

9:35 AM | Q & A

9:40 AM | DEBATE: My Clinical Program Needs an EVLP Service (PRO)
Frank d'Ovidio, MD, FRCS, Columbia University, New York, NY, USA

9:50 AM | DEBATE: My Clinical Program Needs an EVLP Service (CON)
David C McGiffin, MB, BS, FRACS, Alfred Hospital, Melbourne, Australia
8:00 AM - 10:00 AM

Pre-Meeting Symposium 04:

Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease

(Maryland Suite)

(PH, HF, LF, LTX)

CHAIRS: Oksana A. Shlobin, MD and Trevor J Williams, MD

8:00 AM  PH in ILD: Pathophysiology and Epidemiology
  John Granton, MD, University of Toronto, Toronto, ON, Canada

8:15 AM  Q & A

8:20 AM  Shrinking with Age: The Role of Telomerases in ILD and PH-ILD
  Leann Silhan, MD, Johns Hopkins School of Medicine, Baltimore, MD, USA

8:35 AM  Q & A

8:40 AM  Connective Tissue Disease PH-ILD: Which One Matters?
  Jerome Le Pavec, MD, Hôpital Marie Lannelongue, Le Plessis Robinson, France

8:55 AM  Q & A

9:00 AM  Sarcoid-associated Pulmonary Hypertension: An Enigma or a Run of the Mill Complication?
  Robert P Baughman, MD, University of Cincinnati, Cincinnati, OH, USA

9:15 AM  Q & A

9:20 AM  Impact of PH on Transplant Outcomes in ILD
  Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany

9:35 AM  Q & A

9:40 AM  Are PAH Specific Therapies Beneficial in PH-ILD?
  Steven Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

9:55 AM  Q & A
8:00 AM - 10:00 AM

Pre-Meeting Symposium 05: Making It Work: Heart Transplant Challenges from the Surgeon's Perspective

(Virginia Suite)

(HTX, HF, MCS, NHSAH, PEDS)

CHAIRS: Hannah Copeland, MD and Tahir Yagdi, MD

8:00 AM  Out of Time: Surgical Options for Late Graft Failure
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

8:20 AM  Surgical Management of Cardiac Primary Graft Dysfunction
Yoshifumi Naka, MD, Columbia University, New York, NY, USA

8:40 AM  When Great Vessels Go Bad Following Transplantation
Gregorio Rabago, MD, Clinica Universitaria Apartado, Pamplona, Spain

9:00 AM  Valvular Heart Disease after Heart Transplant
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

9:20 AM  Advanced Plumbing: How to Manage Complex Connections in Adult Congenital Heart Transplant Recipients
Jonathan M Chen, MD, Seattle Children's Hospital, Seattle, WA, USA

9:40 AM  PANEL DISCUSSION
8:00 AM - 10:00 AM

Pre-Meeting Symposium 06:

*Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?*

(Delaware Suite)

(ALL)

**CHAIRS:** Daniel Chambers, MBBS, MRCP, FRACP, MD and Lori J West, MD, D.Phil

---

8:00 AM  *Tissue Engineering for Dummies: How to Build a Heart or Lung*
Doris Taylor, PhD, Texas Heart Institute, Houston, TX, USA

8:15 AM  **Q & A**

8:20 AM  *Cell Therapy for the Failing Organ: Patch Up the Heart*
Eduardo Marban, MD, PhD, Cedars-Sinai, Los Angeles, CA, USA

8:35 AM  **Q & A**

8:40 AM  *Cell Manipulation for Transplant Tolerance*
Joren C. Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

8:55 AM  **Q & A**

9:00 AM  *Myeloid Cells to Induce Transplant Tolerance*
Angus Thomson, PhD, DSc, University of Pittsburgh, Pittsburgh, PA, USA

9:15 AM  **Q & A**

9:20 AM  *Stem Cells to Cure the Incurable: Treatment for Chronic Lung and Heart Allograft Dysfunction*
Sonja Schrepfer, MD, PhD, Stanford University Transplant and Stem Cell Immunobiology Lab [TSI], Stanford, CA, USA

9:35 AM  **Q & A**

9:40 AM  *Case Presentation: Back to the Future – Real Life Example of Cell Therapy and Tolerance in Lung Transplantation*
Alice L Gray, MD, Duke University Medical Center, Durham, NC, USA

9:45 AM  *Case-Based Discussion: Back to the Future – Real Life Example of Cell Therapy and Tolerance in Lung Transplantation*
Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
8:00 AM - 10:00 AM
Pre-Meeting Symposium 07: The Future is Here: Emerging Issues in Infectious Disease
(Washington Ballroom 2)
(ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM)

CHAIRS: Me-Linh Luong, MD and Denis Hadjiliadis, MD

8:00 AM Mycobacterium Abscessus and Friends
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

8:15 AM Q & A

8:20 AM RSV and the Paramyxoviruses: Should We Treat?
Peter M Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia

8:35 AM Q & A

8:40 AM The Unwelcome Guests: Strongyloides and Chagas Disease
Fernando Bacal, MD, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil

8:55 AM Q & A

9:00 AM The Fungus Among Us: Scedosporium and Other Emerging Fungi
Orla Morrissey, MD, Alfred Hospital, Melbourne, Australia

9:15 AM Q & A

9:20 AM Running Away With It: C. difficile and Norovirus
Ignacio Echenique, MD, Cleveland Clinic Florida, Weston, FL, USA

9:35 AM Q & A

9:40 AM The Coming Apocalypse: Resistant Gram negatives, B cepaciae, Achromobacter, Stenotrophomonas
Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

9:55 AM Q & A
Pre-Meeting Symposium 08:
Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart – International Perspectives on MCS Issues
(Salons 2-3)
(MCS, HF, HTX, NHSAH)

CHAIRS: Jennifer A. Beckman, MSN-FNP, RN, CHFN and Stephan Schueler, MD, PhD, FRCS

10:15 AM  Coordinator Perspective: Characteristics of a Successful MCS Program
Tonya I Elliott, MSN, RN, CCTC, CHFN, MedStar Washington Hospital Center, Washington, DC, USA

10:30 AM  Q & A

10:35 AM  Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away – The International Perspective
Desiree Robson, RN, BSc (Hons), St Vincent’s Hospital, Sydney, Australia

10:50 AM  Q & A

10:55 AM  Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away - The North American Perspective
Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, BC, Canada

11:10 AM  Q & A

11:15 AM  Collaborative Care in the ICU
Aly El Banayosy, MD, Nazih Zuhdi Transplant Institute, Oklahoma City, OK, USA

11:30 AM  Q & A

11:35 AM  Delivering Optimal Care While Reaching For Exceptional Outcomes - The North American Perspective
Carole Ballew, MSN, University of Virginia Health System, Charlottesville, VA, USA

11:50 AM  Q & A

11:55 AM  Delivering Optimal Care While Reaching For Exceptional Outcomes – The International Perspective
Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria

12:10 PM  Q & A
**10:15 AM - 12:15 PM**

**Pre-Meeting Symposium 09:**

*Donor Heart Selection: Strategies to Improve Organ Utilization*  
(Thurgood Marshall)  
(HTX, LTX, MCS, NHSAH, PEDS)

**CHAIRS:** Jon A. Kobashigawa, MD and Maria G Crespo-Leiro, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 AM</td>
<td><strong>US and European Donor Management Consensus Conferences: Key Messages to Improve Heart and Lung Utilization</strong></td>
<td>Kiran K Khush, MD, MAS, Stanford University, Stanford, CA, USA</td>
<td></td>
</tr>
<tr>
<td>10:35 AM</td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:39 AM</td>
<td><strong>Donor Management vs Organ Reconditioning: Lessons From Lung Transplantion</strong></td>
<td>Arne Neyrinck, MD, PhD, University Hospital Leuven, Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>10:59 AM</td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:03 AM</td>
<td><strong>Heart Allocation Score: Insights from Eurotransplant</strong></td>
<td>Jacqueline M Smits, MD, PhD, Eurotransplant International, Leiden, Netherlands</td>
<td></td>
</tr>
<tr>
<td>11:23 AM</td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:27 AM</td>
<td><strong>DCD Hearts: An Additional Resource or the Answer to the Donor Crisis?</strong></td>
<td>Kumud Dhital, MD, St Vincent’s Hospital, Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>11:47 AM</td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:51 AM</td>
<td><strong>Donor Risk Scores and Allocation Algorithms: Will Numbers Do Better than the Surgeon’s Basic Instinct?</strong></td>
<td>Abbas Ardehali, MD, University of California Los Angeles, Los Angeles, CA, USA</td>
<td></td>
</tr>
<tr>
<td>12:11 PM</td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pre-Meeting Symposium 10:
(in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)

Joint ISHLT/ESC Symposium: Left, Right and Together: The Facts and Future of PH in Left Heart Disease
(Salon 1)

(PH, ALL)

CHAIRS: Stavros Konstantinides, MD, PhD, FESC and Mardi Gomberg-Maitland, MD

10:15 AM Pulmonary Hypertension-Left Heart Disease: Defining Group 2 PH
Irene Lang, MD, Medical University of Vienna, Vienna, Austria

10:35 AM Is All Heart Failure the Same on the Pulmonary Circulation and How Does It Impact Survival?
Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy

10:55 AM Monitoring and Therapeutic Options for Pulmonary Hypertension in Left Heart Disease
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

11:15 AM Provocative Testing in Pulmonary Hypertension in Left Heart Disease
Robert Naeije, MD, Free University of Brussels, Brussels, Belgium

11:35 AM DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease
(PRO)
Jean-Luc Vachiery, MD, Erasme University Hospital – ULB, Brussels, Belgium

11:43 AM DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease
(CON)
Stephan Rosenkranz, MD, Herzszentrums der Universität zu Köln, Köln, Germany

11:51 AM DEBATE REBUTTAL
(PRO)
Jean-Luc Vachiery, MD

11:53 AM DEBATE REBUTTAL
(CON)
Stephan Rosenkranz, MD

11:55 AM A Challenging Case of Pulmonary Hypertension
Myung H. Park, MD, Houston Methodist, Houston, TX, USA

12:00 PM PANEL DISCUSSION
10:15 AM - 12:15 PM

**Pre-Meeting Symposium 11:**

*Multiorgan Transplantation for Lung Recipients: When is Two Better than One?*

(Maryland Suite)

(LTX, HTX)

**CHAIRS:** Peter M Hopkins, FRACP and Lianne G. Singer, MD, FRCPC

10:15 AM  
**Heart-Lung Transplantation is Dead – The Right Ventricle Will Remodel**  
Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

10:30 AM  
**Q & A**

10:35 AM  
**Combined Lung-Liver Transplantation – How Bad Does the Liver Have to Be?**  
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

10:50 AM  
**Q & A**

10:55 AM  
**Combined Lung-Liver Transplantation – Surgical Approach and Post-operative Management**  
John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

11:10 AM  
**Q & A**

11:15 AM  
**Combined Lung-Kidney Transplantation – What to Do with Vulnerable Kidneys Pre-lung Transplant?**  
Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

11:30 AM  
**Q & A**

11:35 AM  
**Ethics and Equity in Multi-Organ Transplantation**  
Edward J. Garrity, MD, MSc, The University of Chicago, Chicago, IL, USA

11:50 AM  
**Q & A**

11:55 AM  
**Is There an Allograft Combi Effect in Multi-Organ Transplantation?**  
Mark Greer, MB BCh, Hanover Medical School, Hannover, Germany

12:10 PM  
**Q & A**
10:15 AM - 12:15 PM

Pre-Meeting Symposium 12:

It’s All in the Translation: CMV from Bedside to Bench and Back Again

(Virginia Suite)

(ALL)

CHAIRS: Jutta K Preiksaitis, MD and Martin Zamora, MD

10:15 AM Be Still My Heart: CMV and CAV
Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain

10:35 AM Q & A

10:39 AM Breathless: CMV and CLAD
Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

10:59 AM Q & A

11:03 AM Measuring the Immune Response to CMV: Expanding Our Options
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

11:23 AM Q & A

11:27 AM The CMV Toolkit: What Do We Have Now?
Kyle L Dawson, PharmD, Houston Methodist, Houston, TX, USA

11:47 AM Q & A

11:51 AM The CMV Toolkit: What Is On the Horizon?
Robin K. Avery, MD, Johns Hopkins, Baltimore, MD, USA

12:11 PM Q & A
Pre-Meeting Symposium 13:

Child's Play: Infectious Risk After Transplant During Everyday Life
(Delaware Suite)
(PEDS, HTX, ID, LTX, NHSAH, PHARM)

CHAIRS: Debra A. Dodd, MD and Richard Kirk, FRCP, FRCPCH

10:15 AM Isolation – So Old Hat!
Michele Estabrook, MD, St. Louis Children's Hospital, St Louis, MO, USA

10:30 AM The Cystic Fibrosis Child – A Risk to their Transplanted Twin or Not?
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

10:45 AM Outbreak – Measles, Varicella and Mumps
Marian G. Michaels, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

11:00 AM Food and Water – Dangerous Stuff!
Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

11:15 AM You Ain't Nothing but a Hound Dog!
Nancy P Blumenthal, DNP, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

11:30 AM Can We Visit Grandma?
Lara Danziger-Isakov, MD, MPH, Children’s Hospital Medical Center, Cincinnati, OH, USA

11:45 AM PANEL DISCUSSION
10:15 AM - 12:15 PM

Pre-Meeting Symposium 14:

Genomics: What Do I Have to Know and How Will It Affect My Practice?
(Washington Ballroom 2)
(NHSAH, BSI, HF, HTX, LTX)

CHAIRS: Evan P Kransdorf, MD, PhD and Bernice L. Coleman, PhD, NP

10:15 AM Genomics: A Crash Course
Edward Cantu, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

10:45 AM Proteomic and Genomic Biomarkers of Allograft Injury: Coming Soon to a Lab Near You
Bruce McManus, MD, PhD, St. Paul's Hospital, Vancouver, BC, Canada

11:00 AM Differences in Minority Tacrolimus Levels: Would Genotyping Shed Light on Dosing?
Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

11:15 AM Behavioral Genetics: Is there a Future for Personalized Medicine to Support Patient Self-Management in Transplantation?
Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

11:30 AM It's Not All Smooth Sailing: Ethical Implications of Genomic Applications in Transplantation
Neal K Lakdawala, MD, Brigham & Women's Hospital, Boston, MA, USA

11:45 AM Emerging Age of Personal Medicine: Need for Genetic Nursing Competencies in Transplantation
Kathleen Calzone, PhD, APGN, FAAN, National Cancer Institute, Bethesda, MD, USA

12:00 PM PANEL DISCUSSION
1:45 PM - 3:45 PM

Pre-Meeting Symposium 15:

Achilles Heel: Infectious Complications in MCS
(Salons 2-3)
(MCS, HTX, ID, NHSAH, PHARM)

CHAIRS: Neil W. Wrightson, RN and Orla Morrissey, MD

1:45 PM  
**MCS Infection – What is the Scope of the Problem?**
Shashank S. Desai, MD, Inova Fairfax Hospital, Falls Church, VA, USA

2:00 PM  
**Q & A**

2:05 PM  
**Preventing DLI: Role of a Dressing Change Protocol**
Barbara Cagliostro, MSN, New York-Presbyterian/Columbia University, New York, NY, USA

2:20 PM  
**Q & A**

2:25 PM  
**If We Can’t See It, Does It Not Exist? Imaging Modalities for Diagnosis of MCSD Infections**
Stanley I. Martin, MD, Geisinger Health System, Danville, PA, USA

2:40 PM  
**Q & A**

2:45 PM  
**Approach to the MCSD Recipient with Bloodstream Infection**
Saima Aslam, MD, MS, University of California, San Diego, CA, USA

3:00 PM  
**Q & A**

3:05 PM  
**PANEL DISCUSSION**

3:25 PM  
**DEBATE: Device Infection, Thrombosis and CVA – It Is All Linked**  
(Pro)
Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

3:30 PM  
**DEBATE: Device Infection, Thrombosis and CVA – It Is All Linked**  
(Con)
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
1:45 PM - 3:45 PM

Pre-Meeting Symposium 16:

When Right is Wrong! Management of the Dying Right Ventricle
(Thurgood Marshall)
(HF, ALL)

CHAIRS: Teresa De Marco, MD and Daniel H. Kim, MD

1:45 PM Deconstructing the Right Ventricle: An Overview of RV Structure and Function, Mechanical, Electrical and Chemical Signaling
J. Eduardo Rame, MD, University of Pennsylvania, Philadelphia, PA, USA

2:02 PM Q & A

2:05 PM Peering Through the Looking Glass: Imaging the Right Ventricle
Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

2:22 PM Q & A

2:25 PM Finger on the Pulse: Hemodynamic Considerations in RV Failure
Ryan J Tedford, MD, Johns Hopkins University, Baltimore, MD, USA

2:42 PM Q & A

2:45 PM RV-PA Coupling in PAH: Can Medical Management Restore the Balance?
Rogerio Souza, MD, University of Sao Paulo, Sao Paulo, Brazil

3:02 PM Q & A

3:05 PM OR in the Morning: “Buffing” the Bad Right Ventricle
Vigneshwar Kasirajan, MD, Virginia Commonwealth University, Richmond, VA, USA

3:22 PM Q & A

3:25 PM Heterotopic Heart Transplant – What’s Old is What’s New Again!
Hannah Copeland, MD, Indiana University, Indianapolis, IN, USA

3:42 PM Q & A
Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation
(Salon 1)
(LTX, ID, LF, MCS, NHSAH, PH)

CHAIRS: John McDyer, MD and Tanya J. McWilliams, MD, PhD

1:45 PM Immunobiology of Aging in Lung Transplantation
Daniel R Goldstein, MD, Yale University, New Haven, CT, USA

2:00 PM Q & A

2:05 PM The Long and Short Of It: Telomerase Mutations and Implications for Lung Transplantation
Mary Armanious, MD, Johns Hopkins University, Baltimore, MD, USA

2:20 PM Q & A

2:25 PM Frailty is a Superior Measure of Age than Date of Birth
Jonathan Singer, MD, University of California, San Francisco, CA, USA

2:40 PM Q & A

2:45 PM Immunosuppressive Regimens Including CNI Sparing Protocols in the Elderly Lung Transplant Patient
Steven Ivulich, PharmD, Alfred Hospital, Melbourne, Australia

3:00 PM Q & A

3:05 PM Infectious Challenges in the Older Lung Transplant Recipient
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

3:20 PM Q & A

3:25 PM DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (PRO)
Erik A. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

3:35 PM DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (CON)
Steven Hays, MD, FRCPC, University of California, San Francisco, CA, USA
Pre-Meeting Symposium 18:

Proximal, Distal, Balloons and Scalpels: Current Issues in CTEPH

(Maryland Suite)

(CH, HF, LF, PEDS)

CHAIRS: William Auger, MD and Olaf Mercier, MD, PhD

1:45 PM - 3:45 PM

1:45 PM Epidemiology and Diagnosis of CTEPH: From Initial Insult to Elusive V/Q Scan
C. Dario Vizza, MD, University of Rome, Rome, Italy

2:05 PM Q & A

2:09 PM The Surgeon’s Paradise: Pre-operative Risk Stratification and Intra-operative Grading System of CTEPH
Michael M. Madani, MD, UCSD Medical Center, San Diego, CA, USA

2:29 PM Q & A

2:33 PM BPA vs PEA: Selection Criteria for the Appropriate Use of Balloon Pulmonary Angioplasty
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France

2:53 PM Q & A

2:57 PM Distal Disease: Who is a Surgical Candidate and Not?
Marc De Perrot, MD, University of Toronto, Toronto, ON, Canada

3:17 PM Q & A

3:21 PM CTEPH Thereafter: How to Define Residual PH After PEA?
Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

3:41 PM Q & A
1:45 PM - 3:45 PM

Pre-Meeting Symposium 19:

*Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates*

(Virginia Suite)

(NHSAH, HF, HTX, LTX, MCS)

**CHAIRS:** Michael G. Petty, PhD, RN, CNS and Michael A. McDonald, MD

1:45 PM  
*Case Presentation for DEBATE 1: You Can Go Your Own Way*
Michael A. McDonald, MD, Toronto General Hospital, Toronto, ON, Canada

1:50 PM  
**DEBATE 1: You Can Go Your Own Way (PRO)**
Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium

2:00 PM  
**DEBATE 1: You Can Go Your Own Way (CON)**
Luke J Burchill, MD, Oregon Health Sciences University, Portland, OR, USA

2:10 PM  
**PANEL DISCUSSION**

2:25 PM  
*Case Presentation for DEBATE 2: MCS: I Don’t Need Anyone’s Help!*
Finn Gustafsson, MD, PhD, ViCare Medical Rigshospitalet, Copenhagen, Denmark

2:30 PM  
**DEBATE 2: MCS: I Don’t Need Anyone’s Help! (PRO)**
Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

2:40 PM  
**DEBATE 2: MCS: I Don’t Need Anyone’s Help! (CON)**
Jeremy Kobulnik, MD, University of Toronto, Toronto, ON, Canada

2:50 PM  
**PANEL DISCUSSION**

3:05 PM  
*Case Presentation for DEBATE 3: Substance Use: It’s OK To Dabble*
Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA

3:10 PM  
**DEBATE 3: Substance Use: It’s OK To Dabble (PRO)**
Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

3:20 PM  
**DEBATE 3: Substance Use: It’s OK To Dabble (CON)**
Jay Baumwol, MBBS, FRACP, Royal Perth Hospital, Perth, Australia

3:30 PM  
**PANEL DISCUSSION**
Pre-Meeting Symposium 20:

**Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation**

(Delaware Suite) (ALL)

**CHAIRS:** Howard Eisen, MD and Glen P Westall, FRACP, PhD

**1:45 PM**  
**Why to Biobank? How It Has Advanced Our Understanding of Transplant Immunobiology?**  
Peter Heeger, MD, Mount Sinai Medical Center, New York, NY, USA

**2:00 PM**  
**Q & A**

**2:05 PM**  
**How to Biobank? Lessons Learned (The Hard Way)**  
Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

**2:20 PM**  
**Q & A**

**2:25 PM**  
**Big Data and Modeling: Turning Diversity Into Patient Care Benefit**  
Octavio Pajaro, MD, Mayo Clinic, Phoenix, AZ, USA

**2:40 PM**  
**Q & A**

**2:45 PM**  
**OMICS in Heart Transplant: Pumping Out x and Answers?**  
Hendrik Milting, PhD, Heart & Diabetes Center, Bad Oeynhausen, Germany

**3:00 PM**  
**Q & A**

**3:05 PM**  
**OMICS in Lung Transplant: Airing Out the Data**  
Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France

**3:20 PM**  
**Q & A**

**3:25 PM**  
**Turning Dream Into Reality: How Will Omics and Big Data Deliver Personalized Medicine?**  
Mario C. Deng, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

**3:40 PM**  
**Q & A**
### Pre-Meeting Symposium 21:

**Unraveling "Chronic Rejection" in the Heart**  
(Washington Ballroom 2)  
(PATH, BSI, HF, HTX, LTX, PEDS)

**CHAIRS:** Carmela D. Tan, MD and Martin J. Goddard, FRCS MRCPa

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:45 PM | **Beyond CAV: Immunopathology, Histopathology and Ultrastructural Pathology in “Chronic Rejection” of the Cardiac Allograft**  
Elizabeth H. Hammond, MD, LDS Hospital, Salt Lake City, UT, USA |
| 2:05 PM | **Q & A** 
| 2:09 PM | **Evidence for Local Antibody Production in Cardiac Allograft Vasculopathy**  
Manon Huibers, PhD, University Medical Center, Utrecht, Netherlands |
| 2:29 PM | **Q & A** 
| 2:33 PM | **Complement and Non-complement Mediated Mechanisms of Graft Injury and Their Role in “Chronic Rejection”**  
William M Baldwin, MD PhD, Cleveland Clinic, Cleveland, OH, USA |
| 2:53 PM | **Q & A** 
| 2:57 PM | **“Chronic Rejection” Elsewhere: Analogs and Lessons from the Transplanted Lung, Kidney and Liver**  
Martin J. Goddard, FRCS MRCPa, Papworth Hospital, Cambridge |
| 3:17 PM | **Q & A** 
| 3:21 PM | **Animal Models of Graft Vasculopathy – Evidence for Antibodies and Potential Therapeutic Targets**  
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany |
| 3:41 PM | **Q & A** |
4:00 PM - 6:00 PM

Pre-Meeting Symposium 22:

**Great Debates in MCS**

(Salons 2-3)

(MCS, HF, HTX, NHSAH)

CHAIRS: Eugene C DePasquale, MD and Steven SL Tsui, MD, FRCS

4:00 PM  
**Case Presentation for DEBATE 1:**  
Age > 70: Destination Therapy, Not Heart Transplant  
Sebastian V Rojas, MD, Hannover Medical School, Hannover, Germany

4:05 PM  
**DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant**  
(PRO)  
Andrew J. Boyle, MD, Piedmont Heart Institute, Atlanta, GA, USA

4:15 PM  
**DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant**  
(CON)  
Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

4:25 PM  
**DEBATE REBUTTAL (PRO)**  
Andrew J. Boyle, MD

4:30 PM  
**DEBATE REBUTTAL (CON)**  
Joseph G Rogers, MD

4:35 PM  
**Case Presentation for DEBATE 2:**  
INTERMACS 4-7: The Time is Now  
Brent C Lampert, DO, The Ohio State University Wexner Medical Center, Columbus, OH, USA

4:40 PM  
**DEBATE 2: INTERMACS 4-7: The Time is Now**  
(PRO)  
Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA

4:50 PM  
**DEBATE 2: INTERMACS 4-7: The Time is Now**  
(CON)  
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

5:00 PM  
**DEBATE REBUTTAL (PRO)**  
Jeffrey J. Teuteberg, MD

5:05 PM  
**DEBATE REBUTTAL (CON)**  
Daniel Zimpfer, MD

5:10 PM  
**Case Presentation for DEBATE 3:**  
Minimally Invasive Implantation is the Procedure of Choice  
Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria
5:15 PM  **DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (PRO)**  
Jan D. Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

5:30 PM  **DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (CON)**  
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

5:45 PM  **DEBATE REBUTTAL (PRO)**  
Jan D. Schmitto, MD, PhD, MBA

5:50 PM  **DEBATE REBUTTAL (CON)**  
Daniel J. Goldstein, MD
Pre-Meeting Symposium 23:

A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR

(Thurgood Marshall)

(HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Palak Shah, MD, MS and A. G. Kfoury, MD, FACC

4:00 PM  
It is Time to Move to Molecular Technologies for Detection of AMR
Elaine F Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

4:20 PM  
Q & A

4:24 PM  
Do We Need Both Histologic and Immunologic Features on Biopsy to Accurately Diagnose Antibody-Mediated Rejection?
Annalisa Angelini, MD, University of Padua, Padua, Italy

4:44 PM  
Q & A

4:48 PM  
What Drug Therapies, What Data for Refractory AMR?
Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

5:08 PM  
Q & A

5:12 PM  
What Immunologic Testing Features Suggest Clinically Significant Antibodies vs an Innocent Bystander?
Kathryn J Tinckam, MD, University Health Network, Toronto, ON, Canada

5:32 PM  
Q & A

5:36 PM  
Management of Antibodies in Heart Transplantation: Insights from 2016 Consensus Conference
Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

5:56 PM  
Q & A
Pre-Meeting Symposium 24:

Endotypes of CLAD and Novel Treatment Strategies

(Salon 1)

(LTX, BSI, PATH, PEDS)

CHAIRS: Tereza Martinu, MD and Stijn E Verleden, PhD

4:00 PM Current and Historical Evidence for Phenotyping of CLAD
Miranda Paraskeva, MBBS, Alfred Hospital, Melbourne, Australia

4:15 PM Q & A

4:20 PM CLAD Endotypes – Diagnosis, Radiology and Pathology
Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

4:35 PM Q & A

4:40 PM Contemporary Medical and Surgical Treatment Options for CLAD Phenotypes – Are All CLAD Patients Created Equal?
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

4:55 PM Q & A

5:00 PM Extracorporeal Photopheresis and Regulatory T cells – Role in CLAD?
Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

5:15 PM Q & A

5:20 PM Cell-Based Therapy for CLAD – Current Evidence and Future Prospects
Cesar Keller, MD, The Mayo Clinic, Jacksonville, FL, USA

5:35 PM Q & A

5:40 PM Future Perspectives: Prevention of CLAD – Why are We Failing and How to Improve?
Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA

5:55 PM Q & A
## 4:00 PM - 6:00 PM

### Pre-Meeting Symposium 25:

**Inflammation and Altered Metabolism in Pulmonary Hypertension**

*(Maryland Suite)*

*(PH, ALL)*

**CHAIRS:** Thenappan Thenappan, MD and John Granton, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:00 PM | **The Pathobiology of Inflammation in Pulmonary Hypertension**  
Marc Humbert, MD, Université Paris-Sud, Clamart, France |
| 4:15 PM | **Q & A**                                                                                                                                |
| 4:20 PM | **The Impact of Insulin Resistance in Pulmonary Hypertension**  
Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA |
| 4:35 PM | **Q & A**                                                                                                                                |
| 4:40 PM | **Inflammatory Cytokines And Their Role In Pulmonary Hypertension**  
Mark Nicolls, MD, Stanford University, Palo Alto, CA, USA |
| 4:55 PM | **Q & A**                                                                                                                                |
| 5:00 PM | **Alterations in Lipid Metabolism in Pulmonary Hypertension**  
Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA |
| 5:15 PM | **Q & A**                                                                                                                                |
| 5:20 PM | **MicroRNAs in Pulmonary Hypertension: Insights in Signaling Pathways**  
Lars Huber, MD, University Hospital of Zurich, Zurich, Switzerland |
| 5:35 PM | **Q & A**                                                                                                                                |
| 5:40 PM | **Neurohormonal and Metabolic Modulations for Improving Right Ventricular-Pulmonary Artery Coupling in PAH**  
Lisa M Mielniczuk, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada |
| 5:55 PM | **Q & A**                                                                                                                                |
Pre-Meeting Symposium 26:

**Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection**

(Virginia Suite) (ALL)

**CHAIRS:** Martha L. Mooney, MD, FACP and Kate Gould, FRCPaTH

**4:00 PM**  
*Donor Derived Infections: The European Perspective*  
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

**4:17 PM**  
Q & A

**4:20 PM**  
*Donor Derived Infections: The North American Perspective*  
Joanna M. Schaeeman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

**4:37 PM**  
Q & A

**4:40 PM**  
*The Infected Donor: Pre-transplant & Post-transplant Management*  
Phillip Zakowski, MD, Tower ID Medical Associates, Inc., Los Angeles, CA, USA

**4:57 PM**  
Q & A

**5:00 PM**  
*The Encephalitic Donor: A Cautionary Tale*  
Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

**5:17 PM**  
Q & A

**5:20 PM**  
*Playing the Odds: The ABCs of NAT for HIV, HCV and HBV in Increased Risk Donors*  
Michael G. Ison, MD MS, Northwestern Memorial Hospital, Chicago, IL, USA

**5:37 PM**  
Q & A

**5:40 PM**  
*The HIV-positive Donor: “Hope” or Havoc?*  
Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

**5:57 PM**  
Q & A
4:00 PM - 6:00 PM
Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease
(Delaware Suite)
(PEDS, HF, HTX, MCS, NHSAH)

CHAIRS: Angela Lorts, MD and Martin Schweiger, MD

4:00 PM VADs for Univentricular Circulation – Fact or Fiction?
Pirooz Eghtesady, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO, USA

4:15 PM Q & A

4:20 PM Can We Get VAD Patients Home?
Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada

4:35 PM Q & A

4:40 PM Collateral Damage From VADs – What Will Compromise Transplant Outcomes?
Kathleen Simpson, MD, Washington University and St. Louis Children’s Hospital, St. Louis, MO, USA

4:55 PM Q & A

5:00 PM ACHD Patients - Why Are They Different?
Leigh C. Reardon, MD, UCLA, Los Angeles, CA, USA

5:15 PM Q & A

5:20 PM DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (PRO)
David Crossland, MRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:30 PM DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (CON)
Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

5:40 PM PANEL DISCUSSION
Pre-Meeting Symposium 28:

Lifecyle Journey of Hepatitis C Heart Failure Patient in 2016
(Washington Ballroom 2)
(PHARM, HF, ID, MCS, NHSAH)

CHAIRS: Jerrica E Shuster, PharmD and Andreas Zuckermann, MD

4:00 PM  Case Presentation: Lifecycle Journey
Jerrica E Shuster, PharmD, Barnes-Jewish Hospital, St. Louis, MO, USA

4:04 PM  Hepatitis C Medications – New Armamentarium Has Arrived!
Adam B Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

4:21 PM  Lifecycle Journey Case Update
Jerrica E Shuster, PharmD

4:25 PM  Chronic Hepatitis C Candidate – Timing of Intervention
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

4:37 PM  Lifecycle Journey Case Update
Jerrica E Shuster, PharmD

4:41 PM  Immunosuppression - A Tricky Balance?
Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

4:58 PM  Lifecycle Journey Case Update
Jerrica E Shuster, PharmD

5:02 PM  Malignancies in Heart Transplant
Donna M. Mancini, MD, New York-Presbyterian Hospital, New York, NY, USA

5:19 PM  Lifecycle Journey Case Update
Jerrica E Shuster, PharmD

5:23 PM  Heavy is the Heart....
Deborah E. Meyers, MD, FRACP, FACC, Texas Heart Institute, Houston, TX, USA

5:45 PM  PANEL DISCUSSION
Opening Plenary Session –

Transplantation: Where Does the Science End and the Art Begin?

[Salon 1-3]

(ALL)

CHAIRS: Duane Davis, MD, MBA and Andrew J. Fisher, FRCP, PhD

8:00 AM Welcome/Program Chair Report
Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:05 AM Thoracic Registry Report
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

8:25 AM IMACS Registry Report
James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

8:35 AM [1] FEATURED ABSTRACT: HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure -1 Year Results from the CE Mark Trial

8:45 AM Expert Discussant Q & A
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

8:50 AM Introduction to Speaker
Reda E. Girgis, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

8:52 AM From Lung Transplant to Lincoln Center
Charity Tillemann-Dick, Soprano, Composer, Presenter, Washington, DC, USA

9:15 AM President’s Report
Duane Davis, MD, Florida Hospital, Orlando, FL, USA

9:30 AM Pioneer Award Recipient Lecture: The Quest for Effective Immunosuppression
Sir Roy Calne, FRCP, FRCS, FRS, Cambridge University, London, United Kingdom
10:30 AM - 12:00 PM

Concurrent Session 01:
Too Much of a Bad Thing?
Complications after Mechanical Support
[Salon 1-3]
[MCS, HF, ID, NHSAH]

CHAIRS: Michel Morshuis, MD and Chetan B Patel, MD

10:30 AM (2) Temporal Changes in Adverse Events in the ENDURANCE Trial
10:45 AM (3) Stroke with Continuous-Flow LVADs
11:00 AM (4) Hemorrhagic Transformation of Ischemic Strokes in Patients with Continuous Flow Left Ventricular Assist Devices
11:15 AM (5) Clinical Outcomes Reveal a Spectrum of Early Right Heart Failure after Left Ventricular Assist Device
11:30 AM (6) Incidence and Impact of Sustained Ventricular Arrhythmias after Continuous-Flow Left Ventricular Assist Device Implantation
11:45 AM (7) Device-Related Infection Rates of Continuous-Flow Ventricular Assist Devices Using a Thoracic Driveline Exit Site
10:30 AM - 12:00 PM

Concurrent Session 02:

On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support

(Thurgood Marshall)

(MCS, BSI, HF, LBCS)

CHAIRS: Martin Strueber, MD and Stavros G Drakos, MD

10:30 AM (8) LVAD Explantation for Cardiac Recovery: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support

10:45 AM (9) Association of Pre-Implant Inflammatory Profile and Functional Recovery with Chronic LVAD Unloading

11:00 AM (10) LVAD Support Is Associated with Reduced Serum VEGF-D Levels

11:15 AM (11) Relationship of Myocardial Fibrosis with the Potential of Mechanical Unloading to Induce Favorable Cardiac Structural and Functional Response

11:30 AM (12) Soluble ST2 Levels in End-Stage Heart Failure and during LVAD Support

11:45 AM (13) Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients with Left Ventricular Assist Devices
10:30 AM - 12:00 PM

Concurrent Session 03:

*Donor Organ Allocation and Management – What’s Hot and New?*

(Maryland Suite)

(LTX, BSI, EEP, ID, LBCS, NHSAH, PEDS, PHARM)

**CHAIRS:** Michael S Mulligan, M and Marc De Perrot, MD

10:30 AM (14) **Lung Allocation Score Does Not Reflect Post-Lung Transplant Outcome in a Use of Low Risk Donor**

10:45 AM (15) **Low Correlation in Longevity between Lung Grafts from the Same Donor**

11:00 AM (16) **‘Unacceptable’ Human Leukocyte Antigens in Lung Re-Transplantation**

11:15 AM (17) **Lung First vs. Liver First Sequence for Combined Lung and Liver Transplantation**

11:30 AM (18) **Single Center Results with Normothermic Ex Vivo Lung Perfusion: A Propensity Matched Analysis**

11:45 AM (19) **Mid and Long-Term Clinical Results of OCS Lung INSPIRE International Trial**
Concurrent Session 04: Keep It Down: New Insights on Immunosuppression
(Virginia Suite)
(HTX, ID, LBCS, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Mario C Deng, MD and Anique Ducharme, MD, MSC

10:30 AM (147) Induction Immunosuppression Strategies and Long-Term Outcomes after Heart Transplantation

10:45 AM (21) Outcomes with Gene Expression Profiling for Cardiac Transplant Recipients within North America

11:00 AM (22) The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy Assessed by Virtual Histology: Results of the SCHEDULE Trial

11:15 AM (23) Duration of Corticosteroid (CS) Use as Maintenance Immunosuppression and Long-Term Outcomes after Adult Heart Transplantation: A Contemporary Analysis of the International Society for Heart and Lung Transplantation (ISHLT) Registry

11:30 AM (24) Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks

11:45 AM (25) Molecular Correlates of Endothelial mTOR Activation in Heart Transplant Recipients
10:30 AM - 12:00 PM

Concurrent Session 05:

*Improving Heart Failure Outcomes with Pills, Procedures and Sex*

(Delaware Suite)

(HF, MCS, NHSAH, PHARM)

**CHAIRS:** Christopher S Hayward, MD and Jose Gonzalez-Costello, MD


10:45 AM (27) **Renal Response to Levosimendan in Patients Listed for Heart Transplantation Predicts Postoperative Renal Function Course**

11:00 AM (28) **Bilateral Sympathetic Denervation Improves Left Ventricular Function and Prevents Post-Infarction Chamber Remodeling in Rats**

11:15 AM (29) **Long-Term Adaptive Servo-Ventilator Treatment Prevents Cardiac Death and Improves Clinical Outcome in Patients with Advanced Heart Failure**

11:30 AM (30) **Laparoscopic Sleeve Gastrectomy: Safe and Effective in Heart Failure and LVAD Patients**

11:45 AM (31) **Bringing Sexy Back: Sexuality and Intimacy Concerns in an Advanced Heart Failure Population Receiving Palliative Care Consultation**
10:30 AM - 12:00 PM

Concurrent Session 06: 

**Pediatric Heart Transplant Outcomes**

(Washington Ballroom 2)

(PEDS, HTX, NHSAH)

**CHAIRS:** Richard E Chinnock, MD and Rakesh K Singh, MD, MS

**10:30 AM (32)** Health Related Quality of Life after Pediatric Heart Transplantation in Young Children

**10:45 AM (33)** Congenital Heart Disease and Severe Peri-Transplant Course Are Associated with Worse Neurocognitive Outcomes in Children Post-Heart Transplant

**11:00 AM (34)** Cancer Recurrence and Mortality After Pediatric Heart Transplantation for Anthracycline Cardiomyopathy

**11:15 AM (35)** Bacterial Infections in Pediatric Heart Transplant Recipients: Epidemiology, Risk Factors and Outcomes

**11:30 AM (36)** Number of Refusals for Donor Quality Does Not Impact Post-Transplant Outcomes in Pediatric Heart Transplantation

**11:45 AM (37)** Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: Coronary Stenting as a Prognostic Indicator
2:00 PM - 3:30 PM

Concurrent Session 07:  
*It's Tough to Make Predictions, Especially about the Future: Outcomes in MCS*  
(Salons 2-3)  
(MCS, HTX, NHSAH)

**CHAIRS:** James L Kirklin, MD and Jeffrey J Teuteberg, MD

**2:00 PM** (38) *Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients* (ROADMAP) – 2 Year Results

**2:15 PM** (39) *Insights from INTERMACS into Patient Characteristics Leading to Futility in LVAD Therapy*

**2:30 PM** (40) *An Updated Bayesian Model for Predicting Mortality in Continuous Flow-Left Ventricular Assist Device Patients*

**2:45 PM** (41) *Muscular Strength Predicts Functional Capacity in Left Ventricular Assist Device Supported Patients*

**3:00 PM** (42) *Long-Term Outcomes in Continuous-Flow Left Ventricular Assist Device Patients with and without ICD*

**3:15 PM** (43) *Impact of Morbid Obesity on Left Ventricular Assist Device Support and Heart Transplantation*
2:00 PM - 3:30 PM

Concurrent Session 08:

Quality Over Quantity?
Quality of Life in MCS
(Thurgood Marshall)
(MCS, EEP, NHSAH)

CHAIRS: Mary Amanda Dew, PhD and Brent C Lampert, DO

2:00 PM (44) Impact of Baseline Measures and Adverse Events on Functional Assessments in the ENDURANCE Destination Therapy Trial

2:15 PM (45) HRQOL Improves from Before to 2 Years After MCS, Regardless of Implant Strategy: Analyses from INTERMACS

2:30 PM (46) Reduced Anxiety and Depression in Patients with Advanced Heart Failure after Left Ventricular Assist Device Implantation

2:45 PM (47) Patient Reported Quality of Life with Mechanical Circulatory Support vs Continued Medical Therapy in Ambulatory Heart Failure Patients

3:00 PM (48) Caregiver Burden in Post-Ventricular Assist Device Patients

3:15 PM (49) Hospital Readmission during Left Ventricular Assist Device Support: Causes, Temporal Trends and Terminal Readmissions
2:00 PM - 3:30 PM

Concurrent Session 09:

Rolling the Dice: Risk Prediction in Cardiac Transplantation
(Salon 1)
(HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

CHAIRS: Donna M. Mancini, MD and Gregorio Rabago, MD

2:00 PM (50) Frailty Measures in Advanced Heart Failure Patients Listed for Transplantation

2:15 PM (51) Risk Stratification to Improve Transplant Benefit in Older Candidates: Are All Comorbidities Created Equal?

2:30 PM (52) Evaluating Hepatorenal Factors for Perioperative Transplant Mortality in Adult Congenital Heart Disease

2:45 PM (53) Influence of the MELD-XI (Model of End-Stage Liver Disease Excluding INR) on Heart Transplant Outcomes

3:00 PM (54) Reversibility of Frailty in Advanced Heart Failure Patients Listed for Transplantation

Concurrent Session 10:

**The Frailty Construct and Body Composition – Impact on Lung Transplant Outcomes**

(Maryland Suite)

(LTX, NHSAH, PEDS, PHARM)

**CHAIRS:** Joshua J Mooney, MD and Jonathan P Singer, MD, MS

**2:00 PM** (56) Frailty Score Predicts Death on the Waiting List, but Not Early Outcome Post Lung Transplantation (LTX)

**2:15 PM** (57) Frailty and Clinical Benefits with Lung Transplantation

**2:30 PM** (58) Improvement in Frailty Is Associated with Improved Disability in Lung Transplantation

**2:45 PM** (59) Change in Body Mass Index at Listing from Primary Transplant to Re-Transplantation Predicts Re-Transplant Survival

**3:00 PM** (60) Pectoralis Muscle Area Change Following Lung Transplantation Is Related to Underlying Disease

**3:15 PM** (61) Outcome in Age-Mismatched Lung Transplant Recipients
2:00 PM - 3:30 PM

Concurrent Session 11:

The Heartbreak of Rejection: All Against the Graft

(Virginia Suite)

(HTX, BSI, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Maryjane A Farr, MD and Kumud K Dhital, MD,PhD

2:00 PM (62) Capillary Damage and Fibrin in Heart Transplantation: Significant Impact on Survival with or without Rejection

2:15 PM (63) Role of Novel Cardiovascular Magnetic Resonance Based Tissue Characterization in the Detection of Cardiac Transplant Rejection

2:30 PM (64) Heart Transplantation without Routine Endomyocardial Biopsies Is Feasible: Experience with a Clinical-Echocardiographic Strategy

2:45 PM (65) Biomarkers Monitoring for Absence of Acute Allograft Rejection

3:00 PM (66) Initial Analysis of the Donor-Derived Cell-Free DNA – Outcomes AlloMap Registry (D-OAR) Study in Heart Transplant Recipients Undergoing Surveillance for Rejection

3:15 PM (67) Utility of Gene Expression (Allomap Score) in Antibody Mediated Rejection Detection
2:00 PM - 3:30 PM

**Concurrent Session 12:**

*Pediatric Lung Transplantation*

(Delaware Suite)

(*PEDS, LTX*)

**CHAIRS:** Carol K Conrad, MD and Stuart C Sweet, MD, PhD

2:00 PM (68) Are We Refusing Good Organs? Outcomes of Ventilator Management of Sub-Optimal Lung Donors

2:15 PM (69) Controlled Donation after Circulatory Death (DCD) Donors and Pediatric Lung Transplant (pLTx): Enhanced Opportunities and Excellent Outcomes

2:30 PM (70) Improved Waitlist and Transplant Outcomes for Pediatric Lung Transplantation After Implementation of the Lung Allocation Score

2:45 PM (71) Respiratory Viral Infections Are Common in the First Year After Pediatric Lung Transplantation: A Multi-Center Prospective Study

3:00 PM (72) Pediatric Lung Transplantation – 25 Year of Experience

3:15 PM (73) The Hard Truth: Outcomes of Adolescent Recipients Following Lung Transplantation
### Concurrent Session 13:

**Philip K. Caves Award Candidate Presentations**

(Washington Ballroom 2)

(ALL)

**CHAIRS:** John A. Belperio, MD and Sonja Schrepfer, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 PM</td>
<td>Increased Angiogenesis and Non-Surgical Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices Are Mediated by Thrombin-Induced Angiopoietin-2</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Feasibility of Detecting Fungal DNA in Exhaled Breath Condensate by the Luminex Multiplex xTAG Fungal PCR Assay in Lung transplant Recipients: A Pilot Study</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Graft-Infiltrating Neutrophils Cannibalize Dying Neutrophils to Produce IL-10 and to Protect Lung Transplants from Ischemia-Reperfusion Injury</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Clara Cell Secretory Protein Limits Small Airway Inflammation and Fibrosis Induced by De Novo Donor Specific Antibodies</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>Early CD20+ B Cell Depletion Attenuates Cardiac Allograft Vasculopathy in Anti-CD154 Treated Non-Human Primate Model</td>
</tr>
</tbody>
</table>
2:00 PM - 3:30 PM

Symposium 29:

**Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH**
(Washington Ballroom 1)
(PH, BSI, LF, LTX, NHSAH, PHARM)

**CHAIRS:** Paul A. Corris, MB BS FRCP and Myung H. Park, MD

**2:00 PM**  
*Combination Therapy in PAH: What Do The Clinical Trials Tell Us?*  
Paul A Corris, MBBS FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**2:20 PM**  
*The Differing Pharmacology Between Drugs in PDE5i and ERA Class and their Interactions*  
Martin Wilkins, MD, Imperial College, London, United Kingdom

**2:40 PM**  
*The Pharmacology of sGC Stimulators from Bench to Bedside, Single Therapy and In Combination*  
Ardeschir Ghofrani, MD, University of Giessen, Giessen, Germany

**3:00 PM**  
*Which Combinations and Upfront or Sequential When Treating PAH?*  
Mardi Gomberg-Maitland, MD, University of Chicago, Chicago, IL, USA

**3:20 PM**  
*PANEL DISCUSSION*
Concurrent Session 14:

Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS

(Salons 2-3)

(MCS, HF)

**CHAIRS:** Mark Slaughter, MD and Thomas Krabatsch, MD, PhD

4:00 PM (80) The Jarvik 2000: Results of the United States Bridge to Transplant Trial

4:15 PM (81) HeartMate 3 Left Ventricular Assist Device Pre- and Post-Approval Experience Through 1 Year at a Single Center

4:30 PM (82) Open Chest Epicardial Voltage Mapping during Left Ventricular Assist Device Implant in Patients with End-Stage Heart Failure

4:45 PM (83) Lessons Learned from over 250 Continuous-Flow Centrifugal Left Ventricular Assist Device Implantation: Growing Experience and Outcomes in Alternative Approaches Era

5:00 PM (84) Less-Invasive Left Ventricular Assist Device Implantations: Experience after More Than 100 Treated Patients

5:15 PM (85) An Examination of Bleeding and Thromboembolic Complications during the First Year of Support with the HeartMate 3 Fully Magnetically-Levitated Left Ventricular Assist Device
Concurrent Session 15: Let’s Be Specific: Donor Specific Antibodies – Challenges Ahead
(Thurgood Marshall)
(HTX, BSI, ID, MCS, PATH, PEDS, PHARM)

CHAIRS: Deborah Budge, MD and Jayan Parameshwar, FRCP

4:00 PM (86) Discordance between C4d Staining by Immunohistochemistry and Immunofluorescence and Clinical Outcomes

4:15 PM (87) Donor Specific Antibodies Associated with Micro- and Macrovascular Coronary Disease and Restrictive Myocardial Damage in Heart Transplanted Patients

4:30 PM (88) The Timeline of DSA after Cardiac Transplantation

4:45 PM (89) Human Leukocyte Antigen-G Polymorphisms Association with Post Heart Transplant Donor Specific Antibodies

5:00 PM (90) Pre-Transplant Donor Specific Antibody Levels Using Single Antigen Bead Assay and Long-Term Survival Post Heart Transplant

5:15 PM (91) De Novo DQ Donor-Specific Antibodies Are Associated with Worse Outcomes Compared to Non-DQ DSA Following Heart Transplantation
4:00 PM - 5:30 PM

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction  
(Salon 1)  
(LTX, BSI, LBCS, PEDS, PHARM)

CHAIRS: Michael T Musk, MBBS and Sangeeta M Bhorade, MD

4:00 PM (92) Results of a First-in-Man Study of Mesenchymal Stem Cell Therapy for Bronchiolitis Obliterans Syndrome

4:15 PM (93) Preliminary Report on the Effect of Mesenchymal Stem Cell (MSC) Infusion in Lung Function on Patients with Chronic Allograft Dysfunction (CLAD)

4:30 PM (94) Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation: A Randomized Controlled Trial

4:45 PM (95) Comparison of Extracorporeal Photophoresis (ECP) or Alemtuzumab (AL) Treatment Efficacy for Chronic Lung Allograft Dysfunction (CLAD)

5:00 PM (96) High Doses of Vitamin D to Reduce Chronic Lung Allograft Dysfunction After Lung Transplantation: A Randomized Trial

5:15 PM (97) A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation
Concurrent Session 17:

Pediatric Mechanical Circulatory Support
(Maryland Suite)
(PEDS, MCS)

CHAIRS: Tajinder P Singh, MD, MSc and
Christina J VanderPluym, MD

4:00 PM (98) Global Experience with the Heartware HVAD® in Pediatric Patients: A Preliminary Analysis

4:15 PM (99) Utilization and Outcomes of Temporary Ventricular Assist Devices in Children: A Report from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs)

4:30 PM (100) In Vitro Examination of the HeartWare Circulite VAD in the Fontan Circulation

4:45 PM (101) Mechanical Circulatory Support as a Bridge to Transplantation in Children with Single Ventricle Physiology: A Multicenter Study

5:00 PM (102) Infectious Complications of Ventricular Assist Device Use in Children in the US: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs)

5:15 PM (103) Measuring the Effect of Dipyridamole and Clopidogrel Using Thromboelastography/Platelet Mapping®: Is There Evidence of a Meaningful Dose-Response Relationship in Children Supported with the Berlin Heart EXCOR Ventricular Assist Device?
4:00 PM - 5:30 PM

Concurrent Session 18:  
*Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance*

(Virginia Suite)  
(BSI, HTX, LTX)

**CHAIRS:** Stephen C Juvet, MD, PhD, FRCPC and Andrew E Gelman, PhD

**4:00 PM**  
[104] *Multi-Transgenic Expression for Improved Xenograft Survival in Pig-to-Baboon Heart Xenotransplantation Model*

**4:15 PM**  
[105] *The Real Time Visualization of Neutrophil Extracellular Trap Formation in Lung Transplants Reveals a Critical Role in Tolerance*

(106) WITHDRAWN

**4:30 PM**  
[374] *Tissue Injury and Loss of Regulatory T Cells Leads to Lung-Specific Autoantibodies Following Lung Transplantation*

**4:45 PM**  
[107] *Leukocytes Transfer More Severe Rejection from Lung Transplant Recipients with Severe PGD into Humanized Mice and Are Sensitive to T Cell Regulation*

**5:00 PM**  
[108] *Thalidomide Treatment Prevents Chronic Graft Rejection after Transplantation in Rats*

**5:15 PM**  
[109] *BOS Is Associated with Increased Cytotoxic Pro-Inflammatory CD8 T and NKT-Like and NK Cells in the Distal Airways*
Concurrent Session 19:

Improving Outcomes: Body and Soul
(Delaware Suite)
(NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH)

CHAIRS: Louise M Fuller, PT and Erin Wells, RN

4:00 PM (110) Change in Body Mass Index over Time after Continuous Flow Left Ventricular Assist Device Implantation

4:15 PM (111) Pre-Lung Transplant Body Composition and Associations with Post Transplant Outcomes

4:30 PM (112) Single Centre Observational Study on Adequacy and Tolerance of Nutrition Support on the First 7 Days of ECMO as Bridge to Lung Transplant

4:45 PM (113) Lung Transplantation Does Not Impact on Daily Physical Activity Despite Substantial Improvements in Respiratory Function and Exercise Capacity

5:00 PM (114) Incidence of Vocal Cord Palsy and Aspiration Status in the Lung Transplant Population

5:15 PM (115) A Multi-Centre Study on the Effects of Iyengar Yoga on Health Related Quality of Life in Patients with Pulmonary Arterial Hypertension
4:00 PM - 5:30 PM

Concurrent Session 20:

Condemnatory or Commendatory Effects of Thoracic Transplantation
(Washington Ballroom 2)
(EEP, HF, HTX, LTX, MCS, NHSAH)

CHAIRS: Helen Gibbs, RN and Soma S Jyothula, MD

4:00 PM (116) Single Versus Double Lung Transplantation in the Setting of Constrained Donor Availability

4:15 PM (117) Changes in Smoking Habits in Potential Lung Transplant (LTX) Candidates

4:30 PM (118) Implementation of the 7-Day National Health Service (NHS) Working Week in UK will be Detrimental to Heart and Lung Transplantation; Fact or Fiction?

4:45 PM (119) Impact of Socioeconomic Status on Bridging with Contemporary Left Ventricular Assist Device (LVAD): Analysis of the UNOS Registry

5:00 PM (120) Socioeconomic Deprivation Is Associated with Worse Survival After Heart Transplantation in England

5:15 PM (121) Cost-Effectiveness of a Blood-Based Biomarker Compared to Endomyocardial Biopsy for the Diagnosis of Acute Allograft Rejection
6:00 PM - 7:00 PM

**Mini Oral 01:**

*Science, Surgery and Shock in MCS*

[Thurgood Marshall]

(MCS, BSI, HTX, NHSAH)

**CHAIRS:** Scott Silvestry, MD and Theodoros Kofidis, MD, PhD, FRCS

6:00 PM  [122] **Access Matters: Survival Advantage with Minimally Invasive Implantation of LVAD as Destination Therapy**

6:05 PM  [123] **Heparin-Free Off-Pump LVAD Implantation Reduces Early Adverse Events Compared with On-Pump Implantation**

6:10 PM  [124] **Short-, Mid- and Long-Term Efficacy of Aortic Valve Repair in Patients Supported with Continuous Flow-Left Ventricular Assist Device**

6:15 PM  [125] **Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation – Comparison of Systematic Mitral Valve Repair vs Surgical Abstention**

6:20 PM  [126] **Use of Impella 5.0 Ventricular Assist Device as a Bridge to Decision during Acute Decompensation of End-Stage Chronic Heart Failure**

6:25 PM  [127] **A Shock Team Improves Survival in Cardiogenic Shock by Decreasing Time to Intervention**

6:30 PM  [128] **Contemporary Outcome of Unplanned Right Ventricular Assist Device for Severe Right Heart Failure After Continuous Flow Left Ventricular Assist Device Insertion**

6:35 PM  [129] **Extracorporeal Membrane Oxygenator Therapy after Heart Transplantation**

6:40 PM  [130] **Increase in Frequency of Terminally Differentiated and Exhausted CD8+ T Cells Is Associated with Worse Clinical Outcomes after Mechanical Circulatory Support Device Implantation**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 PM</td>
<td>(131)</td>
<td>Increased Aortic Stiffness Index Among Patients Bridged to Transplant with Non-Pulsatile Left Ventricular Assist Devices</td>
</tr>
<tr>
<td>6:50 PM</td>
<td>(132)</td>
<td>Changes in Metabolic Substrate Utilization and Pyruvate Mitochondrial Oxidation Mismatch during Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning</td>
</tr>
<tr>
<td>6:55 PM</td>
<td>(133)</td>
<td>A Gene Expression Biomarker Panel for Predicting Mechanical Circulatory Support Outcomes</td>
</tr>
</tbody>
</table>
Mini Oral 02: Donor Dilemmas in Heart Transplantation
(Salon 1) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Daniel Zimpfer, MD and Carmelo A Milano, MD

6:00 PM (134) Impact of a New Urgency-Based Cardiac Allocation System on Candidate Outcomes: Results from a Simulated Allocation Study

6:05 PM (135) Prolonged Cardiac Allograft Donor Distance Does Not Impact Long-Term Survival

6:10 PM (136) Low Ejection Fraction in Young Donor Hearts Is Not Associated with Increased Recipient Mortality

6:15 PM (137) Predicting One-Year Cardiac Transplant Survival Using a Donor/Recipient Risk Assessment Tool

6:20 PM (138) Are Pediatric Donor Hearts Viable in Adult Recipients?

6:25 PM (139) The Overall Concept of Bridging to Transplantation by an Ventricular Assist Device in Comparison to Bridging by Conservative Treatment – Results Using the United Network for Organ Sharing Database

6:30 PM (140) Prolonged Corrected QT Interval in the Donor Heart: Is There a Risk?

6:35 PM (141) Impact of Cytomegalovirus on Survival after Heart Transplant: Analysis of 20,000 Patients from the UNOS Registry Data

6:40 PM (142) Stress Cardiomyopathy in Donor Hearts Does Not Affect the Outcome after Heart Transplantation

6:45 PM (143) Similar Post-Heart Transplant Outcomes with Undersized or Oversized Donors When Left Ventricular End Diastolic Dimension (LVEDD) Is within Range

6:50 PM (144) Heart Transplantation Following Donor Circulatory Death in Patients Bridged to Transplant with Implantable Left Ventricular Assist Devices

6:55 PM (145) Early and Late Outcomes of Cardiac Transplanted Patients with Marginal Donors: A Single Centre 10 Years Experience
## 6:00 PM - 7:00 PM  
### Mini Oral 03:  
**Candidate and Recipient Management in Heart Transplantation**  
(Maryland Suite)  
(HTX, ID, NHSAH, PATH, PEDS, PHARM)  

**CHAIRS:** Simon Maltais, MD, PhD and Daniela Pini, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>Treating the Failing Heart: An Evaluation of the Past Decade</td>
<td>(146)</td>
</tr>
<tr>
<td>6:05 PM</td>
<td>Implications of Amiodarone Use Before Heart Transplantation</td>
<td>(148)</td>
</tr>
<tr>
<td>6:10 PM</td>
<td>Impact of Cytomegalovirus Infection on Longitudinal Gene-Expression Profiling Score: Results from the Outcomes AlloMap® Registry</td>
<td>(149)</td>
</tr>
<tr>
<td>6:15 PM</td>
<td>Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy</td>
<td>(150)</td>
</tr>
<tr>
<td>6:20 PM</td>
<td>Outcomes of Heart Transplantation in Adults with Hypertrophic Cardiomyopathy (HCM): UNOS Registry Analysis</td>
<td>(151)</td>
</tr>
<tr>
<td>6:25 PM</td>
<td>Assessment of Molecular Mechanisms of Non-Transplant Cardiac Hypertrophy in Cardiac Allograft Hypertrophy- An Exploratory Gene Array Study of Myocardial Biopsy Samples</td>
<td>(152)</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>Temporal Trends of Incidence and Types of De Novo Malignancy after Heart Transplantation</td>
<td>(153)</td>
</tr>
<tr>
<td>6:40 PM</td>
<td>Immune Mediators IL-10 and TNF-alpha as a Potential Diagnostic Tool for Detection of Developed Cardiac Allograft Vasculopathy</td>
<td>(155)</td>
</tr>
<tr>
<td>6:45 PM</td>
<td>Differences in the Impact of Donor-Related Variables on Post-Heart Transplantation Outcomes in Mechanically Bridged Recipients and Recipients without Prior Mechanical Support - An Analysis from the ISHLT Registry</td>
<td>(156)</td>
</tr>
<tr>
<td>6:50 PM</td>
<td>Competing Outcomes of Heart Transplantation in Adults Bridged with Total Artificial Heart (TAH): UNOS Registry Analysis</td>
<td>(157)</td>
</tr>
</tbody>
</table>
6:00 PM - 7:00 PM

**Mini Oral 04:**

*Donor and Recipient Management in Lung Transplantation*

(Virginia Suite)

(LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM)

**CHAIRS:** Christophe Pison, MD, PhD and Mark Benzimra, MD, MRCP

6:00 PM (158) **Obstacles to Lung Transplant from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs)**

6:05 PM (159) **Lung Function: How Good Does It Get?**

6:10 PM (160) **Long-Term Impact of Coronary Artery Disease in Lung Transplantation**

6:15 PM (161) **Does Single Lung Transplantation Change Perfusion in Relation to Native Lung in Pulmonary Fibrosis? Implications in Choosing Laterality**

6:20 PM (162) **Simulated Regionalization of Lung Transplantation in the United States**

6:25 PM (163) **The OCS Lung EXPAND International Trial Interim Results**

6:30 PM (164) **Impact of OCS Lung Portable EVLP on Pulmonary Function and Bronchiolitis Obliterans in Standard Lung Transplant Recipients - Prospective Evidence from the OCS Lung INSPIRE Trial Patients**

6:35 PM (165) **On-Demand Immunoglobulin-G Replacement Is Not Associated with Benefits in Lung Transplant Recipients with Hypogammaglobulinemia**

6:40 PM (166) **Carfilzomib-Based Therapy Produces Favorable Outcomes for Antibody Mediated Rejection of the Lung Allograft**

6:45 PM (167) **Total Lymphoid Irradiation (TLI) for the Management of Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplant: A Single Centre Experience**

6:50 PM (168) **Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplantation: Identifying Predictors of Mortality**

6:55 PM (169) **Age Trends for Cystic Fibrosis Patients Undergoing Lung Transplantation: An Analysis of the ISHLT Thoracic Transplant Registry**
Mini Oral 05:

**Pediatrics: Organ Support and Transplantation**

(Delaware Suite)

(PEDS, LBCS, HTX)

**CHAIRS:** Estela Azeka, MD and Chesney Castleberry, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td><strong>[170]</strong> Pancreas: The Forgotten Organ in Children Undergoing Implantable Continuous-Flow VAD Support</td>
</tr>
<tr>
<td>6:05 PM</td>
<td><strong>[171]</strong> Pre-Transplantation Mechanical Circulatory Support Duration Effects Candidacy and Graft Longevity</td>
</tr>
<tr>
<td>6:10 PM</td>
<td><strong>[172]</strong> Steroid Therapy as a Strategy to Treat Hyperfibrinogenemia in Pediatric Ventricular Assist Device Patients: Does It Actually Hasten the Decline?</td>
</tr>
<tr>
<td>6:15 PM</td>
<td><strong>[173]</strong> Impact of Donor Cause of Death on Graft Utilization in Pediatric Heart Transplantation</td>
</tr>
<tr>
<td>6:20 PM</td>
<td><strong>[174]</strong> Impact of Induction Therapy Type in High and Low Risk Pediatric Patients After Heart Transplant: Analysis of the PHTS Database</td>
</tr>
<tr>
<td>6:25 PM</td>
<td><strong>[175]</strong> Increased Frequency of Surveillance Biopsy Does Not Improve Pediatric Heart Transplant Outcomes: Time for a Change in Practice?</td>
</tr>
<tr>
<td>6:30 PM</td>
<td><strong>[176]</strong> Donor-Specific Anti-HLA Antibodies of Immunoglobulin G3 Subclass Correlate with Cellular Rejection after Cardiac Transplantation</td>
</tr>
<tr>
<td>6:35 PM</td>
<td><strong>[177]</strong> Application of New Antibody-Mediated Rejection Classification (pAMR) on Pediatric Heart Transplant: A Retrospective Study*</td>
</tr>
<tr>
<td>6:40 PM</td>
<td><strong>[178]</strong> Pediatric Heart Transplant Waitlist Time Is Increased and Survival Is Decreased in Overweight-Obese (BMI&gt;85%) Individuals</td>
</tr>
<tr>
<td>6:45 PM</td>
<td><strong>[179]</strong> Heart Transplantation in Adolescents: Does Pediatric Experience Improve Outcomes?</td>
</tr>
<tr>
<td>6:50 PM</td>
<td><strong>[180]</strong> The Quilty Effect in Pediatric Heart Transplant Recipients</td>
</tr>
<tr>
<td>6:55 PM</td>
<td><strong>[181]</strong> Circulating Cell-Free DNA as a Non-Invasive Marker of Pediatric Heart Transplant Rejection and Immunosuppressive Treatment</td>
</tr>
</tbody>
</table>
6:00 PM - 7:00 PM

Mini Oral 06:

Pharmacy & Pharmacology and Mechanical Circulatory Support

(Washington Ballroom 2)

(PHARM, HTX, ID, LTX, MCS)

CHAIRS: Peter J Bergin, MBBS, FRAC and Walter Uber, PharmD

6:00 PM (182) Genotype-Guided Warfarin Dosing in Continuous-Flow Left-Ventricular Assist Device (CF-LVAD) Patients

6:05 PM (183) Suppressive Antibiotics for LVAD-Associated Infections: Are They Helpful or Harmful?

6:10 PM (184) CYP3A5 Pharmacogenetic Testing Predicts High Tacrolimus Dose Requirements Early after Cardiac Transplantation

6:15 PM (185) Carfilzomib-Rituximab Desensitization in Sensitized Heart Transplant Candidates: A Single Center Experience

6:20 PM (186) Early Experience with Carfilzomib as an Adjunct to Current Therapies for Donor Specific Antibodies After Lung Transplantation

6:25 PM (187) Hepatitis B Immunity Prior to Lung Transplantation: Three Shots and You’re Out?

6:30 PM (188) Single Center Experience with Medical Therapy for Management of LVAD Pump Thrombosis

6:35 PM (189) Prospective Evaluation of Urine Dipstick for Detection of Significant Hemolysis in Outpatients on CF-LVAD Support

6:40 PM (190) Fibrin Density and Platelet Location Varies Based on HeartMate II Thrombus Site

6:45 PM (191) Clinical Predictors and Outcomes of Patients with Left Ventricular Assist Device Related Gastrointestinal Bleeding in the ROADMAP Study

6:50 PM (192) Increased Risk of Gastrointestinal Bleeding in HeartMate II Compared to HeartWare Left Ventricular Assist Devices – A Single Center Retrospective Cohort

6:55 PM (193) Early Heparin Bridging after Left Ventricular Assist Device Implantation Is Associated with Increased Length of Stay and a High Rate of Hospital Readmission
Sunrise Symposium 01:  
**MCS Challenges and Engineering Solutions**  
(Thurgood Marshall)  
(MCS, HF, HTX, MCS)

**CHAIRS:** Jan D. Schmitto, MD, PhD, MBA and George M. Wieselthaler, MD

**7:00 AM**  
*Flow, Shear and MCS Coagulopathies: Mechanisms, Design Implications, Next Steps*  
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

**7:12 AM**  
Q & A

**7:15 AM**  
*Size Matters: Limitations and Drawbacks of Pump Miniaturization*  
Ulrich Steinseifer, PhD, University Hospital Aachen, Aachen, Germany

**7:27 AM**  
Q & A

**7:30 AM**  
*What Technologies Will Be the Most Impactful to Reduce Adverse Events?*  
Scott C Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

**7:42 AM**  
Q & A

**7:45 AM**  
*Smarter Pumps: Hemodynamic Monitoring and Physiological Control*  
Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria

**7:57 AM**  
Q & A
Sunrise Symposium 02:  
Timing Support in Cardiogenic Shock: When to Move Forward  
(Salon 1)  
(ALL)

CHAIRS: Francisco Arabia, M and Susan M. Joseph, MD

7:00 AM  INTERMACS 0: Making A Case for Severe Refractory Cardiogenic Shock  
Jaime A Hernandez-Montfort, MD MPH, Newark Beth Israel Medical Center, Newark, NJ, USA

7:12 AM  Q & A

7:15 AM  Choice of Support: Evidence Based or Expertise Driven?  
Pranav Loyalka, MD, Memorial Hermann, Houston, TX, USA

7:27 AM  Q & A

7:30 AM  Friday Night Disaster: Considerations Before, During and After the OR  
Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

7:42 AM  Q & A

7:45 AM  Transition from Acute Support to Durable Ventricular Support or Transplant: Challenges and Limitations  
Bart Meyns, MD, PhD, KU Leuven, Leuven, Belgium

7:57 AM  Q & A
Sunrise Symposium 03: *Thoracic Organ Transplantation and Malignancy*  
(Maryland Suite)  
(LTX, HF, HTX, LF, NHSAH, PEDS, PHARM)

**CHAIRS:** Robin Vos, MD, PhD and Cassie C. Kennedy, MD

**7:00 AM**  
*When is Malignancy a Contraindication To or Indication For Lung Transplantation?*  
David Weill, MD, Stanford University Medical Center, Stanford, CA, USA

**7:12 AM**  
Q & A

**7:15 AM**  
*Cancer Screening Guidelines - Are They Good Enough for Thoracic Organ Transplant Recipients?*  
Monique Malouf, FRACP, St. Vincent’s Hospital, Sydney, Australia

**7:27 AM**  
Q & A

**7:30 AM**  
*Lung Transplantation for Patients with Chronic GVHD Following Allogeneic Stem Cell Transplant*  
Samuel Goldfarb, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

**7:42 AM**  
Q & A

**7:45 AM**  
*Management of Patients with Unexpected Cancer in Explanted Lung or in the Pulmonary Allograft*  
Thomas K. Waddell, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

**7:57 AM**  
Q & A
Sunrise Symposium 04:

Let’s Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease

[Virginia Suite]

(PH, LTX, NHSAH, PEDS)

CHAIRS: Jacqueline R. Szmuszkovicz, MD and Maurice Beghetti, MD

7:00 AM Not Every Hole is Created Equal: Congenital Shunt Physiology, Classification and the Association with Pulmonary Hypertension
Warren A. Zuckerman, MD, Columbia University Medical Center, New York, NY, USA

7:12 AM Q & A

7:15 AM ASD with PAH: To Close or Not to Close, That is the Question...
Dana P. Mclothlin, MD, Kaiser San Francisco, San Francisco, CA, USA

7:27 AM Q & A

7:30 AM Feelin’ Blue: Advanced PAH Therapies for Eisenmenger’s Syndrome and Timing of Referral for Transplantation
Maurice Beghetti, MD, HUG Children’s University Hospital, Geneva, Switzerland

7:42 AM Q & A

7:45 AM The Fontan Under Pressure: a Role for PAH Therapies?
Alexander R. Opotowsky, MD, Boston Children’s and Brigham & Women’s Hospital, Boston, MA, USA

7:57 AM Q & A
7:00 AM - 8:00 AM

Sunrise Symposium 05:
*Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology*
[Delaware Suite]

(ALL)

**CHAIRS:** Monica Colvin, MD and Andrew E. Gelman, PhD

7:00 AM  *Where Do We Start? Link Between Innate and Adaptive Immunity in Early Events After Transplantation*
Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

7:15 AM  Q & A

7:20 AM  *The Bat CAV: Mechanisms of the Vanishing Coronaries*
Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany

7:35 AM  Q & A

7:40 AM  *So CLAD You Came! Mechanisms of Chronic Lung Allograft Rejection*
Lee Borthwick, RN, Freeman Hospital, Newcastle upon Tyne, United Kingdom

7:55 AM  Q & A
7:00 AM - 8:00 AM

Sunrise Symposium 06:

*The Fly in the Ointment: Nosocomial Infections*

(Washington Ballroom 2)

(ID, ALL)

**CHAIRS:** Kathleen L. Grady, PhD, APN, FAAN and Margaret M. Hannan, MD

7:00 AM *Educate Before You Medicate: Antimicrobial Stewardship*
Mary Bradbury, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

7:12 AM Q & A

7:15 AM *An Ounce of Prevention is Worth a Pound of Cure: Infection Prevention*
Valentina Stosor, MD, Northwestern University, Chicago, IL, USA

7:27 AM Q & A

7:30 AM *Devices, SIRS and Open Chest – The Role of Antibiotics?*
Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

7:42 AM Q & A

7:45 AM *Outbreak! Infection Clusters and the Transplant Center*
Barbara D Alexander, MD, Duke University, Durham, NC, USA

7:57 AM Q & A
8:00 AM - 10:00 AM

Plenary Session:

*Where is the Future for Innovation?*

[Salons 2-3]

[(ALL)]

**CHAIRS:** John Dark, MB, FRCS and Lori J. West, MD, D.Phil

**8:00 AM**  **Innovation in an Age of Risk Adversity and Regulation**
Robert M Califf, MD, US Food and Drug Administration, Washington, DC, USA

**8:25 AM**  **(194) FEATURED ABSTRACT: Functional Assessment of the Donor Heart Following Circulatory Death and Clinical Transplantation**

**8:35 AM**  **Expert Discussant Q & A**
Kumud K Dhital, MD, PhD, St Vincent’s Hospital, Sydney, Australia

**8:40 AM**  **Cell Therapy for Advanced Lung Disease: Pathway to the Clinic**
Dennis Wigle, MD, Mayo Clinic, Rochester, MN, USA

**9:00 AM**  **(195) FEATURED ABSTRACT: A Study of Donor Ex-Vivo Lung Perfusion in UK Lung Transplantation (DEVELOP-UK)**

**9:10 AM**  **Expert Discussant Q & A**
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

**9:15 AM**  **Research and Innovation by Crowdfunding**
Denny Luan, Experiment, San Francisco, CA, USA

**9:35 AM**  **Minimizing the Risk of Preventable Patient Deaths**
Michael Shabot, MD, Memorial Hermann Health System, Houston, TX, USA
10:30 AM - 12:00 PM
Concurrent Session 21:

**Pimp My Pump: Novel MCS Design and Management**
(Salons 2-3)
(MCS, HF, NHSAH)

**CHAIRS:** George Javorsky, MBBS, FRACP and Ugolino Livi, MD

10:30 AM (196) **Invasive Hemodynamic Ramp Test:** A Comparison of Ventricular Unloading between Current Generation Continuous-Flow LVADs

10:45 AM (197) **HVAD Waveform as a Surrogate Marker of Cardiac Index and Pulmonary Capillary Wedge Pressure**

11:00 AM (198) **LVAD Device Design Features and Operational Settings Minimize von Willebrand Factor Degradation**

11:15 AM (199) **Impact of Aortic Valve Closure on Adverse Events and Outcomes with the HeartWare HVAD**

11:30 AM (200) **Competing Flow Between Partial Circulatory Support and Native Cardiac Output: A Computational Fluid Dynamics-Study**

11:45 AM (201) **Minimally Invasive Exchange of the Heart-Mate II (HMII) Left Ventricular Assist Device (LVAD) to the Intrapericardial Heart-Ware Ventricular Assist Device (HVAD)**
10:30 AM - 12:00 PM

Concurrent Session 22:

*What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS*

(Thurgood Marshall)

(MCS, HF, NHSAH, PHARM)

CHAIRS: Anna L Meyer, MD and Ulrich Jorde, MD

10:30 AM (202) Use of Long Acting Octreotide in an Outpatient Clinic Reduces the Rate of Gastro-Intestinal Bleeding in Continuous Flow LVAD Patients

10:45 AM (203) Serial Evaluation of Von Willebrand Factor Performance with a Fully Magnetically Levitated Centrifugal Continuous Flow Left Ventricular Assist Device

11:00 AM (204) Danazol for the Treatment of Gastrointestinal Bleeding in Left Ventricular Assist Device (LVAD) Patients: A Multicenter Experience

11:15 AM (205) Vascular Abnormalities of the Nasal Mucosa Are Associated with Gastrointestinal Bleeding During Continuous Flow LVAD Support

11:30 AM (206) Warfarin Sensitive Patients Have Higher Risk of Gastrointestinal Bleeding and Device Thrombosis on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support

11:45 AM (207) Predictors of Out-of-Therapeutic-Range INR during Support with Continuous-Flow Left Ventricular Assist Device
Concurrent Session 23: Choosing a Gift: Donor Selection
(Salon 1)
(HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Luciano Potena, MD, PhD and David A Baran, MD

10:30 AM (208) Early Results of Heart Transplantation Using Donation after Circulatory Death Donors

10:45 AM (209) Heart Transplantation from Donors Outside Standard Acceptability Criteria Using Ex-Vivo Normothermic Preservation

11:00 AM (210) Utility of Heart Transplant by Waitlist Mortality and Donor/Recipient Match

11:15 AM (211) High Donor Sequence Number Grafts Can Be Safely Transplanted into Select Patients

11:30 AM (212) Too Much Information: Interaction of Donor Sequence and Acceptance in the UNOS Database

11:45 AM (213) Intermediate Outcomes with Ex-Vivo Allograft Perfusion for Heart Transplantation
10:30 AM - 12:00 PM

Symposium 30:

**JHLT at ISHLT: The Year in a Capsule**

(Maryland Suite)

(ALL)

**CHAIRS:** Jonathan N Johnson, MD and Maryl R. Johnson, MD

10:30 AM **Introduction and Recognition of Top Papers of the Year**
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women's Hospital, Boston, MA, USA

10:40 AM **Highlights of Heart Transplantation and Mechanical Circulatory Support**
Eugene C DePasquale, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

10:55 AM **EXPERT DISCUSSANT: Highlights of Heart Transplantation and Mechanical Circulatory Support**
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

11:00 AM **Highlights of Lung Transplantation**
Howard J. Huang, MD, Baylor University Medical Center, Dallas, TX, USA

11:15 AM **EXPERT DISCUSSANT: Highlights of Lung Transplantation**
John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:20 AM **Highlights of Pediatric Heart and Lung Transplantation**
Ranny Goldwasser, MD, University Hospital Heidelberg, Heidelberg, Germany

11:35 AM **EXPERT DISCUSSANT: Highlights of Pediatric Heart and Lung Transplantation**
David Morales, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

11:40 AM **Highlights of Pulmonary Hypertension**
Bradley Maron, MD, Brigham and Women’s, Boston, MA, USA

11:55 AM **EXPERT DISCUSSANT: Highlights of Pulmonary Hypertension**
Myung H. Park, MD, Houston Methodist, Houston, TX, USA
Concurrent Session 24:

What’s New in Primary Graft Dysfunction Post Lung Transplantation
(Virginia Suite)
(LTX, BSI, ID, LBCS, NHSAH, PEDS, PHARM)

CHAIRS: Jason D Christie, MD and Helen M Whitford, MBBS, FRACP

10:30 AM [214] Plasma RIP3 Is Decreased in PGD after Lung Transplantation

10:45 AM [215] Role of Donor Microbiota in the Development of Primary Graft Dysfunction Following Human Lung Transplantation

11:00 AM [216] Profiling Biomarkers of Inflammation and Tissue Injury during Human Ex Vivo Lung Perfusion in the DEVELOP-UK Study


11:30 AM [218] Down Regulation of microRNA-21 Is Significantly Associated with Signaling and Activation of the Toll-Like Receptor in Human Lung Transplant Recipients with Primary Graft Dysfunction

11:45 AM [219] Redefining Primary Graft Dysfunction after Lung Transplantation
10:30 AM - 12:00 PM

Concurrent Session 25:

Beyond Adherence: What’s New Out There?

(Delaware Suite)
(NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

CHAIRS: Connie White-Williams, RN, PhD and Christiane Kugler, PhD

10:30 AM (220) Impact of Early Adoption of Affordable Care Act Medicaid Expansion on Heart Transplant Listings in the United States

10:45 AM (221) Medical Adherence in the Late-Term after Lung Transplant

11:00 AM (222) Adequate Health Literacy Is Associated with Sufficient Physical Activity: Findings from the BRIGHT Study

11:15 AM (223) Testing the Efficacy of a Multicomponent Theory-Based Tailored Behavioral Medication Adherence Intervention in Transplantation: The MAESTRO-TX RCT

11:30 AM (224) Self-Efficacy and Adherence Are Predictors of Quality of Life in Patients with Left Ventricular Assist Devices

11:45 AM (225) A Multicenter Quality of Life (QoL) Survey Regarding LVAD Drivelines: A Look Beyond the Medical Aspects
10:30 AM - 12:00 PM

Concurrent Session 26:

Mechanisms of AMR: Can We Protect The Body From The Anti-Body?
(Washington Ballroom 2)
(BSI, HTX, LTX, MCS, PEDS)

CHAIRS: Marilia Cascalho, MD, PhD and John R Greenland, MD, PhD

10:30 AM (226) Left-Ventricular Assist Device Is Associated with Elevated Serum Levels of Natural IgG Reactive to Apoptotic Cells and Oxidized Epitopes

10:45 AM (227) T-Cell Dependence of Antibody Response to Blood Group A-Antigen

11:00 AM (228) Exosomes from Rejected Syngeneic Cardiac Grafts Express Myosin and Vimentin and Immunoregulatory miRNA and Induce Graft Rejection

11:15 AM (229) NK Cells Require the Secretion of Interferon-γ to Mediate Allograft Vasculopathy in a Model of Antibody-Mediated Chronic Rejection

11:30 AM (230) Bortezomib and ONX0914 in Experimental Heart Transplantation

11:45 AM (231) Ibrutinib Suppresses De Novo Alloantibodies and Recall Antibody Responses in a Mouse Model of Allosensitization: A Preliminary Report
2:00 PM - 3:30 PM

Concurrent Session 27: 
Are Two Pumps Better Than One? 
RV Failure and MCS
(Salons 2-3)
(MCS, HF, NHSAH, PH)

CHAIRS: Daniel J. Goldstein, MD and Ivan Netuka, MD, PhD

2:00 PM (232) Risk Factors Associated with Right Ventricular Assist Device Implantation: Insights from INTERMACS

2:15 PM (233) A Novel, Highly Discriminatory Risk Model Predicting Acute Severe Right Ventricular Failure in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implant

2:30 PM (234) Chemokine Receptor Down Regulation in Mechanical Circulatory Support Patients with Right Ventricular Failure

2:45 PM (235) Biventricular Bridge to Transplant: Total Artificial Heart (TAH) vs Thoratec Paracorporeal VADs (PVADs) Outcomes Post Heart Transplant (HT)

3:00 PM (236) Early Results of Biventricular Support with Durable, Intracorporeal Continuous Flow Centrifugal Ventricular Assist Devices: Analysis from INTERMACS

3:15 PM (237) Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events in Intermacs
2:00 PM - 3:30 PM

Concurrent Session 28:

*Pump Thrombosis: What’s Hot with the Clot*

(Thurgood Marshall)

(MCS, HF, NHSAH)

CHAIRS: Andrew J Boyle, MD and Andre R Simon, MD, PhD

2:00 PM (238) Outcomes of Medical and Surgical Therapy for Patients with Left Ventricular Assist Device Pump Thrombosis

2:15 PM (239) Diagnosis and Treatments of Three Different Types of Blood Flow Abnormalities in Patients Supported with HeartWare HVAD: Analysis of More Than 600 Cases

2:30 PM (240) Does High Blood Pressure Early Post LVAD Implant Increase the Risk of Pump Thrombosis?

2:45 PM (241) Utility of Echocardiography in Defining Inflow Cannula Malposition in Left Ventricular Assist Device and the Association with Adverse Outcome

3:00 PM (242) Micro-Emolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices

3:15 PM (243) Hemolysis Does Not Lead to Increased Discordance between Measured APTT and ANTI-XA Levels in Patients with Continuous-Flow Left Ventricular Assist Devices
Concurrent Session 29:

The Dark Side of Heart Transplant: Living With CAV

(Salon 1)

(HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Sonia Mirabet, MD and Vivek Rao, MD, PhD

2:00 PM (244) Myocardial Capillary Loss in Cardiac Allograft Vasculopathy: A Longitudinal Case-Control Study

2:15 PM (245) Development of a Clinical Prediction Model for Cardiac Allograft Vasculopathy: Comparison of Three Multivariate Methods

2:30 PM (246) Incremental Value to Coronary Angiography by Optical Coherence Tomography for Detection and Interpretation of Cardiac Allograft Vasculopathy

2:45 PM (247) Circulating Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and miRNA Are Induced in Cardiac Transplant Recipients with Cardiac Allograft Vasculopathy

3:00 PM (248) Early Use of Antiplatelet Therapy and Development of Cardiac Allograft Vasculopathy: A 5 Year Outcomes Analysis

3:15 PM (249) Utility of sAXL, hs-cTnT, Lp-PLA2, GDF-15 Biomarkers and Th1/Treg Ratio in the Detection of Cardiac Allograft Vasculopathy
2:00 PM - 3:30 PM

Concurrent Session 30:
What You Need to Know About Donors and Early Outcome Following Lung Transplantation
(Maryland Suite)
(LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Bryan A Whitson, MD and Dirk Van Raemdonck, MD, PhD

2:00 PM (250) Treating Donor Lung Inflammation by Blocking Interleukin-1β – An In Vitro Therapy Testing Platform for Ex Vivo Lung Perfusion

2:15 PM (251) Donation After Circulatory Death (DCD) versus Donation After Brain Death (DBD): Contrasting Donor and Recipient Characteristics in the ISHLT DCD Lung Transplant (LTx) Registry

2:30 PM (252) Long-Term Persistence of Alveolar Macrophages in Donor Lungs after Human Lung Transplantation

2:45 PM (253) Does Donor Age Impact Recipient Survival Post-Lung Transplant: A Study of the International Society of Heart and Lung Transplantation Database

3:00 PM (254) Airway Inflammation in the Donor Prior to Explant Increases the Risk of Primary Graft Dysfunction

3:15 PM (255) Donor Derived Exosomes Expressing Lung Associated Self-antigens (Collagen V and K alpha 1 Tubulin) in Acute and Chronic Rejection Following Human Lung Transplantation
2:00 PM - 3:30 PM

Concurrent Session 31: Pediatric Early Post Transplant Problems
(Virginia Suite)
(PEDS, HTX, MCS)

CHAIRS: Janet N Scheel, MD and Kurt R Schumacher, MD

2:00 PM (256) Regional Variation in the Use of 1A Status Exceptions for Pediatric Heart Transplant Candidates: Is This Equitable?

2:15 PM (257) The Use of Urgent Listing Exceptions in Pediatric Heart Transplantation: Is Waitlist Survival Equivalent to Standard Criteria Patients?

2:30 PM (258) Mechanical Circulatory Support after Pediatric Heart Transplantation

2:45 PM (259) A Novel Donor Risk Scoring System to Predict 1-Year Mortality in Pediatric Heart Transplantation

3:00 PM (260) Development and Validation of a Major Adverse Transplant Event (MATE) Score to Predict Graft Loss after Pediatric Heart Transplantation

3:15 PM (261) Early Neurologic Outcomes after Pediatric Heart Transplantation
Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring and Treatment
(Delaware Suite)
(ID, HTX, LTX, MCS, NHSAH)

CHAIRS: Aric L Gregson, MD and Amparo Sole, MD, PhD

2:00 PM (262) Clinical Characteristics and Outcomes of Mycobacterium abscessus Isolation in Lung Transplant Candidates and Recipients: A Systematic Review

2:15 PM (263) Universal Versus Culture-Directed Pre-Emptive Treatment (CDPET) among Lung Transplant Recipients: A Propensity-Score Matched Analysis

2:30 PM (264) Interim Analysis: A Study of QuantiFERON-CMV-Directed CMV Prophylaxis Versus Standard-of-Care to Reduce Late CMV Reactivation in Patients Undergoing Lung Transplantation

2:45 PM (265) A Pre-Transplant Humoral Immunity Score to Identify Risk of Severe Infection in Heart Recipients. A Multicenter Study

3:00 PM (266) Quantiferon Monitor: A Novel Assay for Prediction of Infectious Risk in Heart Transplant Recipients

3:15 PM (267) Positron Emission Tomography Accurately Diagnosis Ventricular Assist Device Infection
2:00 PM - 3:30 PM

Concurrent Session 33:
“A Bipartisan Effort:” Antibodies and Complement in Heart and Lung Allografts
(Washington Ballroom 2)
(PATH, BSI, HF, HTX, LTX, PEDS)

CHAIRS: Elizabeth N Pavlikso, MD and Patrick Bruneval, MD

2:00 PM (268) PU.1 and CD34 Immunohistochemistry for the Diagnosis of Antibody-Mediated Rejection in the Heart

2:15 PM (269) Histologic Features of Mixed Rejection in Heart Transplantation: More Than Just Cellular + Antibody-Mediated Rejection?

2:30 PM (270) Clearance of C3d Immunostaining Occurs More Often and Earlier Than Clearance of C4d after Antibody Mediated Rejection: An Earlier Marker for Resolving Rejection?

2:45 PM (271) Intrapulmonary Local Production of Antibodies Specific to Donor Major Histocompatibility Complex Class I in Association with the Progression of Chronic Rejection in Lung Allografts

3:00 PM (272) Complement-Fixing Donor Specific Antibody and Pathologic Findings in Lung Allografts

3:15 PM (273) Insufficient Post-Transplant Immunosuppression Induces Restrictive Allograft Syndrome-Like Fibrosis in the Pleura and Lung Parenchyma After Lung Transplantation
2:00 PM - 3:30 PM

Symposium 31:

Performing Under Pressure: Lung Transplantation in PH and PAH
(Washington Ballroom 1)
(PH, ALL)

CHAIRS: Reda E. Girgis, MD and Walter Klepetko, MD

2:00 PM  
Prognosis of PAH: Eligibility and Timing of Transplant Referral  
Antonio Roman, MD, Hospital Universitari Vall d'Hebron, Barcelona, Spain

2:15 PM  
The LAS for PAH: Impact of New Revisions  
Sangeeta Bhorade, MD, Northwestern Memorial Hospital, Chicago, IL, USA

2:30 PM  
PH and the risk of Primary Graft Dysfunction in Lung Transplantation  
James Lee, MD, University of Pennsylvania, Philadelphia, PA, USA

2:45 PM  
Matching Bridging Strategies to Unique Clinical Situations in PH and Lung Transplant  
Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

3:00 PM  
Perioperative and Early Postoperative Challenges in PH and Lung Transplantation  
Martin Strueber, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

3:15 PM  
PANEL DISCUSSION
Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS (Salons 2-3) (MCS, HTX, NHSAH)

CHAIRS: Shashank S Desai, MD and Yuriy Pya, MD

4:00 PM (274) Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope Dependent Advanced Heart Failure Patients: Insights from the ROADMAP Study

4:15 PM (275) Physician Prediction of Outcomes in Ambulatory Patients with Advanced Heart Failure

4:30 PM (276) Effect of Body Mass Index on Outcomes of Heart Transplant Candidates Supported by Continuous-Flow Left Ventricular Assist Devices (CF-LVADs)

4:45 PM (277) Red Cell Distribution Width (RDW) Predicts 90-Day Mortality in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients

5:00 PM (278) Heart Failure Etiology Influences Outcomes after Continuous-Flow LVAD Implantation

5:15 PM (279) Survival Following Orthotopic Heart Transplantation in Bridge-to-Transplant Heartware HVAD versus Heartmate II Patients
Concurrent Session 35:

Too Thick or Too Thin? Assessing Anticoagulation in MCS
(Thurgood Marshall)
(MCS, HF, NHSAH, PHARM)

CHAIRS: Nir Uriel, MD and Nader Moazami, MD

4:00 PM (280) Aspirin Responsiveness Predicts Mucosal Bleeding Events in Patients with Continuous-Flow Left Ventricular Assist Devices

4:15 PM (281) Genomic Reprogramming of the Platelet Transcriptome with Chronic LVAD Support

4:30 PM (282) Coagulation Factors Abnormalities in LVAD Patients with Anti-Factor 10a and PTT Discordance

4:45 PM (283) Bleeding Complications after Left Ventricular Assist Device Implantation: Association of Events and Impact on Survival

5:00 PM (284) Use of Four-Factor Prothrombin Concentrate Complex in LVAD Recipients Undergoing Transplantation: Impact on Blood Loss, Blood Use, Blood Bank Costs and Clinical Outcomes

5:15 PM (285) Aortic Root Thrombus Formation in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs)
4:00 PM - 5:30 PM

Concurrent Session 36:

Is It Really A Wonderful Life? Problems Post Heart Transplant
(Salon 1)
(HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Adriana Torres, MD and Marco A Caccamo, DO

4:00 PM (286) Outcomes in Patients Older Than 60 Years of Age Undergoing Orthotopic Heart Transplantation Since Broadening of Eligibility Criteria

4:15 PM (287) Neoplasia after Heart Transplantation. Differences in Incidence and Prognosis between Genders. Data from the Spanish Post-Heart Transplant Tumor Registry

4:30 PM (288) Donor Age Associated with Short-Term and Recipient Age Associated with Long-Term Mortality in Heart Transplantation

4:45 PM (289) The Obesity Epidemic and Its Effect on Donor Body Mass Index and Recipient Survival- A UNOS Database Review of Heart Transplantation

5:00 PM (290) Outcomes of Heart Transplantation in Adults with Sarcoidosis: UNOS Registry Analysis

5:15 PM (291) Cytomegalovirus Infection after Cardiac Transplantation
Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression (Maryland Suite) (LTX, BSI, ID, NHSAH, PEDS, PHARM)

**CHAIRS:** Massaki Sato, MD and Kevin M. Chan, MD

*4:00 PM (292)* Shortened Allograft Epithelial Telomere Length - A Lasting Legacy of Donor Age and Smoking History

*4:15 PM (293)* Implication of Human Leukocyte Antigen (HLA) Mismatching on Survival and CLAD After Lung Transplantation

*4:30 PM (294)* FVC, TLC and CT as Independent Predictors for Prognosis after Onset of CLAD

*4:45 PM (295)* Baseline Lung Allograft Dysfunction Negatively Impacts Survival Following Lung Transplantation

*5:00 PM (296)* Evaluation of an FVC-Based Definition of Restrictive Chronic Lung Allograft Dysfunction (CLAD) in a Multi-Center Cohort

*5:15 PM (297)* A Multicenter Study on Long-Term Outcomes after Lung Transplantation Comparing Donation after Circulatory Death and Donation after Brain Death
4:00 PM - 5:30 PM

Concurrent Session 38:

*New Insights in Pulmonary Hypertension*

(Virginia Suite)

(PH, BSI, HF, HTX, LTX, MCS, PEDS, PHARM)

**CHAIRS:** Ryan J Tedford, MD and Antonio B Roman, MD, PhD

**4:00 PM** (298) *Subclinical Pulmonary Hypertension Is Common and Associated with Increased Mortality in a Large Electronic Medical Record-Based Cohort*

**299 WITHDRAWN**

**4:15 PM** (387) *Right Ventricular Dyssynchrony and Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension: Insights Form Echocardiography and Cardiopulmonary Exercise Test*

**4:30 PM** (300) *Exercise Hemodynamics in PAH: Lessons Utilizing an Indwelling Hemodynamic Monitor*

**4:45 PM** (301) *Right Ventricular Reserve Limitation in Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension*

**5:00 PM** (302) *Influence of Pulmonary Hypertension on Adverse Outcomes Following Non-Cardiac Surgery*

**5:15 PM** (303) *Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study*
Concurrent Session 39:

Junior Faculty and Trainee Council’s Clinical Case Dilemmas: The Best of the Best

[Delaware Suite]

(ALL)

CHAIRS: Mitesh V Thakrar, MD and Hermann Reichenspurner, MD, PhD

4:00 PM  [304] Will Relaxation Improve Things?

4:05 PM  Expert Discussant
David O Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

4:09 PM  MODERATED DISCUSSION

4:15 PM  [305] Can Anything Make It Better?

4:20 PM  Expert Discussant
Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada

4:24 PM  MODERATED DISCUSSION

4:30 PM  [306] Are You Ready to Take the Next Step?

4:35 PM  Expert Discussant
Sharon A Hunt, MD, Stanford Univ Med Ctr, Stanford, CA

4:39 PM  MODERATED DISCUSSION

4:45 PM  [307] Why Don’t These Drugs Work Anymore?

4:50 PM  Expert Discussant
Margaret M Hannan, MD, Mater Hospital, Dublin, Ireland

4:54 PM  MODERATED DISCUSSION

5:00 PM  [308] Who’s Going to Fix This Now That It’s Broken?

5:05 PM  Expert Discussant
George M Wieselthaler, MD, Univ of California, San Francisco, CA

5:09 PM  MODERATED DISCUSSION

5:15 PM  [309] Does Size Matter Anymore?

5:20 PM  Expert Discussant
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

5:24 PM  MODERATED DISCUSSION
Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity (Washington Ballroom 2) (PHARM, HTX, ID, LTX, MCS, NHSAH)

CHAIRS: Adam B Cochrane, PharmD and Haifa Lyster, MSc

4:00 PM (310) Evaluation of Anticoagulation and Non-Surgical Major Bleeding in Recipients of Continuous-Flow Left Ventricular Assist Devices

4:15 PM (311) A Multidisciplinary Team-Based Process Improves Outpatient Anticoagulation Quality in Patients with Continuous-Flow Left-Ventricular Assist Devices

4:30 PM (312) Post Transplant Thrombosis and Atrial Arrhythmia May Be Safely Managed by Direct Oral Anticoagulants in Cardiac Transplant Patients

4:45 PM (313) Durability of Bortezomib for Treatment of Antibody Mediated Rejection in Cardiac Transplantation

5:00 PM (314) Do Your Patients Take Their Tablets?... High Prevalence of Non-Adherence to Immunosuppression in Lung Transplant Recipients (LTR)

5:15 PM (315) Effect of Aerosolized Antipseudomonals on Pseudomonas Recurrence and Bronchiolitis Obliterans Syndrome after Lung Transplantation
6:00 PM - 7:00 PM

Mini Oral 07:

Patient Management and Outcomes in MCS
(Thurgood Marshall)
(MCS, HF, NHSAH)

CHAIRS: Gregory A Ewald, MD and Paul J Mohacsi, MD

6:00 PM [316] Characteristics and Outcomes of African American LVAD Recipients: A Single Center Experience

6:05 PM [317] Infectious Complications after Cardiac Transplantation in Patients Bridged to Transplantation with Mechanical Circulatory Support Devices Versus Medical Therapy

6:10 PM [318] Multicenter Canadian Experience with the Heartware HVAD - 5 Year Update

6:15 PM [319] Surgical Management of Driveline Infection in Continuous Flow Left Ventricular Assist Devices

6:20 PM [320] The Value of PET-CT Scans in Patients with Ventricular Assist Devices

6:25 PM [321] Predictors of Long Term Survival on Left Ventricular Assist Device Support

6:30 PM [322] Risk of Death or Rehospitalization After LVAD and Baseline Cognitive Status

[323] MOVED TO CONCURRENT SESSION 47

6:35 PM [693] When Antibiotics Are Not Enough: Frequency, Etiology and Durability of the Surgical Management of Driveline Infections

6:40 PM [324] Effects of LVADs on Exercise Performance in Heart Failure

6:45 PM [325] Left Ventricular, Biventricular and Total Artificial Heart Support are Associated with Similar Levels of Allosensitization in Bridge-to-Transplant Patients: An Analysis of the UNOS Database

6:50 PM [326] Log Files from the HVAD: What Can Daily and Long-Term Changes in Flow Tell Us about Patients?

6:55 PM [327] Electrical Remodeling After Continuous-Flow Left Ventricular Assist Device Implantation
6:00 PM - 7:00 PM

Mini Oral 08:

Technology, Physiology and Complications in MCS
(Salon 1)
(MCS, HTX, NHSAH)

CHAIRS: Bart Meyns, MD, PhD and Michael S Kiernan, MD

6:00 PM (328) Generating Pulsatility by Pump Speed Modulation with Continuous-Flow Total Artificial Heart in Awake Calves

6:05 PM (329) Impact of Left Atrial Appendage Occlusion on Thromboembolic Complications in Patients Supported by the Heartmate II Left Ventricular Assist Device

6:10 PM (330) Resource Utilization and Hospital Readmission Rates Associated with Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices

6:15 PM (331) Does Preoperative Atrial Fibrillation Increase the Incidence of Thromboembolic Complications in Patients Supported with Long-Term LVADs?

(332) MOVED TO CONCURRENT SESSION 41

6:20 PM (1066) LVAD Outflow Cannula Systolic Slope in Patients with Left Ventricular Assist Devices: A Marker of Myocardial Contractility

6:25 PM (333) Biologically-Inspired Spiral Laminar-Flow Generation and Its Role in Cardiovascular Implantable Devices

6:30 PM (334) Association of Body Mass Index and Thrombosis in Left Ventricular Assist Device Recipients

6:35 PM (335) The Impact of Angiotensin II Type 1 Receptor Antibodies on Morbidity and Mortality of Heart Mate II Supported Patients

6:40 PM (336) Gynecological Complications in Female Patients with Left Ventricular Assist Device Support

6:45 PM (337) Rate Responsive Pacing Improves Aerobic Exercise Capacity and 6 min Walk in CF-LVAD Patients
MELD Score Is the Most Significant Parameter Predicting Outcome in Patients Receiving Long-Term Ventricular Assist Device After Extracorporeal Life Support

Evidence of Mild Hepatic Dysfunction Identifies Patients Most Likely to Experience Improvement in Renal Function Following Mechanical Circulatory Support
6:00 PM - 7:00 PM

Mini Oral 09:

**Risk Factors and Lung Transplant Outcomes**

(Maryland Suite)

(LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM)

**CHAIRS:** Ramsey R Hachem, MD and Are M Holm, MD, PhD

6:00 PM (340) **Association of Anti DQ Donor Specific Antibody with Antibody Mediated Rejection in Lung Transplantation**

6:05 PM (341) **Early Donor Specific Antibodies Correlate with a Distinct Peripheral Cellular Immune Phenotype after Lung Transplantation**

6:10 PM (342) **The Prognostic Value of Blood Eosinophilia on Survival After Restrictive CLAD Diagnosis**

6:15 PM (343) **Outcomes in Lung Transplant Recipients with Mycobacterium Abscessus Infection**

6:20 PM (344) **Analysis of the Airways Virome after Lung Transplantation and Its Association with Clinical Outcomes**

6:25 PM (345) **Impact of Donor Positive End Expiratory Pressure on Lung Utilization Rates and Short and Long Term Outcomes**

6:30 PM (346) **Donor Derived Variables as Predictors of Prolonged Hospital Stay after Transplant Surgery among Patients with Lung Transplantation**

6:35 PM (347) **Sarcopenia of Respiratory Muscle in Lung Transplantation Patients Is Not a Poor Predictor of Early Survival**

6:40 PM (348) **Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients**

6:45 PM (349) **Bilateral Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension: Cardiac Remodelling at One Year**

6:50 PM (350) **Importance of Thoracic Shape for Postoperative Pulmonary Function in Living Donor Lobar Lung Transplantation**

6:55 PM (351) **Interleukin 12-Dependent CMV-Specific CD4+ T Cell Proliferation, T-bet Induction and Effector Function During Primary Infection Are Key Determinants for Early Immune Control in Lung Transplant Recipients**
6:00 PM - 7:00 PM
Mini Oral 10:

\[ \text{Heart Transplantation and Heart Failure} \]

\[ \text{(Virginia Suite)} \]

\[ \text{HTX, BSI, LTX, NHSAH, PATH, PEDS, PHARM} \]

\[ \text{CHAIRS: Peter MacDonald, MD, PhD and Jack G Copeland, MD} \]

[352] WITHDRAWN

6:00 PM (585) Multicenter Evaluation of a National Organ Sharing Policy for Highly Sensitized Patients Listed for Heart Transplantation in Canada

6:05 PM (353) Survival After Heart Transplant for Previously Palliated Complex Congenital Cardiac Patients

6:10 PM (354) Donor and Recipient Risk Factors for Combined Heart-Lung Transplantation

6:15 PM (355) Combined Heart and Kidney Transplant: A 23 Year Experience

6:20 PM (356) Heart-Lung Transplantation for Congenital Heart Disease: A 25 Years Single Center Experience

6:25 PM (357) Heart-Lung Transplantation: A Viable Option for Systemic Sclerosis

6:30 PM (358) Repeated Levosimendan Infusions in Refractory Heart Failure. Single Center Experience.

6:35 PM (359) The Hemodynamic Effects of Milrinone in the Beta-Blocker Era

6:40 PM (360) Value of N-Terminal Pro-Brain Natriuretic Peptide in the Assessment of Aerobic Capacity in Heart Failure Patients

6:45 PM (361) Correlation of GDF-15 with Worsening Functional Capacity and Echocardiographic Parameters in Idiopathic Dilated Cardiomyopathy

6:50 PM (362) Vepoloxamer [Purified Sodium-Free Poloxamer-188] Improves LV Systolic Function in Dogs with Advanced Heart Failure and Protects Failing Cardiomyocytes from Calcium Overload

6:55 PM (363) Impact of Health Literacy on Knowledge and Self-Care in Heart Failure Patients, Pre- and Post-Intervention
6:00 PM - 7:00 PM

Mini Oral 11:

Models in Transplantation: From Mouse to Rat to Pig to Human

(Delaware Suite)

(BSI, HTX, LTX, MCS)

CHAIRS: Marcelo Cypel, MD and Stephen Ensminger, MD, DPhil

6:00 PM (364) Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with Splenic B-Cell Reduction: A Study of Multiparameter Flow Cytometry

6:05 PM (365) Assessment of Neonatal Tolerance to Blood Group A-Antigen in a Mouse Model of ABO-Incompatible Heart Transplantation

6:10 PM (366) Impact of Methylprednisolone on the Development of Myocardial Edema in Hearts Donated After Circulatory Death During Ex Vivo Perfusion

6:15 PM (367) Cytokine Filtration Modulates Pulmonary Metabolism and Edema Formation During Ex Vivo Lung Perfusion

6:20 PM (368) Pre- and Reconditioning of DCD Donor Lungs on Ex-Vivo Lung Perfusion by Methylprednisolone

6:25 PM (369) Cyclosporine A Can Mitigate Mitochondrial Dysfunction in Lung Grafts during Ex Vivo Lung Perfusion: A Potent Contributor for Better Preconditioning

6:30 PM (370) Prolonged Warm Ischemia Prevents Lung Allograft Acceptance in Lung Transplantation from Donation after Cardiac Death in the Mouse

6:35 PM (371) Protective Effect of Imatinib on Ischemia-Reperfusion Injury in Rat Lung

6:40 PM (372) MOVED TO CONCURRENT SESSION 46

6:40 PM (373) MHC-Inbred CLAWN Miniature Swine as Preclinical Large Animal Model for Lung Transplantation

6:45 PM (374) MOVED TO CONCURRENT SESSION 18

6:45 PM (477) Circulating Cytokines vs. Leukocytes: A Therapeutic Target during Ex Vivo Lung Perfusion

6:50 PM (375) Recapitulating T Cell Development in the Immature Environment of the Neonate to Induce Transplant Tolerance
6:00 PM - 7:00 PM

Mini Oral 12:

**Applied Health Research and Pulmonary Hypertension**

(Washington Ballroom 2)

(NHSAH, EEP, HTX, LTX, MCS, PEDS, PH)

**CHAIRS:** Caron L Burch, MSN and Ioana R Preston, MD

6:00 PM (376) **Associations Among Care Dependency, Cognition and Self-Efficacy in Patients with Left Ventricular Assist Devices (LVADs)**

6:05 PM (377) **Care Giver Support for Heart Transplant: Does the Type of Provider Matter?**

6:10 PM (378) **Effects of Pre-Transplant Depression and Anxiety Symptoms on Morbidity and Mortality Post-Heart Transplant: A Retrospective Cohort Study**

6:15 PM (379) **Variability in Depressive Symptoms Among Heart Transplant Patients Across Different Countries: A Cross-Sectional Study**

6:20 PM (380) **Functional Outcomes and Quality of Life in Patients Undergoing Extracorporeal Membrane Oxygenation Pre or Post Lung Transplantation - An Observational Study**

6:25 PM (381) **Nurse Practitioners Provide Safe and Effective Care to Patients in the First Year after Cardiac Transplantation in a Combined Nurse Practitioner-Physician Clinic**

6:30 PM (382) **Inflammatory Cytokines and Markers of Vascular Remodeling and Angiogenesis Are Associated with Functional Capacity, Hospitalizations and NT-ProBNP Levels in Patients with Pulmonary Arterial Hypertension**

6:35 PM (383) **Elevated Diastolic Pulmonary Gradient Is Common in the Acute Respiratory Distress Syndrome but Does Not Predict Mortality**

6:40 PM (384) **Short-Term Venoarterial Extracorporeal Membrane Oxygenation for Endobronchial Hemorrhage after Pulmonary Endarterectomy**

6:45 PM (385) **Searching for CTEPH; a Swedish National Follow-Up after an Episode of Acute Pulmonary Embolism**

6:50 PM (386) **Incremental Benefit of Echocardiographic Imaging and Cardiopulmonary Exercise Test in Prognostic Evaluation of Idiopathic Pulmonary Arterial Hypertension**

FRIDAY April 29, 2016
(387) MOVED TO CONCURRENT SESSION 38

6:55 PM  (986) Impaired Right Ventricular Function after Exercise Assessed by First-Pass Radionuclide Angiography in Pulmonary Hypertension
7:00 AM - 8:00 AM

Sunrise Symposium 07: 
*Clear as Mud: Assessing the Right Ventricle*
(Thurgood Marshall)
(MCS, ALL)

**CHAIRS:** Pascal N. Leprince, MD, PhD and Palak Shah, MD, MS

7:00 AM  How Do We Assess RV Function and Predict RV Dysfunction After LVAD?
Michael S. Kiernan, MD, Tufts Medical Center, Boston, MA, USA

7:15 AM  Q & A

7:20 AM  Peri-operative Approach to RV Dysfunction
Tobias Deuse, MD, PhD, University of California – San Francisco, San Francisco, CA, USA

7:35 AM  Q & A

7:40 AM  What If We Guess Wrong? The Approach to Chronic RV Dysfunction
Susan M Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

7:55 AM  Q & A
7:00 AM - 8:00 AM

Sunrise Symposium 08:

Rethinking Valvular Disease in Heart Failure

(Maryland Suite)

(HF, HTX, MCS, NHSAH, PEDS, PH)

CHAIRS: Tuvia Ben Gal, MD and Richard Cheng, MD

7:00 AM  Lost Cause: When is the Ventricle Too Poor to Fix the Aortic Valve?
Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Centre NRW, Bad Oeynhausen, Germany

7:12 AM  Q & A

7:15 AM  The Forgotten Valve: Lessons to be Learned in Tricuspid Regurgitation
Ivan Knezevic, MD, University Clinical Centre, Ljubljana, Slovenia

7:27 AM  Q & A

7:30 AM  Medical / Percutaneous Treatment of Mitral Valve Disease: The Future Beckons
Sofia C Masri, MD, University of Washington, Seattle, WA, USA

7:42 AM  Q & A

7:45 AM  Mitral Intervention with Poor LVEF: Worth the Risk?
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

7:57 AM  Q & A
Sunrise Symposium 09:

Lung Transplant Benefit is More Than Just Survival

[Virginia Suite]

(LTX, ALL)

CHAIRS: Fabienne Dobbels, MSc, PhD and Cynthia J. Gries, MD, MSc

7:00 AM What is Health-Related Quality of Life Really, and Does Lung Transplant Improve It?
Christiane Kugler, RN, PhD, University Witten, Witten, Germany

7:12 AM Neurocognitive Changes After Lung Transplantation – Are They Important?
Patrick Smith, PhD, MPH, Duke University, Durham, NC, USA

7:24 AM Integrating Quality of Life and Survival Outcomes in Lung Transplantation
Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA

7:36 AM How to Assess Functional Impairment and Disability Post Lung Transplant
Jonathan P Singer, MD, University of California, San Francisco, CA, USA

7:48 AM PANEL DISCUSSION
7:00 AM - 8:00 AM

Sunrise Symposium 10:

*Ambulatory ECMO in Adults: We Like to Move It, Move It*  
(Delaware Suite)  
(NHSAH, HF, HTX, LTX, MCS)

**CHAIRS:** Maria C Gazzaneo, MD and Kevin C. Carney, MSN, CRNP, CCTC

7:00 AM  *What Lessons Can We Learn From Our Children?*  
Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

7:12 AM  *Medical Considerations in the Ambulation of ECMO patients*  
Enrique Diaz Guzman Zavala, MD, University of Alabama, Birmingham, AL, USA

7:24 AM  *It Takes a Village: Implementing Ambulatory ECMO in the Adult Setting*  
Bryan Boling, RN, BSN, DNpc, University of Kentucky, Lexington, KY, USA

7:36 AM  *Physiotherapy Considerations in the Ambulation of ECMO Patients*  
Kate Hayes, BPhysio (Hons), MPhysio (Cardio), PhD(c), The Alfred Hospital, Melbourne, Australia

7:48 AM  PANEL DISCUSSION
Sunrise Symposium 11: Controversies in Pediatric Heart Failure
(Washington Ballroom 2)
(PEDS, HF, NHSAH, PHARM)

CHAIRS: Joshua D. Sparks, MD and Thomas Moller, MD, PhD

7:00 AM Pharmaceutical Options – Are The New Ones Any Better?
Robert E. Shaddy, MD, The Children’s Hospital, Philadelphia, PA, USA

7:12 AM Q & A

7:15 AM Who Dies Suddenly And Can We Prevent It?
Robert G. Weintraub, FRACP, FACC, Royal Children’s Hospital, Melbourne, Australia

7:27 AM Q & A

7:30 AM Making Palliative Care Part of the Plan
Elizabeth Blume, MD, Children’s Hospital, Boston, MA, USA

7:42 AM Q & A

7:45 AM Will the New ISHLT Pediatric Heart Failure Registry (iPHFR) Save Lives or Just Create More Work?
Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

7:57 AM Q & A
Sunrise Symposium 12: 

**Precision Medicine in Transplantation: Drug Levels and Beyond**

(Washington Ballroom 1) (ALL)

**CHAIRS:** Mandeep R. Mehra, MD, MBBS, FACC, FACP and Patricia Ging, PharmD

7:00 AM  **Pharmacogenetics: Is It Ready for Prime Time?**
Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

7:15 AM  **Q & A**

7:20 AM  **Genetic Predictors of Medication-Induced Adverse Effects**
Christina Aquilante, PharmD, University of Colorado, Aurora, CO, USA

7:35 AM  **Q & A**

7:40 AM  **Therapeutic Gene Modulation – What Can We Learn From CF?**
Denis Hadjiliadis, MD, University of Pennsylvania, Philadelphia, PA, USA

7:55 AM  **Q & A**
Concurrent Session 41:

You Get Out What You Put In: Assessing Risk in Mechanical Support

(Thurgood Marshall)

(MCS, HTX, NHSAH)

CHAIRS: Cumara C Sivathasan, MBBS, FRCS and Jennifer A Cowger, MD, MS

8:00 AM (388) Destination Therapy in a Single European Country. Insights from the ITAMACS Registry

(389) WITHDRAWN

8:15 AM (332) Mechanical Circulatory Support for the Fontan Circulation

8:30 AM (390) Permanent Atrial Fibrillation and 1-Year Clinical Outcome in Patients with Left Ventricular Assist Device Implants

8:45 AM (391) Differential Assessment of von Willebrand Factor Dysfunction in Durable Mechanical Circulatory Support: A Plead for Standardization

9:00 AM (392) Relationship of Factor II and Factor X Activity with International Normalized Ratio (INR) in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients: A Cross-Sectional Study

9:15 AM (393) Multi-Institutional Analysis of Temporal Patterns and Nature of Neurological Events after Left Ventricular Assist Device Implant
8:00 AM - 9:30 AM

Concurrent Session 42: Difficult Decisions in Mechanical Support
(Maryland Suite) (MCS, HTX, NHSAH)

CHAIRS: Alejandro M Bertolotti, MD and Jerry D Estep, MD

8:00 AM (394) Utilization and Outcomes of Ventricular Assist Device Support in Adult Congenital Heart Disease: An Analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)

8:15 AM (395) ECMO with Multiple-Organ Failure: Can Liver Dialysis Improve Survival?

8:30 AM (396) Characteristics and In-Hospital Outcomes of Adults Undergoing Extracorporeal Membrane Oxygenation

8:45 AM (397) Outcomes of Continuous-Flow Left Ventricular Assist Device Insertion for Acute Myocardial Infarction and Cardiogenic Shock: Importance of Bridging Strategy

9:00 AM (398) Equivalent Mortality but Higher Morbidity in Patients Receiving Temporary Mechanical Support Prior to Permanent LVAD Implantation

9:15 AM (399) Outcome of Patients Treated with Left Ventricular Assist Device (LVAD) as Bridge to Transplantation (BTT) or Bridge to Candidacy (BTC) vs. Marginal Heart Transplantation
8:00 AM - 9:30 AM

Concurrent Session 43:  
*Paying the Tolls: Effects of Bridge to Transplant*  
(Virginia Suite)  
(HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

**CHAIRS:** Finn Gustafsson, MD, PhD and Jan F Gummert, MD, PhD

8:00 AM (400) **LVAD BTT Risk Score Predicts 1-Year Mortality in Patients Bridged to Transplant with a CF-Left Ventricular Assist Device (LVAD)**

8:15 AM (401) **Impact of Mechanical Circulatory Support Before Cardiac Transplantation on Early and Late Rejection, Allograft Vasculopathy and Survival: Analysis of the ISHLT Adult Heart Transplant Registry**

8:30 AM (402) **Continuous Flow Left Ventricular Assist Device as a Risk Factor for Intraoperative Vasoplegia during Orthotopic Heart Transplantation**

8:45 AM (403) **Obesity and Wait-List Outcomes in Patients with Continuous Flow Left Ventricular Assist Devices as Bridge to Transplantation**

9:00 AM (404) **Does Left Ventricular Assist Device Mechanics Impact Pre Cardiac Transplant Allosensitization and Post-Transplant Survival?**

9:15 AM (405) **Outcome of Patients Having Multiple Mechanical Circulatory Support Devices before Orthotopic Heart Transplantation**
8:00 AM - 9:30 AM

Concurrent Session 44:

Lung Transplantation – Advanced Diagnostics!

(Delaware Suite)

(LTX, BSI, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Allan R Glanville, MBBS, MD, FRACP and Arne Neyrinck, MD, PhD

8:00 AM (406) Microarray Analysis of Endobronchial Lung Transplant Biopsies: Detection of T-cell Mediated Inflammation in a Safer Biopsy

8:15 AM (407) Mitochondria Release Leads from Human Lung Transplant Recipients Promotes Primary Graft Dysfunction

8:30 AM (408) Endothelial-Bound TLR-Dependent CX3CR1+CCR2-Ly6Clow Monocytes in Donor Lungs Mediate Primary Graft Dysfunction Following Murine Lung Transplantation

8:45 AM (409) Normothermic Donor Lung Preservation with Portable EVLP Maintains IL-33-Driven Epithelial Integrity and Suppresses Inflammation in the Recipient

9:00 AM (410) Long Pentraxin3 Deficiency Enhance Chronic Lung Allograft Dysfunction in a Mouse Orthotopic Lung Transplantation Model

9:15 AM (411) Biological Effects of Mesenchymal Stem Cell (MSC) Therapy in Patients with Chronic Lung Allograft Dysfunction (CLAD)
Concurrent Session 45: Pediatric Heart Failure
(Washington Ballroom 2)
(PEDS, HF, HTX)

CHAIRS: Heather T Henderson, MD and Yuk M Law, MD

8:00 AM (412) Risk Factors at Presentation Predict Outcomes of Pediatric Myocarditis: A Contemporary Multi-Center Cohort

8:15 AM (413) A Prospective Randomised Open-Label Clinical Trial of Rapid versus Prolonged Captopril Initiation and Up-Titration in Paediatric Cardiology Inpatients

8:30 AM (414) Utilization and Safety of Long-Term Carvedilol in Pediatric Dilated Cardiomyopathy: A Multicenter Study from the Pediatric Cardiomyopathy Registry

8:45 AM (415) Outpatient Subcutaneous Treprostinil for Pediatric Single Ventricle Patients

9:00 AM (416) Readmission Following Acute Myocarditis in Pediatric Patients

9:15 AM (417) Variability in Resource Utilization and Outcomes in Cardiomyopathy and Heart Failure Related Hospitalizations among Pediatric Hospitals in the United States: Potential Role for a Collaborative Learning Network
8:00 AM - 9:30 AM

Concurrent Session 46:

*From ‘Jeans’ to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics*

(Washington Ballroom 1)

(BSI, HF, HTX, LTX, MCS)

CHAIRS: Joshua Diamond, MD and Edward Cantu, MD

8:00 AM (418) Regulated Necrotic Cell Death Mediated by Calpain and RIPK Is Induced by Prolonged Hypothermic Ischemia Followed by Normothermic Reperfusion

8:15 AM (419) The Donor Heart after Withdrawal of Life Support

8:30 AM (420) Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury

8:45 AM (421) Reproducibility of Genomic Data Using Standards-Cell Free DNA to Monitor Rejection after Heart Transplantation

(422) MOVED TO POSTER SESSION 2 – LUNG TRANSPLANTATION

9:00 AM (372) Lung Storage in Hydrogen-Rich Saline Attenuates Lung Ischemia-Reperfusion Injury

9:15 AM (423) The Epigenomic Landscape of Dilated Cardiomyopathy
9:45 AM - 11:45 AM

Plenary Session:

*Pushing New Scientific Frontiers: It’s In Our Heritage*  
(Thurgood Marshall)  
*(ALL)*

CHAIRS: Jeffrey J. Teuteberg, MD and Maryl R. Johnson, MD

9:45 AM  **AWARDS PRESENTATIONS**

10:05 AM  **Lifetime Achievement Award to Adrian and Jean Kantrowitz**  
Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

10:15 AM  **The Influence of the Microbiota in Immunity and Transplantation**  
Jonathan S Bromberg, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA

10:40 AM  **(424) FEATURED ABSTRACT: PREVENTion of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT)**

10:50 AM  **Expert Discussant Q & A**  
Jan D Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

10:55 AM  **Precision Medicine in Organ Transplantation: Moving from Off the Rack to Bespoke**  
Alexandre Loupy, MD, PhD, Necker Hospital, Paris, France

11:15 AM  **PRESIDENT’S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (PRO)**  
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women’s Hospital, Boston, MA, USA

11:30 AM  **PRESIDENT’S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (CON)**  
Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA
Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS (Thurgood Marshall) (MCS, HF, NHSAH, PH)

CHAIRS: J. Eduardo Rame, MD and Evgenij V Potapov, MD, PhD

12:00 PM [425] The Worldwide Experience of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease

[426] WITHDRAWN

12:15 PM [323] Association of Late Aortic and Tricuspid Valve Regurgitation and Outcomes While on Left Ventricular Assist Device Therapy

12:30 PM [427] Totally Percutaneous RVAD/ECMO Configuration Provides Versatile Support for RV Failure

12:45 PM [428] Mitral Regurgitation Is Associated with Right Ventricular Pulsatile Loading and Early Right Heart Failure After Left Ventricular Assist Device

1:00 PM [429] Elevated Transpulmonary Gradient Is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension Treated with Continuous-Flow Left Ventricular Assist Devices (CF-LVAD)

1:15 PM [430] Pulmonary Hypertension Results in Worse Post-Transplant Survival in Left Ventricular Assist Device Patients
Concurrent Session 48:  
Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient  
(Maryland Suite)  
(MCS, HTX, NHSAH)

CHAIRS: Annemarie Kaan, MCN, RN and Sean P Pinney, MD

12:00 PM  A National Survey of Palliative Care Services within INTERMACs Centers
12:15 PM  Patient-Caregiver Relationships and Outcomes after LVAD Implantation
12:30 PM  Pre-Operative Predictors for Admission to a Rehabilitation Facility after LVAD Implantation and Its Impact on Long Term Survival
12:45 PM  Assessment of Cognitive Function Prior to and After Implantation of Left Ventricular Assist Device
1:00 PM  Substantial Reduction in Driveline Infection Rates with the Modification of Driveline Dressing Protocols
1:15 PM  Survival and Thrombotic Events in Left Ventricular Assist Device Patients Are Not Influenced by Socioeconomic Status
Concurrent Session 49:  
My Heart Is Broken: Primary Graft Dysfunction and Early Problems  
(Virginia Suite)  
(HTX, BSI, ID, MCS, NHSAH, PATH, Peds, PHARM)  

CHAIRS: Javier Segovia, MD, PhD and Ivan Knezevic, MD

12:00 PM (437) Vasoplegia After Heart Transplantation: Unraveling the Enigma
12:15 PM (438) Application of the ISHLT Criteria for Primary Graft Dysfunction After Cardiac Transplantation: Risk Factors and Outcomes from a High-Volume Center
12:30 PM (439) Recipient and Donor Risk Factors Associated with Primary Graft Failure Requiring Temporary Mechanical Circulatory Support < 24 Hours After Heart Transplantation
12:45 PM (440) Monocyte-Derived Macrophages Contribute to Primary Graft Dysfunction Following Cardiac Transplantation
1:00 PM (441) Extracorporeal Membrane Oxygenator or Ventricular Assist Device for Primary Graft Failure after Orthotopic Heart Transplantation?
1:15 PM (442) ECMO for Primary Graft Failure Following Orthotopic Heart Transplantation
12:00 PM - 1:30 PM

Concurrent Session 50:

Recipient Factors and Outcome After Lung Transplantation – Are We Getting It Right?

[Delaware Suite]

(LTX, BSI, ID, NHSAH, PATH, PHARM)

CHAIRS: Laurie D Snyder, MD and Goran Dellgren, MD, PhD

12:00 PM (443) Impact of Multi-Drug Resistant Bacteria Detected De Novo Early after Lung Transplantation on Morbidity and Mortality

12:15 PM (444) IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation

12:30 PM (445) Effect of De Novo Donor Specific Antibodies on the Incidence of Acute Cellular Rejection beyond One Year of Lung Transplantation

12:45 PM (446) Metabolic Profile of Broncho-Alveolar Lavage Fluid in Lung Transplant Recipients Suggests Potential Early Biomarkers of Bronchiolitis Obliterans Syndrome

1:00 PM (447) C4d-Negative Antibody-Mediated Rejection After Lung Transplantation

1:15 PM (448) Outcomes in Lung Transplantation Following Allogeneic Stem-Cell Transplantation: A Pan-European Experience
Concurrent Session 51:
*Heart Failure Risk Prediction: From Molecules to Mechanism*
(Washington Ballroom 2)
(HF, BSI, HTX, NHSAH)

**CHAIRS:** Kiran Khush, MD, MAS and Manreet Kanwar, MD

12:00 PM (449) *Discharge ST2 Predicts Heart Failure Readmissions in Patients with Acute Decompensated Heart Failure (ADHF)*

12:15 PM (450) *Modulation of Local and Systemic Relaxin-2 in Patients with End-Stage Chronic Heart Failure*

12:30 PM (451) *Clinical Genetics in Cardio-Oncology*

12:45 PM (452) *Cardiac Serum Biomarkers in Friedreich Ataxia May Reflect Fibrosis, Myocyte Injury and Degree of Hypertrophy*

1:00 PM (453) *Low Partial Pressure of End-Tidal Carbon Dioxide Predicts the Future Ventricular Assist Device Implantation in Patients with Chronic Advanced Heart Failure*

1:15 PM (454) *LVOT VTI Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort*
12:00 PM - 1:30 PM

Concurrent Session 52:

Factors Determining Outcomes in Pulmonary Hypertension
(Washington Ballroom 1)
(PH, BSI, HF, LTX, PEDS, PH, PHARM)

CHAIRS: Bradley Maron, MD and C. Dario Vizza, MD

12:00 PM (455) Polymer Based Nanotherapeutics Prevent the Progression of Pulmonary Hypertension in a Rat Model

12:15 PM (456) Incidence and Outcomes of Children with Idiopathic Pulmonary Arterial Hypertension - Results from a Bi-National Population Based Study

12:30 PM (457) Characteristics and Outcomes of 30-Day Hospital Readmissions in Children with Pulmonary Hypertension: A Multi-Institutional Analysis

12:45 PM (458) Use of PAH-Specific Therapy in World Health Organization Group III Pulmonary Hypertension: A Systematic Review and Meta-Analysis

1:00 PM (459) Outcome of Patients with Chronic Thromboembolic Disease in the Absence of Pulmonary Hypertension on Echocardiogram

1:15 PM (460) Pre-operative Determinants of Reperfusion Lung Injury after Pulmonary Thromboendarterectomy
6:00 PM - 7:00 PM
Poster Session 1
[Exhibit Hall B & C]

Basic Science (BSI, HF, HTX, LTX, MCS, PATH, PEDS)

[461] Ex Vivo Expanded Human Regulatory T Cells Suppress Allograft Induced Immune Responses in a Humanized Mouse Mode

[462] Presence of Endothelial to Mesenchymal Transition in End-Stage Human Myocardial Samples- Documentation in Human Heart Failure for the First Time

[463] Kinetics of Dendritic and Polyfunctional T Cell Responses in a Mouse Minor Mismatched Orthotopic Single Lung Transplant Model

[464] Reconditioning of Prolonged Warm Ischemic Lungs by High-Dose Bronchodilator Inhalation during Ex Vivo Lung Perfusion in a Canine Lung Transplantation Model

[465] Elevation in Activin A to Follistatin Ratios Following Lung Transplantation- A Potential Mediator and Therapeutic Target for CLAD?

[466] MicroRNA Analysis in a Mouse Heterotopic Tracheal Transplant Model

[467] Polymerized Human Serum Albumin as an Osmotic Molecule to Support Ex-Vivo Lung Perfusion

[468] Influence of Fatty Acids, Acetate and Ketones on Myocardial Substrate Selection and TCA Cycle Intermediates During Hypothermic Machine Perfusion of Donor Hearts

[469] Lung Microbiome Predicts Myeloid Derived Suppressor Cell Response in Lung Transplant

[470] Variable Effects of Serotonin Receptor Antagonists on the Development of Transplant Vasculopathy in Murine Aortic Allografts

[471] The Establishment of an Ex Vivo Lung Perfusion in a Rat Lung Transplantation Model

[472] The Interleukin 4 Receptor- Potentiates the Effect of Oncostatin M Receptor on the Release of FGF23 by Cardiomyocytes
[473] Combined Heart and Liver Retrieval after Circulatory Death with Normothermic Machine Reperfusion in a Porcine Model

[474] Refinement of Ex Vivo Lung Perfusion Techniques for Better Microvasculature Maintenance in Lung Grafts

[475] A Novel Nanoscale Formulation of Hydrophobic Src Tyrosine Kinase Inhibitor PP2 Prevents Pulmonary Ischemia Reperfusion Induced Acute Lung Injury

[476] Donor Versus Recipient Origin of Fibroblasts in Murine Lung Allograft Fibrosis

[477] MOVED TO MINI ORAL 11

[478] Development of an Unsupervised Classification with Multi-Level Analysis of the Heart Transplant Endomyocardial Biopsy

[479] WITHDRAWN

[480] Electrophysiological Investigations of Human iPS Cell-Derived Engineered Heart Tissue in a Guinea Pig Infarction Model

[481] WITHDRAWN

[482] aPC Pretreatment of hEPCR-Expressing PAECs Attenuates Endothelial Cell Damage and Thrombosis

[483] Control of Cardiomyocyte Proliferation Through p53/Mdm2-Regulated MicroRNAs

[484] Characteristic Trends during DCD Withdrawal


[486] Ex Vivo Treatment of Donors with Nebulized N-Acetylcysteine Partially Improved Post-Transplant Lung Function

[487] The Impact of Sevoflurane Preconditioning in Experimental Mouse Lung Transplantation


[489] Temporal Assessment of Endothelial to Mesenchymal Transition as a Contributor to Fibrosis in a Mouse Model of Heart Failure

[490] Identification of Hypoxic Cells in Lung Grafts for Future Cell Targeted Therapy for Obliterans Bronchiolitis
[491] Impact of Myocardial Load on the Preservation of Donor Heart Function during Ex Vivo Perfusion

[492] Ex Vivo Testing of New Genetical Modifications for Cardiac Xenotransplantation

[493] Mitochondrial Proteins Possess Antigenicity and Can Cause Rejection

[494] Allogeneic and Xenogeneic Immunity Is Potently Suppressed by Expanded Regulatory T Cells (Tregs) from Human Thymus

[495] Targeting Human Follicular T-B Cell Interactions to Prevent Antibody Mediated Allo-Immune Responses

[496] Mass Cytometric Deep Cellular Profiling of BAL in Human Lung Transplantation

[497] WITHDRAWN

[498] Xenogeneic Lung Transplantation: Extending Life-Supporting Organ Function Using Multi-Transgenic Donor Pigs and Targeted Drug Treatments

[499] mTOR Inhibitors Ameliorate Ischemia-Reperfusion Injury through Endothelin-A Modulation and Reduction of Free Radical Production

[500] CD8+ IL-17 Responses and Obliterative Airway Disease Persist in T-bet-/- Mouse Recipients of Lung Transplant Treated with Low Dose Azithromycin Therapy

[501] Modulation of Nesfatin, Visfatin and Resistin in Patients Undergoing Heart Transplantation

[502] Modulation of Leukocyte-Endothelium Interactions with rATGs after Ischemia-Reperfusion Injury in an Experimental Human Perfusion Model

[503] The Immunobiology of the Y Chromosome in Embryonic Stem Cell Transplantation for Tissue and Organ Regeneration

[504] A Nude Mouse Model of Allosensitization Induced by Adoptive Transfer of Splenic T Helper Cells

[505] Relationship between Grafts' Quality, Glucose Consumption and IL-6 Production during Ex Vivo Lung Perfusion

[506] Does a Leukocyte Filter Show Benefit in Ex-Vivo Lung Perfusion?
Heart Transplantation

[507] The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients

[508] Tissue Characterization Using Novel CMR Based T1 and T2 Mapping Detects Early Myocardial Injury in Heart Transplant Recipients

[509] Donor-Specific HLA-DQ Antibodies May Contribute to Poor Graft Outcome After Heart Transplantation

[510] The Impact of Late Antibody Mediated Rejection with Graft Dysfunction on Cardiac Allograft Vasculopathy and Survival

[511] The Number of Human Leukocyte Antigen DR Mismatch Is Associated with Early Post-Transplant Acute Cellular Rejection Among Heart Transplantation Recipients

[512] Gene Expression Profiling to Predict and Define Cardiac Allograft Acute Cellular Rejection

[513] Diagnostic Value of Quantitative Tissue Markers (T2 Mapping and ECV) for Acute Cardiac Rejection Diagnosis: A Preliminary Experience

[514] Organ Preservation and Reperfusion Influence on Outcome after Heart Transplantation

[515] Elevated Rho Kinase (ROCK) Activity Correlates with Acute Rejection in Heart Transplant Recipients

[516] Telomere Length in Aortal Tissue and Heart Allograft Rejection in Patients after Transplantation

[517] Loss of Correlation Between Naive and Memory Class-Switched B-Cells in Heart Recipients with Acute Cellular Rejection

[518] High Grade Cellular Rejection and Infection Post Heart Transplantation: Is There a Link?

[519] Trends of Early and Late Rejection Rates Following Heart Transplantation Over the Past Two Decades: Real World Data from a National Tertiary Center Registry

[520] Prolonged Ischemic Time of Donor Hearts: Indication for Additional Cardioplegic Preservation Before Graft Implantation?

[521] Risk Stratification for Developing Cardiovascular Allograft Vasculopathy in Heart Transplant Recipients: Evaluation by Annual Intravascular Ultrasound
Perfusion Cardiac Magnetic Resonance Imaging in Cardiac Allograft Vasculopathy

What Are the Important Factors for Cardiac Vasculopathy Development After Heart Transplantation?

Impact on Graft Survival of Medical Treatment and Percutaneous Coronary Intervention in Cardiac Allograft Vasculopathy

Cardiac Allograft Vasculopathy Assessed by 64 Slice Dual-Source Coronary Computed Tomographic Angiography: Retrospective Analysis of a Monocentric Experience

Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients

Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy?

The Clinical Application of Non-Invasive Assessment of Coronary Flow Reserve via Rubidium PET in Heart Transplant Patients

Coronary Physiology Assessment After Heart Transplantation

Rejection and Cardiac Allograft Vasculopathy Are Both Associated with Increased Incidence of Sudden Cardiac Death Post-Heart Transplant: A Meta-Analysis

Optical Coherence Tomography Guided Allograft Vasculopathy Interventions: A New Frontier

Evaluating Potential Risk Factors for Worsening Cardiac Allograft Vasculopathy

Immunosuppression and Cardiac Allograft Vasculopathy: A Multivariate Odds Ratio Analysis

Dobutamine Stress Echocardiography to Detect Early Cardiac Allograft Vasculopathy

Cardiac Allograft Donor Age Is Associated with Increased Baseline Coronary Plaque Burden but Not with Its Progression as Assessed by Intravascular Ultrasound

Elevated Levels of Gut Microbe Metabolite Trimethylamine N-Oxide (TMAO) Levels Are associated with Graft Arterial Disease Following Murine Heart Transplantation

Steps towards Personalization of Clinical Care in Era of Precision Medicine. Time Dependent Immune Phenomapping in Heart Transplantation and Emergence of Anti-HLA Class I and II Antibodies
[538] Proteinuria the First Year After Heart Transplantation Is Associated with a Higher Rate of Decline in Glomerular Filtration Rate

[539] Assessment of Cotinine Shows a Dose-Dependent Effect of Smoke Exposure on the Long Term Survival after Heart Transplantation

[540] Safety and Efficacy of Immunoadsorption in Heart Transplantation Program

[541] Predictive Value of HLA and MICA Antibodies Monitoring during First Year after Heart Transplantation

[542] Evolutive Tendency and Prognostic Value of Galectin-3 Serum Levels After Heart Transplantation

[543] Tricuspid Annuloplasty Definitely Improves Patient Outcomes in the First Year After Heart Transplantation

[544] Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients

[545] Early and Long Term Results of Heart Transplantation after Reoperative Sternotomy

[546] Temporal Changes on the Risk of New Onset Diabetes Following Cardiac Transplantation Over 30 Years

[547] Reduction in Post-Heart Transplant ICU and Total Length of Stay by Standardization of Care Via a Multidisciplinary Approach

[548] Use of a Highly Sensitive Assay for Cardiac Troponin T as an Adjunct to Diagnose Acute Rejection after Cardiac Transplant

[549] Outcomes in Patients Older than 65 Years of Age Post Heart (HT) & Heart-Kidney Transplant (HKT)

[550] Relationship Between Brachial Artery Flow-Mediated Dilation and Clinical Characteristics of Heart Transplant Recipients

[551] Poor Blood Pressure Control Is Independently Associated with Renal Dysfunction After Heart Transplant

[552] Post Heart Transplant Cancer Diagnosis Association with Human Leukocyte Antigen-G Genotypes

[553] Association between Karnofsky Functional Scale and Survival in Patients Listed for Heart Transplantation

[554] The Impact of Donor Specific Antibodies on Antibody Mediated Rejection
Body Mass Index Adversely Affects Survival in Left Ventricular Assist Device Bridged Patients Undergoing Heart Transplantation

Association of Heart Transplant Recipient Age and Body Mass Index with Microcirculatory Remodeling

Clinical Implication of Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: Do We Really Have to Care All the DSA Positive Patients?

Higher Rate of Hospitalizations for Infection and Cancer Than Rejection in Low Risk Heart Transplant Patients Followed by Gene Expression Profiling

Evaluation of Left Ventricular Myocardial Mechanics in Heart Transplant Recipients Using Three-Dimensional Speckle Tracking Echocardiography

Significant Tricuspid Insufficiency After Cardiac Transplantation: Which Risk Factor Has the Most Influence

Our Experience with the Use of Allomap in Multiple Organ Recipients

Limiting the Number of Endomyocardial Biopsies Does Not Impact One Year Survival Following Heart Transplantation

Vibration Controlled Transient Elastography for Identification of Hepatic Fibrosis in Patients Evaluated for Cardiac Transplantation or Left Ventricular Assist Device: A Pilot Study

Cardiac Troponin T in Heart Donors: Impact on Morbidity and Mortality After Transplantation

When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era

Characteristics and Co-Morbidities in Heart Transplant Recipients Who Survive into Their Eighties

Preoperatively Impaired Renal Function Does Not Affect Long-Term Survival in Heart Transplanted Patients

How to Achieve Improved Outcome after Heart Transplantation?

Predictors of Normal Coronary Angiography in Older Donors: Results from a Prospective National Study

Optimal Timing of Heart Transplantation After Heart-Mate II Left Ventricular Assist Device Implantation

The Fate of Donor Hearts Rejected for Transplant: A Single Institutional Experience
| [572] | Donor Heart Turn Down, Is It Rational? |
| [573] | The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation |
| [574] | Risk Factors of Waiting List Mortality for Patients Awaiting Heart Transplant |
| [575] | Impact of Size Mismatch on Heart Transplant Outcomes |
| [497] | WITHDRAWN |
| [576] | WITHDRAWN |
| [577] | Pre-Operative Pulmonary Hypertension Does Impact Long Term Outcomes Following Heart Transplantation: Review of the United Network for Organ Sharing Database |
| [578] | Does Pulmonary Hypertension Affect Survival after Heart Transplantation Based on Recipient Body Mass Index? |
| [579] | Influence of Duration of Continuous-Flow Ventricular Assist Device Support on Post-Transplant Outcome — Results Using the United Network for Organ Sharing Database |
| [580] | A Novel Cardiac Allocation Score for Predicting Wait-List and Post Transplant Survival |
| [581] | Changing Characteristics of Heart Transplant Donors and Their Effect on Recipient Mortality |
| [582] | Impact of Donor Hypernatremia on Outcome After Cardiac Transplantation |
| [583] | Hypertonic Saline Solution Preserves Left Ventricular Function and Inhibit Myocardial Injury Triggered by Brain Death in Rats |
| [584] | Thyroid Hormone Use During Cardiac Transplant Organ Procurement |
| [585] | MOVED TO MINI ORAL SESSION 10 |
| [586] | Evaluation of Thoracic Exception Policy for Highly Sensitized Patients |
| [587] | The Interval between Brain Stem Death and Cardiac Assessment Influences the Retrieval of Hearts for Transplantation |
| [588] | A Comparison of ECMO, LVAD and Biventricular Support in Bridging to Heart Transplant in the OPTN Database |
| [589] | The Role of Japanese Medical Consultant System on Improving Outcomes of Cardiac Recipients from Old Donors or Donors Who Died of Post-Resuscitation and Anoxia |
The Paradoxical Relationship between Donor Distance from Transplant Center and Survival after Heart Transplantation

The Use of Social Media Application Software Using Smartphones in Donor Heart Evaluation

Retrieval Team Initiated Early Donor Management (Scouting) Increases Donor Heart Acceptance Rate for Transplantation

Time-Varying Mortality Risk Score for Candidates Awaiting Cardiac Transplantation

Marijuana and Listing for Heart Transplant: A Global Survey

Donor Age for Heart Transplantation Does Not Affect Short or Mid-Term Outcomes

Assessment of FEV1 Decline after Lung Transplantation Using Functional Respiratory Imaging

Lung Transplant Outcome: Eplets Compatibility and DSA Development

A Single Donor TARC/CCL17 Promotor Polymorphism Correlates with Serum TARC/CCL17 Levels and Is Associated with Impaired Clinical Outcome after Lung Transplantation

Bile Acid Aspiration Associates with CLAD and Affects the Bronchial District Lipid Profile: Targeted Bile Acid Metabolomics and Lipidomics in Bronchial Washing

Delayed Non-Myeloablative Irradiation after Lung Transplantation to Induce Allograft Acceptance in a Large Animal Model

The Presence of Complement (C4d) Broncho-Alveolar Lavage in Phenotypes of Chronic Lung Allograft Dysfunction

Molecular Detection of Community Acquired Respiratory Viral Infections (CARV) and the Risk of BOS in Lung Transplant (Ltx) Recipients

Natural History of Chronic Lung Allograft Dysfunction (CLAD) and Impact of Azithromycin (AZ) in Lung Transplant (LT) Recipients
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>604</td>
<td>FVC and FEV1 Decline in Chronic Lung Allograft Dysfunction (CLAD) Phenotypes</td>
</tr>
<tr>
<td>605</td>
<td>Long-Term Outcome of Double Lung Retransplantation After Heart and Lung Transplantation for Chronic Lung Allograft Dysfunction</td>
</tr>
<tr>
<td>606</td>
<td>Role of CD4+CD25highCD127- Treg Cells in Long Term Outcome of Lung Recipients</td>
</tr>
<tr>
<td>607</td>
<td>Impact of Persistent Versus Transient Donor Specific HLA- Antibodies on Graft Outcome Following Lung Transplantation</td>
</tr>
<tr>
<td>608</td>
<td>Short Term Safety and Tolerance of Mesenchymal Stem Cells (MSC) Infusion as Cell Therapy for Patients Experiencing Treatment-Refractory Moderate Chronic Lung Allograft Dysfunction (CLAD)</td>
</tr>
<tr>
<td>609</td>
<td>Serial Parametric Response Mapping to Diagnose Bronchiolitis Obliterans Syndrome</td>
</tr>
<tr>
<td>610</td>
<td>Bronchial &amp; Alveolar Lipidomic Profile as a Marker of the Immunological and Functional Status of the Lung Allograft</td>
</tr>
<tr>
<td>611</td>
<td>Association of Prolonged Hospital Stay during Transplant Surgery with Long Term Outcomes among Patients with Lung Transplantation</td>
</tr>
<tr>
<td>612</td>
<td>Serum miRNAs as Potential Biomarkers for the Bronchiolitis Obliterans Syndrome after Lung Transplantation</td>
</tr>
<tr>
<td>613</td>
<td>Influence of Non-Donor Specific Antibodies on Chronic Lung Allograft Dysfunction -A New Risk Factor in Lung Transplantation?</td>
</tr>
<tr>
<td>614</td>
<td>A National Survey of Practice and Perceptions Regarding Anti-Fibrotic Medication in Lung Transplant Recipients</td>
</tr>
<tr>
<td>615</td>
<td>How Important Is Coronary Artery Disease When Considering Lung Transplant Candidates?</td>
</tr>
<tr>
<td>616</td>
<td>Racial and Ethnic Differences in Pre-Transplantation Panel Reactive Antibodies and Outcome Following Lung Transplantation</td>
</tr>
<tr>
<td>617</td>
<td>WITHDRAWN</td>
</tr>
<tr>
<td>618</td>
<td>Depression, Quality of Life and Mortality Early Following Lung Transplantation</td>
</tr>
<tr>
<td>619</td>
<td>Outcome of Patients with End-Stage Pulmonary Hypertension Who Received Double Lung Transplantation Instead of Heart-Lung Transplantation: A Comparative Retrospective Study</td>
</tr>
</tbody>
</table>
[620] Lung Transplant Recipient Survival Following Urgent Inpatient Candidacy Evaluation

[621] De Novo Anti-HLA Class II Donor Specific Antibodies after Lung Transplantation Are Associated with Mortality after Lung Transplant Failure


[623] Sequential Bronchoalveolar Lavages Reflect Distinct Pulmonary Compartments: Clinical and Research Implications in Lung Transplantation

[624] Lung Transplantation and Concomitant Treatment of Significant Coronary Artery Disease: Insights from a Single-Center Experience

[625] The Optimal Number of Transbronchial Biopsies Needed to Evaluate Rejection in the Lung Allograft

[626] Early Diagnosis of Gastroesophageal Reflux Disease After Lung Transplantation Using the RSI and Impact of Surgical Techniques: Minimally Invasive or Clamshell Incision, What Is Better?

[627] V/Q SPECT CT in Screening for Pulmonary Embolus Following Lung Transplantation

[628] Is Routine Respiratory Viral PCR Testing in Lung Transplant Recipients Helpful?

[629] Altered Surfactant Turn-Over Immediately after Lung Transplantation Is Associated with Impaired Graft Function at Three Months

[630] Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Outcomes after Lung Transplantation

[631] Impact of Pre-Transplant Sensitization on the Development of Anti-HLA Antibodies after Lung Transplantation: A Prospective Pilot Study


[633] Peri-Operative Transfusion Practices in Lung Transplant Patients

[634] Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database

[635] Impact of Operator and Anesthesia Choice on Bronchoscopic Biopsy Yield and Complications
Outcome of Single Lung Transplantation for Lymphangioleiomyomatosis

Microarray Analysis of Transbronchial Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-cell Mediated Inflammation

Usage of Aprotinin (Trasylol) in Bilateral Lung Transplantation - Friend or Foe?

Early Acute Kidney Injury in Lung Transplantation Is Associated with Significant Mortality

Extracorporeal Photopheresis in Chronic Lung Allograft Dysfunction: Data Support Their Use?

Quantitation of the Effect of Azole Antifungals on Tacrolimus Clearance

IVIG Infusions Deplete Donor-Specific HLA Antibodies in Lung Transplant Recipients

Desensitization Therapy Before Lung Transplantation

Intravenous Immunoglobulin in Sensitized Lung Transplant Recipients and Early Outcomes

Trough Blood Concentrations Are an Accurate Indicator of Tacrolimus Exposure Early Post Lung Transplantation

Pre-Treatment High Titer DSA Is Associated with Non-Responsiveness to Carfilzomib-Based AMR Therapy in Lung Transplant Recipients

Prolonged Administration of Twice Daily Bolus Intravenous Tacrolimus Early after Lung Transplantation

Mechanical Circulatory Support (MCS, BSI, HF, ID, NHSAH, PH, PHARM)

Diagnosis and Management of Pump Thrombosis in Patients with Continuous-Flow Ventricular Assist Devices

Thrombolysis for Pump Thrombosis after LVAD: Weighing Benefits and Risks

Clopidogrel Does Not Increase Incidence of Bleeding in LVAD Patients

Risk Factors of Gastrointestinal Bleeding after Continuous Flow Left Ventricular Assist Device
LVAD Support Increases Plasma Iron Species: Implications for a Pathophysiologic Relationship between LVAD-Associated Hemolysis and Thrombosis

Danazol as a Treatment to Reduce Reoccurrence of Hospitalization for Gastrointestinal Bleeding in Patient with Continuous Flow Left Ventricular Assist Device

The Use of Heparin in the Setting of Elevated LDH and Suspected LVAD Pump Thrombus; a Single Center Experience

Preoperative Risk Factors for Stroke After HeartWare Left Ventricular Assist Device Implantation: Texas Heart Institute Experience

Microbubbles in Patients with LVADs: Echocardiographic Markers for LVAD Pump Thrombosis?

Clinical Variables Associated with Gastrointestinal Bleeding in Patients Supported by Continuous-Flow Left Ventricular Assist Devices

The Clinical Relevance of Transcranial Doppler Detection of Micro-Embolic Signals in Patients with Heartmate II

ABO Blood Group and Left Ventricular Assist Device Therapy: A Multi-Institutional Analysis Detects Significant Differences in Outcomes

Intermittent Low Speed Software (Lavare Cycle) May Not Reduce the Incidence of Gastro-Intestinal Bleeding Events in Patients with HeartWare HVAD

Clinical Predictors of Pump Thrombosis in Explanted Ventricular Assist Devices

Effect of an Institutional Protocol for Gastrointestinal Bleeding in Left Ventricular Assist Device Patients

Severity of Hemolysis Is Associated with Death and Ischemic Stroke during Veno-Arterial Extracorporeal Membrane Support

Speed Reduction Does Not Restore High Molecular Weight Von Willebrand Multimers during Heart Mate II Support: An In-Vivo Analysis

A Multicenter Evaluation of Octreotide for Ventricular Assist Device Related Gastrointestinal Bleeding

Eptifibatide in the Treatment of Pump Thrombosis: What Is the Prescription?

Abnormal Pre-Operative Mixing Studies Identify VAD Patients at High Risk for Spontaneous Bleeding
[668] Correlation of LVAD Outflow Graft Orientation with Aortic Root Thrombosis Rationalized by Patient Specific Computational Fluid Dynamics Simulations

[669] Drive Line Infections Are Not Associated with an Increased Incidence of Thromboembolic Complications in Patients on Continuous Flow LVAD Support

[670] The Incidence of Spontaneous Intracranial Hemorrhage Is Associated with Infection in Patients with Mechanical Circulatory Support

[671] Pre-Implant GI Evaluation and 12 Month Risk of GI Bleeding among Patients with CF-LVAD

[672] A Novel Technique to Study Arteriovenous Malformations in Left Ventricular Assist Device Patients with Gastrointestinal Bleeding

[673] Three-Fold Increase in Bleeding Rate in LVAD Patients Bridged with Enoxaparin for Sub-Therapeutic INR

[674] Use of Rosendaal Method for Calculating Time above Therapeutic INR Range as a Tool to Assess Relative Bleeding Risk in Patients with Left Ventricular Assist Devices

[675] The Effect of Preoperative Serum Iron Levels on Thromboembolic Events after Left Ventricular Assist Device Implantation

[676] Usefulness of a Multipronged Strategy to Prevent Device Thrombosis in HeartMate II Left Ventricular Assist Devices

[677] Elevated Levels of 11-dehydrothromboxane B2 in Urine Is Associated with an Increased Risk of Bleeding in Patients Supported with a Continuous Flow-Left Ventricular Assist Device

[678] Reoperation for Bleeding Does Not Adversely Impact Long-Term Outcomes in LVAD Recipients

[679] Intestinal Microbiota Changes in Left Ventricular Assist Device Supported Patients with Gastrointestinal Bleeding

[680] Aortic Valve Opening Status and Gastrointestinal Bleeding Risk in Patients with HeartWare HVAD

[681] Triple Antithrombotic Therapy in Patients with Left Ventricular Assist Devices: A Single Center Experience

[682] Impact of Atrial Fibrillation on Pump Thrombosis and Thromboembolic Events in Long-Term Left Ventricular Assist Device Therapy

[684] Continuous-Flow LVAD Support Alters Gastrointestinal Vascularity: A Likely Contributor to LVAD-Associated Gastrointestinal Bleeding

[685] Discharge Lactate Dehydrogenase (LDH) Level Predicts Early Device Thrombosis in Patients with HEARTMATE II Left Ventricular Assist Devices: A Retrospective Cohort Analysis

[686] Elevated Preoperative Plasma Free Hemoglobin and Hemin May Predict LVAD Thrombosis

[687] The Use of IntegriIn Alone or in Combination with Heparin or Argatroban for Suspected Pump Thrombosis in Patients with Left Ventricular Assist Devices

[688] ABO Blood Group and Bleeding Post-LVAD

[689] Impact of Reduced Antiplatelet Therapy on Early Hematologic Adverse Events During Heart Mate II Support

[690] New Method to Route the Driveline of Implantable Left Ventricular Assisted Device for Prevention from Driveline Infection

[691] Surgical Treatment of Mediastinitis with Omentoplasty in Ventricular Assist Device Patients: Report of Referral Center Experience

[692] Infectious Complications in Extracorporeal Membrane Oxygenation (ECMO) Patients

[693] MOVED TO MINI ORAL SESSION 07

[694] Surgical Management of Driveline Infections in Patients with Ventricular Assist Devices

[695] Left Ventricular Assist Device Related Infections: Does the Time of Onset Matter?

[696] Increased Driveline Infection with Betadine Antisepsis: Considerations for Chlorhexidine Intolerant Patients

[697] Effect of Tunneling Method on Driveline Infection: Looking Beyond the Silicone-Skin Interface (SSI) Registry

[698] Driveline Angle Is Crucial to Prevent Exit Site Infection in Patients with HeartMate II

[699] Comparison of Device-Related Infections between Two Continuous Flow Ventricular Assist Devices
[700] Left Ventricular Assist Device – Related Infection: Long-Term Treatment Efficacy with Pump Exchange

[701] MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome?

[702] Immune Competence Status as Related to Infection in Heart Transplants after Ventricular Assist Device Implantation

[703] Distal Limb Perfusion - A Necessary Third Cannula in Extracorporeal Membrane Oxygenation

[704] Hemolysis Is Associated with an Elevated Blood Pressure During Heart Mate II Support

[705] Readmission During Long-Term Follow-Up After Left Ventricular Assist Device Implantation

[706] Right Ventricular Failure in Patients with Left Ventricular Assist Devices Is Associated with Downregulated Chemokine Receptors and Altered Right Ventricular Pressure Waveforms

[707] Readmission within 30 Days after Left Ventricular Assist Device Implantation Is Associated with Increased Long-Term Mortality

[708] Comparing Changes in Aortic and Mitral Valve Function with Axial (AX) Versus Centrifugal (CR) Left Ventricular Assist Devices

[709] Aortic Valve Opening Status and Stroke Risk in Patients with HeartWare HVAD

[710] Worsening Aortic Regurgitation During HeartWare HVAD Support Is Common Despite Optimization of Pump Speed and Use of the Lavare Cycle

[711] Evaluating Predictive Parameters for Right Ventricular Failure During LVAD Implantation in a Single Center Patient Cohort

[712] Inflow Restriction in the HeartMate II LVAD: A Late Complication

[713] Combined Therapy of Ventricular Assist Device and Extracorporeal Membrane Oxygenator for Profound Acute Cardiopulmonary Failure

[714] Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients

[715] Incidence and Outcomes After Stroke on Rotary Flow Ventricular Assist Device Support

[716] Predictors of Readmission in Long-Term Continuous Flow Left Ventricular Assist Device Support
Worsening Renal Function after Ventricular Assist Device Placement Is Associated with Twice the Risk of Death over 3 Years

Circulating Biomarkers of Hemolysis Are Not Significantly Increased among Patients Supported with Micro-Axial Flow Catheters

Retained Blood Syndrome Impacts Outcomes after Left Ventricular Assist Device Implantation

RV Longitudinal Strain Predicts RV Failure and Other Adverse Events Post LVAD Implantation

The Impact of LVAD Complications on Short-Term Outcomes after Heart Transplantation

Outflow Graft Obstruction of the Heart Ware HVAD Left Ventricular Assist Device: A Single Center Case Series

Survival and Driveline Infection Rates in Patients on Chronic Immunosuppressive Therapy Who Undergo Left Ventricular Assist Device Implantation

Fatal Flaw — Driveline Fracture as a Rare but Serious Complication of Mechanical Circulatory Support with Left Ventricular Assist Devices

Risk Factors for the Development of Severe Hyperbilirubinemia after Left Ventricular Assist Device Implantation

Use of Tissue Plasminogen Activator (tPA) to Successfully Treat HeartWare LVAD (HVAD) Pump Thrombosis

New Definition, Same Old Problem: Characterizing the Condition of Right Heart Failure in INTERMACS

Avoiding Readmission After LVAD Implantation: Can We Predict It?
Identification of MicroRNA Expression Profile of Different Types of Rejection During the First Year After Heart Transplantation with Next Generation Sequencing Technology

Pathology of Ventricular Assist Devices: A Tertiary Care Center’s 15-Year Experience

Creating Standardized Reporting for Non-Rejection Lung Transplant Pathology to Improve Interobserver Agreement

Histomorphology and C4d Expression Are Poor Predictors of Antibody-Mediated Rejection (AMR) in Lung Transplant Recipients

Airway Centered Neutrophils in Post-Transplant Transbronchial Biopsies: A Poor Predictor of Infection

Ultrastructural Examination of Lung Transplant Allografts for Pulmonary Alveolar Proteinosis
Economics, Ethics, Public Policy (EEP, HF, HTX, MCS, NHSAH)

[735] Expensive Taste: US Medicare Policy Regarding Destination Therapy VADs Leads to Additional Medical Costs

[736] Financial Impact of Extracorporeal Life Support on Survivors Versus Non-Survivors

[737] Success of Left Ventricular Assist Device Therapy in Rural United States Residents

[738] Need and Supply of Heart Replacement Therapy in Italy, with U.S. as Benchmark

[739] Morbid Obesity in Heart Transplant Does Not Affect One Year Survival

[740] Outcome of Heart Transplantation in Patients Supported by ECMO: Is the APACHE IV Score a Predictor of Survival?

[741] Impact of Advanced Heart Failure on Hospital Readmissions in the Elderly

[742] Establishing Institutional Costs in the Year Before and After VAD Implant and Before Heart Transplant

[743] Ethical Analysis of Withdrawing Total Artificial Heart Support

[744] Cost-Effectiveness Comparison of Intra Aortic Balloon Pump versus Left Ventricular Assist Devices as Bridge to Heart Transplant (BTT) Strategies
Heart Failure

[745] Beneficial Effects of Sildenafil in Patients with Severe Tricuspid Regurgitation; Improvement in Quality of Life and Exercise Capacity

[746] Perceived Health Status in Adult Fontan Patients: The Impact of Previous Heart Failure Hospitalization

[747] Impact of Education Alone vs. Education and Medical Intervention vs. Standard Treatment in Re-Hospitalization for Heart Failure

[748] Heart Failure Patients’ Quality of Life and Perception of Palliative Care

[749] Association of sST2 with GDF-15 and Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy

[750] GDF-15 Correlates Positively with Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy

[751] Characterization of Patients with Predominantly Intramural Coronary Amyloidosis

[752] Echocardiographic Predictors of Admission among Ambulatory Patients with HFrEF

[753] Right Ventricular T1 Mapping: A Feasibility Study

[754] Fick Cardiac Index Predicts Disease Progression in UNOS Status 2 Patients

[755] Utility of Wireless Pulmonary Artery Pressure Measurement System (CardioMEMS®) in Heart Failure Patients with Non-Cardiac Advanced Organ Failure or Organ Replacement

[756] Prevalence of Advanced Heart Failure (AdHF) Utilizing the Latest Published Definitions Yields Higher Than Previously Published Data

[757] Monocyte Gene Expression before and after LVAD Implantation

[758] Are All Patients Equal in Response to Intra-Aortic Balloon Counterpulsation?


[760] Surgical Therapy in End-Stage Heart Failure: Should We Change Our Vision?

[761] Role of a Multidisciplinary Shock Team in the Management of Cardiogenic Shock
Thymoglobulin Provides Protection Against Ischemia Reperfusion in the Immediate Post-Transplant Period

Immunosuppressant Regimen over Time and Their Association with Rejection, Graft Failure and Mortality

Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe

Early Post-Operative Acute Kidney Injury in Heart Transplant Recipients: Who Gets It and Does It Matter?

Long-term Effect on Albuminuria and Glomerular Filtration Rate of a Calcineurin Inhibitor-Free Everolimus Based Immunosuppressive Regimen after Heart Transplantation

Impact of Treatment with m-TOR Inhibitors on Platelet Reactivity in Heart Transplant Patients Treated with Clopidogrel. Preliminary Results

Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation

Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do?

Lack of Rejection Despite Period of No Immunosuppression: The NoTac Case Series

Towards Reduced Nephrotoxicity Following Heart Transplantation by Extended-Release Calcineurin Inhibition- A Single Center Observational Study

Novel Effect of Everolimus in Heart Transplant Recipients - Attenuation of Myocardial Hypertrophy and Improvement of Diastolic Function

Alloantibody Desensitization Therapy in Bridge-to-Transplant Patients on Continuous-Flow Left Ventricular Assist Device Support

CD38+DR+ Expression on Peripheral Monocytes and TLR2 Expression on Plasmocytoid Dendritic Cells May Be Early Markers for Severe Infection in Heart Transplantation

Outcomes of Rheumatic Heart Disease Following Heart Transplantation: ISHLT Registry Data

Outcomes of Heart Transplantation after Long-Term Circulatory Support by Ventricular Assist Devices with Driveline/Pump Infection
Cytomegalovirus Seropositivity Is Associated with Increased One Year Acute Rejection in Heart Transplant Recipients

CMV Reactivation Using Valganciclovir vs Valacyclovir in Moderate Risk Heart Transplant Recipients

Initial Experience of Heart Transplantation in India

Treatment of Sleep Apnea with Heart Transplantation: Does It Help?

Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production

A Novel Risk Score to Predict Prolonged Post-Operative Length of Stay after Heart Transplantation

Simple Technique for Open Sternal Wound Closure after Cardiac Transplant or LVAD

Post Heart Transplant Abandoned Lead Fragments: How to Avoid It?

The Prognostic Impact of One-Year Hemodynamics on Long-Term Survival After Heart Transplantation

Desensitization in Total Artificial Heart Patients

Palliative Care Integration into Cardiac Transplant Recipient Care: A Retrospective Case Series

Risk of Post-Transplant Renal Dysfunction Is Increased in Patients Supported with Continuous-Flow Left Ventricular Assist Devices

Heart Transplantation in Seniors: The Impact of Age on Outcomes?

Heterotopic Heart Transplantation in Argentina

Psychiatric Morbidity in De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression

Transplantation versus Ventricular Assist Device for the Management of End-Stage Heart Failure: An Observational Comparison of Clinical and Economic Outcomes

WITHDRAWN

WITHDRAWN

Impact of Number of Pregnancies on Allosensitization and Heart Transplant Outcomes
[796] Extra-Corporeal Membrane Support as Bridge to Transplant - An Outcome Analysis of United Network for Organ Sharing Registry

[797] Risk of Tumor Transmission After Thoracic Allograft Transplantation from Adult Donors with Central Nervous System Neoplasm - A UNOS Database Study

[798] Use of Prothrombin Complex Concentrates (PCCs) in Patients Undergoing Heart Transplant Surgery: Clinical Experience at a University Hospital

[799] Patients Save Lives: Donor Designation at the PCP Office

[800] Cardiac Surgery after Heart Transplantation - Elective Operation or Last Exit Strategy?

[801] Population Profile Submitted to Cardiac Transplantation in a Brazilian Hospital: Comparison Involving the Registry of ISHLT

[802] Recipient Related Predictors of Mortality after Heart Transplantation: Results from a Contemporary Irish National Cohort

[803] Comparison of the Clinical Outcomes After De Novo Heart Transplantation Between Adults with and without Congenital Heart Disease

[804] Prothrombin Complex Concentrate Reduces Intraoperative Blood Product Utilization in Heart Transplantation

[805] The Impact of Gender Mismatching on Early and Late Outcomes Following Heart Transplantation

[806] Prolonged Left Ventricular Assist Device Support Does Not Affect Post-Transplantation Survival

[807] Effects of Increasing Donor Age on the Risk of Permanent Pacing after Orthotopic Heart Transplantation

[808] Impact of Donor to Recipient Weight Ratios on Outcome After Cardiac Transplantation

[809] Severity of Hypertension After Heart Transplant: Does It Impact Outcome?

[810] Renal Function at One Year after Cardiac Transplantation but Not Acute Kidney Injury Is Highly Associated with Long-Term Survival and Loss of Renal Function

[811] Usefulness of the “Impact Score” to Predict One-Year Mortality in a Hispanic Heart Transplant Cohort at a Single Center in Latin America

[812] Impact of Recipient Body Mass Index on Orthotopic Heart Transplantation Outcomes
[813] Retrospective Single Centre Comparison of Outcomes between Standard Criteria and Marginal Criteria Brain Dead Heart Transplantation

[814] Sarcopenia as a Predictor of Postoperative Hospital Stay in Heart Transplant Recipients

[815] Increased Donor Selectivity Does NOT Decrease Primary Graft Failure After Heart Transplantation

[816] Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction Following Heart Transplantation: A Single Center Experience

[817] Primary Graft Failure Following Cardiac Transplantation Is Associated with Elevated Pre-Transplant Levels of Pro-Inflammatory Factors

[818] Primary Graft Dysfunction after Heart Transplantation with High Frequency of Marginal Donor Hearts

[819] Prognostic Value of High Sensitivity Troponin-T to Identify Patients at Risk of Primary Graft Dysfunction After Heart Transplantation

[820] Chronic Lung Disease Fev1/Fvc <70% and Primary Graft Dysfunction; a Marker for Prolonged Intubation Immediately Post-Transplantation

[821] WITHDRAWN

[822] Cardiac Allograft Sinus Tachycardia Is Associated with Impaired Exercise Tolerance

[823] Heart-to-Heart: Using Patients’ Native Hearts to Promote Lifestyle Change Post-Transplant

[824] Long-Term Outcome of Bridge to Recovery in Patients with Advanced Heart Failure Due to Idiopathic Cardiomyopathy

[825] Education Status as a Predictor of Outcomes in Orthotopic Heart Transplantation

[826] Quality of Life after Urgent Heart Transplantation

[827] Impact of Reduced Creatinine Clearance on Early Heart Transplantation Outcomes: A Propensity Score Adjusted Analysis
**Lung Transplantation**

(LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM)

(828) Comparison of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) Between Living-Donor Lobar Lung Transplantation and Cadaveric Lung Transplantation

(829) Prevalence of Antibody Mediated Rejection in Lung Transplant Recipients with Clinical Dysfunction and/or Histological Damage: The PADOVA Experience

(830) Outcomes of Suspected Antibody-Mediated Rejection Post-Lung Transplantation

(831) Lung Transplantation in Septuagenarians

(832) A Strategy of Performing Coronary Artery Bypass Grafting (CABG) Prior to Wait-Listing Candidates for Lung Transplantation (LT) Is Safe and Feasible

(833) Lung Transplantation on Pirfenidone: A Single Center Experience

(834) Combined Lung-Liver Transplantation: An Analysis of the UNOS Database

(835) Lung Transplantation for Systemic Sclerosis: Long-Term Survival, Freedom from BOS and Readmission Rates

(836) ECMO as a Bridge to Lung Transplantation: An Analysis of the UNOS Database

(837) WITHDRAWN

(838) WITHDRAWN

(839) Pulmonary Hypertension in COPD: A Survival Analysis of Patients Listed for Lung Transplantation

(840) Gender Differences in Long-Term Survival during the LAS Era: A Single Institution Analysis of 848 Transplant Recipients

(841) Lung Transplantation in the LAS Era: Long-Term Analysis

(842) Uncontrolled DCD with Prolonged Ex Vivo Lung Perfusion (EVLP): A Feasible Model for Donor Lung Recovery and Allocation

(843) Detection of Lung-Specific Exosome in Perfusates of Ex Vivo Lung Perfusion System

(844) Lung Transplantation after Ex-Vivo Lung Perfusion in Two Scandinavian Centres

222 THURSDAY April 28, 2016
Carbapenem-Resistant Klebsiella Pneumoniae in Lung Transplantation Recipients

Donor Derived Disease Transmission Events in Thoracic Organ Transplantation: Data Reviewed by the OPTN Ad Hoc Disease Transmission Advisory Committee

Trichosporon Infection in Lung Transplant Patients: An Emerging Fungal Infection?

Fungal Colonization and Infection in Lung Transplant Recipients Receiving Posaconazole Prophylaxis

Not Donor’s but Recipient’s Airway Organisms Are Relevant to Post-Lung Transplant Pneumonia

Use of Oral Ribavirin for Respiratory Viral Infections in Lung Transplant Patients

Assessment of CMV Specific T-Cell Immunity by the Quantiferon-CMV Assay in Lung Transplant Recipients: Brazilian Pilot Study

Outcomes Associated with Ganciclovir-Resistant Cytomegalovirus in Lung Transplant Recipients

Posaconazol Tablets in Lung Transplant Recipients: Plasma Trough Levels and Influencing Factors

Up to Six Years Experience of Lobar Lung Transplantation

10 Year Survival After Lung Transplantation: A Single Center Experience

Combined Lung-Liver Transplantation: The United States Experience

Lung Transplantation from Donation after Circulatory Determined Dead (DCD) Donors: A Single Centre Experience

Risk Factors for De Novo Malignancy Following Lung Transplantation

Gene Expression Profiling of Bronchoalveolar Lavage Cells during Aspergillus Colonization of the Lung Allograft

Outcomes in Lung Transplant Recipients with COPD with and without Alpha-1-Antitrypsin Deficiency: Single Center Experience Over Four Decades

Intermediate-Term Change of Pulmonary Function and Lung Volume after Bilateral Living Donor Lobar Lung Transplantation
| [862] | Thoracic Cavity Volume Change after Lung Transplantation According to the Underlying End-Stage Lung Disease |
| [863] | Characteristics of Various Categories of Controlled Donors after Circulatory Death Do Not Affect Outcome after Lung Transplantation; an Analysis of ISHLT DCD Registry Data |
| [864] | Cervical Neoplasia in Female Lung Transplant Recipients: Inadequate Screening and a High Burden of Disease |
| [865] | Body Mass Index in Lung Transplant Candidates: A Single Center Results |
| [866] | Soluble CD14 and LBP as Markers for Primary Graft Dysfunction |
| [867] | Systemic Inflammatory State of the Organ Donor and Risk for Primary Graft Dysfunction Following Lung Transplantation |
| [868] | Involvement of Rho-Kinase in Lung Ischemia-Reperfusion Injury Pathogenesis: Molecular Analysis in an Isolated Rat Lung Perfusion Model |
| [869] | Primary Graft Dysfunction in Lung Transplantation: A Detailed Predictive Model |
| [870] | Elevated Plasma PAI-1 Levels in the Donor Are Associated with the Development of Primary Graft Dysfunction in Lung Transplant Recipients |
| [871] | Obese Recipients of Lung Transplant Have an Increased Risk of Primary Graft Dysfunction |
| [872] | Pre-Transplant Frailty Is Associated with Hospital Readmissions and Rejection Following Lung Transplantation |
| [873] | The Prevalence and Prognostic Significance of Frailty in Patients with Advanced Lung Disease Referred for Lung Transplantation |
| [874] | Frailty in Transplantation. The FIT Study |
| [875] | Pregnancy Outcomes in 30 Lung Transplant Recipients |
Mechanical Circulatory Support

[876] Outcome of CentriMag Extracorporeal Mechanical Circulatory Support Use in Critical Cardiogenic Shock (INTERMACS 1) Patients

[877] WITHDRAWN

[878] Right Ventricular Failure Post LVAD Implantation Corrected with Biventricular Support: An In-Vitro Model

[879] The Effect of Inflow Cannula Length on the Intraventricular Flow Field of the EvaHeart LVAD-Assisted Heart

[880] WITHDRAWN

[881] Modulation of Autonomic Tone Assessed by Heart Rate Variability in Advanced Heart Failure Patients Treated with an Extra-Aortic Counterpulsation (EACP) System: A Single Center Experience

[882] Off-Pump HeartWare HVAD Left Ventricular Assist Device Implantation

[883] Association between Intraventricular Position of Inflow Cannula and Clinical Outcomes in LVAD Recipients

[884] Computed-Tomography Guided Apex Marking for Lateral Thoracotomy LVAD Implantation

[885] GLP In-Vivo Study and Durability Testing for Miniaturized EVAHEART KAIZEN [EVA-kai] System

[887] Left Ventricular Unloading in Relation to Cannula Position during Invasive Hemodynamic Ramp Test in Axial Flow Pumps

[888] Left Ventricular Assist Device Implantation by Lateral Thoracotomy to the Descending Aorta: A Propensity Matched Analysis to Standard Sternotomy Approach

[889] Pathological Substrate of intermittent Low Speed Process on the Native Aortic Valve of Patients Assisted with Left Ventricular Assist Device


[891] ECPELLA: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device

[892] Initial Experience with a Percutaneous Dual Lumen Single Cannula Strategy for Temporary Right Ventricular Assist Device Support Following Durable LVAD Therapy
[893] Sustainability of Pulmonary Hypertension Reversal Before and After Heart Transplantation in Patients Bridged with Continuous-Flow LVADs: Axial- vs Centrifugal-Flow

[894] LVAD Implantation in Patients on ECLS

[895] Is the Diameter of the Outflow Graft the Crucial Difference in Stroke Rates Between Heartmate II and HVAD? A Computational Fluid Dynamics Study

[896] Minimally Invasive Heartware HVAD Implantation with Outflow Graft Anastomosis to the Left Subclavian Artery

[897] Effect of HeartMate PHP on Resting Hemodynamics in Low Cardiac Output Patients Undergoing Elective High-Risk PCI

[898] Acute Hemodynamic Effects of Percutaneously-Deployed Axillary Intra-aortic Balloon Counterpulsation Pumps in Patients with Advanced Heart Failure

[899] Evaluation of Changes in Flow Associated with HeartMate II Inflow Cannula Angle Change

[900] Acoustic Analysis of a Continuous-Flow Left Ventricular Assist Device before and after Suspected Pump Thrombosis


[902] Validity and Reliability of a Next Generation Non-Invasive Blood Pressure Monitor in Patients with Continuous-Flow Left Ventricular Assist Device

[903] Role of Mechanical Support in Post Myocardial Infarction Septal Defects Percutaneous Repair

[904] North American Experience with Biventricular HVAD Total Artificial Heart as a Successful Bridge to Orthotopic Heart Transplantation

[905] Outcomes Following Minimally Invasive Implantation of a Centrifugal Continuous-Flow Left Ventricular Assist Device

[906] Minimally-Invasive Access and Off-Pump LVAD Implantation - Strategies to Improve Outcomes

[907] Safety of Trans Esophageal Echocardiogram Guided Percutaneous Insertion of Bi-Caval Dual Lumen Cannula (AVALON ELITE®) for Veno-Venous Extracorporeal Membrane Oxygenation

[908] A Mock Circulatory System to Research the HeartWare Pump Flow Waveform
[909] WITHDRAWN

[910] A Novel Cardiac Coordinate Modeling System for Three Dimensional Quantification of Inflow Cannula Malposition in HeartMate II Left Ventricular Assist Device Implantation


[912] Digitizing Medication Adherence Monitoring with a Novel Ingestible Nanosensor - First in Man Application Among Recipients of Continuous Flow Left Ventricular Assist Devices


[914] Expanded Experience with Percutaneous Placement of Axillary-Subclavian Intra-Aortic Balloon Pump that Permits Sitting Upright and Ambulation in Patients with Advanced Heart Failure

[915] Contemporary Outcomes of Mechanical Circulatory Support for Cardiogenic Shock: Single Center Experience of over 300 Patients


[917] Mid Term Results of Mechanical Circulatory Support in the Netherlands, a Single Centre Experience from the University Medical Centre Utrecht (UMCU)

[918] Persistent Hyponatremia Early after LVAD Implantation Does Not Result in Poor Long-Term Outcomes

[919] Single Center Experience with Successful Left Ventricular Assist Device Explantation Following Myocardial Recovery

[920] 1040 Consecutive Adult Patients Treated with Extracorporeal Membrane Oxygenation for Refractory Postcardiotomy Cardiogenic Shock, Longterm Follow-Up

[921] How Does the Effect of Opening the Pericardium on Right Ventricular Failure after LVAD Implantation

[922] Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS) - Non-Pulsatile Implantable LVAS vs. Extracorporeal LVAD as Bridge to Transplantation

[923] Differences in Heat Generation Between Axial and Centrifugal Continuous Flow Left Ventricular Assist Devices
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation of Functional Capacity Scores After Left Ventricular Assist Device Implantation in Cases with End-Stage Heart Failure</td>
<td>924</td>
</tr>
<tr>
<td>Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management</td>
<td>925</td>
</tr>
<tr>
<td>Readmission Rates in Patients with Left Ventricular Assist Devices</td>
<td>926</td>
</tr>
<tr>
<td>Clinical Outcomes and Survival after Continuous-Flow Left Ventricular Assist Device Therapy in United States Veterans: A Single Center Experience</td>
<td>927</td>
</tr>
<tr>
<td>Application of Extracorporeal Membrane Oxygenator (ECMO) Support in Adult Patients with Cardiogenic Shock as a Bridge to Implantable Left Ventricular Assist Device (LVAD)</td>
<td>928</td>
</tr>
<tr>
<td>The Value of N-Terminal Pro-Brain Natriuretic Peptide After LVAD Implantation</td>
<td>929</td>
</tr>
<tr>
<td>Hospital Readmission and Survival Rates One Year Post-ECMO Discharge</td>
<td>930</td>
</tr>
<tr>
<td>The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection</td>
<td>931</td>
</tr>
<tr>
<td>Improved Medical Resource Use by Deploying a Novel Multidisciplinary Team-Based In-Hospital MCS Unit</td>
<td>932</td>
</tr>
<tr>
<td>PCI in Patients Supported with CF-LVADs: Indications, Safety and Outcomes</td>
<td>933</td>
</tr>
<tr>
<td>Changes in Lipid Profile Subfractions on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Therapy</td>
<td>934</td>
</tr>
<tr>
<td>Palliative Care Integration for Patients Receiving Left Ventricular Assist Device as Destination Therapy</td>
<td>935</td>
</tr>
<tr>
<td>Greater Reduction in NT Pro-BNP Levels Post LVAD Is Associated with a Greater Improvement in Diabetes Control</td>
<td>936</td>
</tr>
<tr>
<td>Prealbumin as a Predictor of Mortality After LVAD Implantation</td>
<td>937</td>
</tr>
<tr>
<td>Sodium Nadir during Left Ventricular Assist Device Implantation Is Not Associated with Increased Mortality</td>
<td>938</td>
</tr>
<tr>
<td>Measuring Blood Pressure in Patients with Continuous-Flow Left Ventricular Assist Devices</td>
<td>939</td>
</tr>
<tr>
<td>The Nutritional Risk Index as a Marker for Outcomes Following Left Ventricular Assist Device Implantation</td>
<td>940</td>
</tr>
<tr>
<td>Integration of Palliative Care in End of Life Care for Patients on Durable Mechanical Circulatory Support</td>
<td>941</td>
</tr>
</tbody>
</table>
[942] Hospital Readmissions After Left Ventricular Assist Device Implantation

[943] Quality of Life among LVAD Recipients: A Comparison of Bridge-to Transplant vs. Destination Therapy Patients


[945] A Single Center U.S. Experience with the Implementation of Mandatory Patient and Caregiver Pre-Ventricular Assist Device Implantation Education

Nursing, Health Sciences, Allied Health
(NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

[946] Is Functional Status a Mediator of the Effect of the Sickness Behavior & Discomforts Symptom Clusters on Quality of Life in Heart Failure Patients?

[947] High Rates of Post-Transplant Depressive Symptoms Identified Using the CES-D

[948] The Positive Outcomes for Patients Receiving Animal Assisted Therapy after Lung Transplantation

[949] Pre Lung Transplant Patients’ Ability to Predict Post Lung Transplant Quality of Life with and without CLAD

[950] Relationship of Depression Symptoms with Sense of Coherence Among Japanese Patients After Implantation of Left Ventricular Assist Device

[951] Associations and Differences in Behavioral and Emotional Symptoms Among Parents, Teachers, and School-Aged Youth: The School Experience After Pediatric Heart Transplantation (HT)

[952] Implant Strategy Is Related to Health-Related Quality of Life at 2 Years After LVAD Implantation: An INTERMACS Analysis

[953] Patients Previously Supported by Veno-Arterial Extra Corporeal Membrane Oxygenation Have Good Long Term Quality of Life

[954] Cognitive Function and Self-Care in Patients with Left Ventricular Assist Devices (LVADs)

[955] Does Age Affect Exercise Outcomes for Adult Cystic Fibrosis Lung Transplant Recipients?
The Challenges Associated with the Ongoing Management of Heart Transplantation in Young Adults, Including Transitioning from Paediatric to Adult Care

Use of In-Situ Simulation Technique to Implement a Mechanical Circulatory Support Emergency Response System in the Pediatric Setting

Lung Transplant Patients and Carers Report Unmet Palliative Care Needs

A 7 Center Review of Left Ventricular Assist Device (LVAD) Caregiver Perceptions

Tales of Roller Coaster Rides and Resilience: Lung Transplant Caregivers in Their Own Words

Getting a New Life: Women Living with a Left Ventricular Assist Device

Non-Adherence to Medical Advice Does Not Impact Survival in a Bridge to Transplant (BTT) Left Ventricular Assist Device (LVAD) Program

A Review of Warfarin Management in Patients Supported with a Heartware HVAD Using Home INR Testing

Implementing a Change Package to Improve the Anti-Coagulation Management of Pediatric Patients on Ventricular Assist Devices

Validating the Effectiveness of Ventricular Assist Device-Specific Education during the Pre-Discharge Phase

Slow-Paced Respiration Therapy to Treat Sleep Disturbance and Symptoms in Pulmonary Arterial Hypertension

Opportunities and Restrictions in Digitizing VAD Care
[968] Impact of Infant Nutritional Status on Outcomes in Lung Transplant

[969] Evaluation of Epstein-Barr Viral Loads as a Predictor of Development of Post-Transplant Lymphoproliferative Disorder

[970] Prevalence of Malnutrition and Growth in Children after Lung Transplantation

[971] Improving Health Management: The Development of an Adolescent Specific Education Program

[972] Pediatric Extracorporeal Membrane Oxygenation Support as Treatment for Refractory Cardiogenic Shock

[973] Cannula Site Management Strategies in Pediatric Ventricular Assist Device (VAD) Patients

[974] Incidence of Thrombo-Embolic Events of Intra-Corporeal Ventricular Assist Devices in Pediatrics – EUROMACS Analyses

[975] ECMO Support in Infant Less Than 3 kg: Indications, Complications and Outcomes

[976] Bridging Children to Transplant with Short Term VADs Does Not Affect Post-Transplant Mortality

[977] Successful Treatment of VAD Pump Thrombosis in Four Pediatric Patients

[978] Sensitization across the Age Spectrum Post VAD: Can We Detect Differences between Adults and Children?

[979] WITHDRAWN

[980] Worldwide Use of SynCardia Total Artificial Heart in Pediatric Population: A 30 Year Experience

[981] Pediatric Implantable Left Ventricular Assist Device Experience

[982] Cost Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy

[983] Jarvik 2000 in Pediatrics as a Bridge to Trasplantation or as Destination Therapy: Perioperative Management
Pulmonary Hypertension
(PH, BSI, HF)

(984) WITHDRAWN

(985) WITHDRAWN

(986) MOVED TO MINI ORAL SESSION 12

(987) Clinical and Pathologic Features in Lung or Heart and Lung Transplanted Patients with a Diagnosis of Pulmonary Sarcoidosis

(988) An Analysis of Mechanism of Hypoxia in Chronic Thromboembolic Pulmonary Hypertension

(989) Exercise CMR Can Evaluate RV Function and Hemodynamics in Patients with Pulmonary Arterial Hypertension: A Pilot Study

(990) Parenchymal Lung Disease in PAH Patients Managed with Prostacyclin Agonists

(991) Phenotypic Differences in Pulmonary Hypertension Due to Left Heart Disease (PHLHD) and Reversibility with Left Ventricular Assist Devices (LVAD)

(992) Tricuspid Regurgitation Is Associated with Pulmonary Hemodynamics and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension But Does Not Alter the Geometry of Right Ventricular Contraction

(993) A Coding Polymorphism in PFAS (The Gene Encoding Phosphoribosylformylglycinamidine Synthase) Is a Determinant of Prostacyclin Dose

(994) Left Ventricular Failure after Surgery to Correct Right Ventricular Pressure Overload in Pulmonary Hypertension Patients

(995) Pulmonary Pulse-Wave Transit Time Is a Noninvasive Marker of Intrinsic Pulmonary Vascular Disease

(996) WITHDRAWN

(997) Right Atrial Pressure to Stroke Volume Ratio Predicts Mortality in Pulmonary Arterial Hypertension

(998) The Long Noncoding RNA MEG3 Is an Emerging Factor in Hypoxia-Induced Pulmonary Hypertension

(999) Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2

(1000) Fasudil Prevents Pulmonary Vascular Remodeling in a Rat Model of Pulmonary Hypertension with Left Heart
[1001] Riociguat Significantly Improved SpO2 during Exercise in Patients with CTEPH

[1002] Multi-Disciplinary Care Impacts Mortality in Children with Idiopathic Pulmonary Arterial Hypertension – Results from a Bi-National Population Based Study

[1003] Serum Cytokine Profiling in Pulmonary Arterial Hypertension

[1004] PVR Predicts Cardiac Hospitalizations in Pulmonary Hypertension Associated with HFrEF and HfPEF

[1005] Right Ventricular Performance with Exercise Declines Predictably in Patients with Idiopathic PAH

[1006] Change in PH Therapy from PDE5i to Riociguat Is Associated with Significant Incremental Increase in Cardiac Index, Decrease in Pulmonary Vascular Resistance and Mean Arterial Pressure

[1007] Survival of the PAH and CTEPH Patients in the Swedish Pulmonary Arterial Hypertension Register 2000-2014

[1008] Autologous Transfusion of Stored Red Blood Cells Impairs Endothelium-Dependent Vasodilatation in Experimental Pulmonary Arterial Hypertension. This Effect Is Reversed by Inhaled Nitric Oxide
6:00 PM - 7:00 PM
Poster Session 3
(Exhibit Hall B & C)

Infectious Diseases
(ID, HTX, LTX, MCS, NHSAH, PHARM)

(1009) WITHDRAWN

(1010) Antimicrobial Activity of Cysteamine Against Antibiotic Resistant Pathogens Isolated from Cystic Fibrosis and Non- CF Patients Including Mycobacterium abscessus Complex from Lung Transplant Recipients

(1011) Posaconazole Tablets Exposure in the Real-Life of Lung Transplantation

(1012) Successful Heart Transplantation in Patients with Total Artificial Heart Infections

(1013) Stopping Conventional Showering Decreases Pseudomonas Exit Site Infections in Left Ventricular Assist Device Patients

(1014) The Impact of the Exit Site Left Ventricule Assist Device Power Supply on Infection Incidence: A Single Center Experience

(1015) Bacteremia Is Associated with Increased LVAD Mortality

(1016) Successful Heart Transplantation in Patients with Active Staphylococcus Bloodstream Infection and Suspected Mechanical Circulatory Support Device Infection
Lung Transplantation
(LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM)

(1017) Transplantation of Lungs Recovered from Donors After Euthanasia Results in Excellent Long-Term Outcome

(1018) Bile Acid in Donor Bronchial Wash as a Biomarker of Gastric Acid Aspiration to Determine Suitability of Donor Lungs for Transplantation

(1019) Cadaveric Lobar Lung Transplantation Based on the Experiences of Living-Donor Lobar Lung Transplantation

(1020) Regional Variation in Lung Transplantation in the Era of the Lung Allocation Score

(1021) Strategies of Donor Lung Preservation after Cessation of Circulation in Controlled DCDs

(1022) A Survival Benefit in More Recent Eras for Lung Transplant Recipients with a LAS in the Upper Quartile

(1023) Preformed HLA Specific Antibodies in Adult Cardiothoracic Transplantation - Does the Presence of Low Levels Matter?

(1024) OTO Score and Medium-Term Survival in Lung Transplantation

(1025) Management and Outcomes of Incidental Donor Derived Pulmonary Embolism

(1026) The Paradoxical Impact of Warm Ischemia on Lung Allograft Survival

(1027) Does Hanging Donors Be Really Marginal for Lung Transplantation?

(1028) ABO Compatibility in Lung Transplantation

(1029) Correlation New UNOS LAS and ET LAS

(1030) How Big Is the Pool of Rejected Donor Lungs That Potentially Could Become Transplantable with EVLP? A Single Center Analysis of Registered Donor Data

(1031) Refinement of Lung Donor Scoring System with Consideration for Negative Impact of Prolonged Donor Intubation Time

(1032) Clinical Outcomes of Lung Transplantation from Extended Criteria Donor Lungs

(1033) Massive Donor Transfusion Increases Recipient Early Mortality after Lung Transplantation

FRIDAY April 29, 2016 235
Lung Transplantation from Uncontrolled Circulatory Death Donors: Potential Benefits and Barriers

HLA-DQB-Matching Is Feasible and Does Not Prolong Wait Times for Lung Transplant Recipients

The Association between Donor-Recipient Race Matching and Survival Following Lung Transplantation Differs Based on Recipient Race

Veno-Arterial Extracorporeal Life Support (ECLS) After Bilateral Lung and Heart-Lung Transplantations for Pulmonary Hypertension

Interim Results of a Phase II Clinical Trial Comparing Outcomes of Recipients of Lungs Recovered from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) Assessed by Ex Vivo Lung Perfusion (EVLP) and CT Scan to Outcomes of Recipients of Lungs from Brain-Dead Donors (BDDs)

Mechanical Circulatory Support (MCS, BSI, HF, ID, NHSAH, PH, PHARM)

Successfully Weaned Patients after VA ECMO Due to Cardiogenic Shock: Etiology and 1-Year Survival

Left Ventricular Assist Device Placement with Concomitant Ventricular Reconstruction for Aneurysmal Disease

Left Ventricle Mechanical Circulatory Support Implantation as Successful Bridge to Transplantation for Patients with Cardiac Cachexia

A Novel Combined Endpoint Integrating Quality of Life Can Inform Decisions about VAD in Ambulatory Advanced Heart Failure

Myocarditis Treated with VA-ECMO: A Single Centers Experience

Implantation of Continuous Flow-Left Ventricular Assist Devices (CF-LVAD) in the Extremely Obese (BMI ≥40 kg/m2): A Single Center Experience

Cardiopulmonary Resuscitation – Is Veno-Arterial Extracorporeal Membrane Oxygenation an Option?

Is “Cardiopulmonary Exercise Testing” Essential to Indicate Ventricular Assist Device in Patients with INTERMACS Profile 4-7?

Clinical and Hemodynamic Profile of Bridge to Recovery Patients Implanted with a Continuous Flow LVAD
[1048] Impact of Venous-Arterial Extracorporeal Membrane Oxygenation Standardized Guidelines: Worth the Effort?

[1049] Patient Selection for Ventricular Assist Devices: What Happens in Real Practice?

[1050] Does INTERMACS Classification Predict Outcomes after LVAD Implantation?


[1052] Combined Renal Risk Score Predicts Post-Implant Renal Failure in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients

[1053] No Distance Is Too Great: A Patient’s Commute to Their Implantation Center Is Not Associated with Worse Outcomes Following Placement of a Left Ventricular Assist Device

[1054] Impact of Preoperative Glycemic Control on Long-Term Mechanical Circulatory Support Device Implantation

[1055] Role of ECMO in Acute Myocardial Infarction Complicating Cardiogenic Shock

[1056] Characteristics of Non-Compliant (NC) LVAD Patients

[1057] Arrhythmia History Predicts Morbidity and Mortality Following LVAD Implantation

[1058] QRS Duration Predicts Outcomes Following Implantation of a Left Ventricular Assist Device


[1060] Impact of Preoperative Variables on Hospital Length of Stay in Patients Undergoing Continuous Flow LVAD Implantation

[1061] Understanding Perceived Racial and Gender Differences in LVAD Use on the Transplant Waitlist

[1062] WITHDRAWN

[1063] How Can We Predict Bi-Ventricular Assist Device Requirement?

[1064] Pre-Extra Corporeal Membrane Oxygenation (ECMO) MELD Score May Predict Meaningful Survival

[1065] Mean Arterial Pressure to Central Venous Pressure Ratio – A Novel Marker for Right Ventricular Failure after Left Ventricular Assist Device Placement

[1066] MOVED TO MINI ORAL SESSION 08
Changes in Left Ventricular Pacing Lead Impedance Correlate with Changes in Pulmonary Capillary Wedge Pressure during Hemodynamic Ramp Tests

Assessment of Ventricular Remodeling Post-LVAD with 3D Echocardiography and Surface Analysis

A Retrospective Cohort Analysis of Chimney Graft Versus Percutaneous Perfusion Techniques for Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Refractory Cardiogenic Shock

Blood Product Utilization in Continuous Flow Left Ventricular Assist Devices: Single Institution Trends

Considering LV Dimension Is Important in Assessing the Risk of Right Ventricular Failure after Left Ventricular Assist Device Implantation

Incidence and Predictors of Left Ventricular Functional Recovery on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support

Can Patients with Restrictive Physiology Be Successfully Bridged to Transplant with Left Ventricular Support Alone Versus Biventricular Support?

Invasive and Noninvasive Hemodynamic Measures Correlate in Patients with Continuous Flow Left Ventricular Assist Devices

Effect of Biventricular Support on Exercise Capacity Compared to Left Ventricular Support Alone: Is This the Right Time for Endurance Testing?

Individual Optimal Blood Pressure Determined by Cerebral Autoregulation Monitoring During and After Continuous-Flow Left Ventricular Assist Device Implantation

Impact of Aortic Insufficiency on Unloading Properties of Continuous-Flow Left Ventricular Assist Devices

Implications of Exercise Oscillatory Ventilation Post Ventricular Assist Device Implantation

The Role of Inertgas-Rebreathing Method During Exercise Testing in LVAD Patients

Correlation of Non-Invasive Flow Estimation of the Axial-Flow Left Ventricular Assist Device with Fick and Thermal Cardiac Output

To Compress or Not to Compress: Revisiting the Use of Chest Compressions in LVAD Patients

Routine Postoperative Cardiac Monitoring with Hemodynamic Transesophageal Echocardiography (hTEE) for Patients with Left Ventricular Assist Device (LVAD)

[1084] Changes in Lipid Profile Following Durable Mechanical Circulatory Support: Confirming the “Lipid Paradox” in Heart Failure

[1085] Standardized Telephone Intervention Algorithm for Improved Ventricular Assist Device Outpatient Management


[1087] Oxydative Stress in Heart Failure Patients after Implantation of Continuous Flow Left Ventricular Assist Devices

[1088] Feasibility of 24-Hour Advanced Ambulatory Blood Pressure and Hemodynamic Monitoring in Patients with Continuous-Flow Left Ventricular Assist Device

[1089] Lessons from a 7-Year Experience Using a Rescue-to-Bridge Strategy with TandemHeart to HeartMate II for Severe Refractory Cardiogenic Shock

[1090] Outcomes with Implementation of Algorithmic Hemodynamic Ramps in Patients with Continuous Flow LVADs

[1091] Specialized Heart Clinic Versus Standard Anticoagulation Clinic Warfarin Management in Patients with Left Ventricular Assist Devices

[1092] Invasive Hemodynamic Testing in Ambulatory Left Ventricular Assist Device Patients

[1093] Inpatient Rehabilitation of Biventricular Support Patients - A Special Challenge

[1094] 3D Surface Analysis of RV and LV Shapes as Predictors of Post-LVAD RV Failure

[1095] Vascular Reactivity Analysis in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVADs) - The Role of Endothelial Function in Continuous Flow Physiology

[1096] Pump Speed Increase Improves Submaximal Exercise Tolerance in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients-A Double Blind Randomized Trial

[1097] Coagulation and Inflammation Profiles with Axial and Centrifugal Flow LVADs

[1098] Advanced Heart Failure Therapies in a High Risk Urban Population
[1099] Clinical Experience with Long-Distance Transportation of Patients on Acute Mechanical Circulatory Support Devices

[1100] Lactate Dehydrogenase Isoenzyme Monitoring in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs)

[1101] Patients with Continuous-Flow Left Ventricular Assist Devices Have a Reduced Baroreceptor Sensitivity Compared to Healthy Controls

[1102] WITHDRAWN

[1103] Investigating a Novel Synergy Applying Remote Ischemic Conditioning to Modulate the Altered Physiology of Continuous Flow Left Ventricular Assist Devices, to Reduce Stroke and Other Adverse Effects: The IMPULSE Trial Pilot Results

[1104] Plasma Proteomics in Left Ventricular Assist Device Recipients: A Pilot Study

[1105] Does Right Ventricular-Arterial Coupling Predict Early Right Heart Failure in LVAD Recipients?

[1106] The Effect of Cardiac Rehabilitation on Functional Capacity, Psychological Symptoms and Quality of Life in Patients with a Left Ventricular Assist Device

[1107] Outcomes of Ventricular Assist Device Therapy for Patients at an INTERMACS Profile 1: Single Center Experience


[1109] The Role of Neurohormonal Therapy in Patients with Left Ventricular Assist Devices

[1110] Evaluation of Systemic Heparin vs. Bivalrudin Anticoagulation in Patients Supported by Extracorporeal Membrane Oxygenation

[1111] Evaluating the Safety and Efficacy of Enoxaparin in Bridging Mechanical Circulatory Support (MCS) Patients from Subtherapeutic to Therapeutic INR in an Outpatient Setting

[1112] The Role of Biventricular Assist Device on Patients with Multiorgan Failure Due to Fulminant Myocarditis: Single-Center Experience
<table>
<thead>
<tr>
<th>#</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1113</td>
<td>Utility of a Novel Biomarker, Symmetric Dimethylarginine, to Assess Renal Function in Pediatric Heart Transplant Recipients</td>
</tr>
<tr>
<td>1114</td>
<td>Risk of Death Due to Cardiac Arrest in Pediatric Heart Transplantation: Query of the UNOS Database</td>
</tr>
<tr>
<td>1115</td>
<td>Heart Failure Related Hospitalizations in Children with Single Ventricle Heart Disease: Prevalence, Risk Factors for Mortality and Economic Burden</td>
</tr>
<tr>
<td>1116</td>
<td>Correlation between Solid Phase Assays and Positive CDC Crossmatches in a Surrogate Transplant Model</td>
</tr>
<tr>
<td>1117</td>
<td>Developmental Delay Is Not a Risk Factor for Poor Outcome in Pediatric Heart Transplantation</td>
</tr>
<tr>
<td>1118</td>
<td>Functional Status of Children Supported on LVADs at Transplant: How Does It Compare to Children on Inotropic Support?</td>
</tr>
<tr>
<td>1119</td>
<td>Platelet Activation, Receptor Shedding and Aggregation in Pediatric Patients with Congenital Heart Disease Undergoing Cardiopulmonary Bypass</td>
</tr>
<tr>
<td>1120</td>
<td>Emergency Department Utilization by Pediatric Heart Transplant Recipients</td>
</tr>
<tr>
<td>1121</td>
<td>Impact of Pediatric Obesity on Heart Transplantation</td>
</tr>
<tr>
<td>1122</td>
<td>Near Infra-Red Spectroscopy in Pediatric Heart Failure: A Novel Application of a Promising Technology</td>
</tr>
<tr>
<td>1123</td>
<td>Insights into Mixed Cellular and Antibody-Mediated Rejection (MR) in Pediatric Heart Transplant Recipients</td>
</tr>
<tr>
<td>1124</td>
<td>A Surprising Era Effect on Cardiac Allograft Vasculopathy: What Can We Learn and What Does This Mean for the Future?</td>
</tr>
<tr>
<td>1125</td>
<td>The Use of the Terminal Complement Inhibitor Eculizumab in Pediatric Heart Transplant Recipients</td>
</tr>
<tr>
<td>1126</td>
<td>The Impact of Age on the Incidence and Prevalence of Moderate to Severe Cellular Rejection Detected by Routine Surveillance Biopsy in Pediatric Heart Transplantation</td>
</tr>
<tr>
<td>1127</td>
<td>Rehospitalization Following Pediatric Heart Transplant: Frequency, Indications and Outcomes</td>
</tr>
<tr>
<td>1128</td>
<td>Utility of the Routine Screening Echocardiogram After Endomyocardial Biopsy for Identification of Hemopericardium or Tricuspid Valve Injury</td>
</tr>
</tbody>
</table>
[1129] Prolonged Donor Ischemic Time Is Not Associated with Worse Cardiac Graft Function in Children

[1130] Timing of Tacrolimus Initiation and Impact on Renal Injury in Pediatric Heart Transplant Patients

[1131] Poverty Is an Independent Socioeconomic Risk Factor for Death Following Pediatric Heart Transplant

[1132] Unhealthy Weight Gain in Pediatric Post-Heart Transplant Patients: Incidence and Risk Factors

[1133] Temporary Inactivation from the Waitlist Due to Decline in Health Does Not Affect Mid-Term Outcomes among Pediatric Heart Transplant Recipients

[1134] Allergies and Autoimmune Disorders in Children after Heart Transplantation

[1135] WITHDRAWN

[1136] Preliminary Study: Left Ventricular Torsion in Clinically Stable Heart Transplant Recipients in Children

[1137] Venous Congestion Is Associated with Renal Impairment in Children with Cardiovascular Disease

[1138] Nutritional Status of Children Undergoing Heart Transplantation at the Heart Institute of São Paulo (Incor) between 2013-2015

[1139] Impact of Routine Surveillance Biopsy Intensity on the Diagnosis of Moderate to Severe Cellular Rejection and Survival After Pediatric Heart Transplantation

[1140] Calcineurin-Inhibitor Minimization in Pediatric Heart Transplant Recipients

[1141] Pre-Clinical Testing Results for a New Infant-Sized VAD

[1142] Posterior Reversible Encephalopathy Syndrome after Pediatric Heart Transplantation

[1143] Genetics of Pediatric Cardiomyopathy

[1144] Hospital Readmissions in Children Following Orthotopic Heart Transplantation: Do Social Factors Matter?

[1145] School Intervention: An Essential Element of Heart Transplant Care

[1146] Steroid Maintenance in Preventing Rejection and Its Effects on Post-Transplant Morbidity

[1147] ADMA Does Not Correlate with Markers of Cardiac Dysfunction in Pediatric Heart Transplant Recipients

[1148] Exercise Tolerance in Pediatric Heart Transplantation Patients with Non-Cameral Coronary Artery Fistulae
Coronary Flow Reserve Predicts Graft Loss in Pediatric Heart Transplant Patients

The End-of-Life Experience in Pediatric Heart Transplant Recipients

Milrinone Use for Inotropic Support in Pediatric Acute Heart Failure: Utilization, Safety and Markers of Efficacy

Pediatric Myocarditis in a Contemporary Multi-Center Cohort

A Single Center Pediatric Heart Recipients to Adult Services Retrospective Study of Sentinel Events

Coronary Allograft Vasculopathy: A 25 Year Pediatric Experience

Pediatric Myocarditis: Variations in Immunotherapy and Impact on Outcomes

Long-Term Survival in Pediatric Heart Transplantation: A 30-Year Single-Center Experience

Antibody Mediated Rejection Is Associated with Worse Outcome Than Acute Cellular Rejection after Pediatric Heart Transplant

Liver Abnormalities and Post-Transplant Survival in Fontan Patients

Modified Model for End-Stage Liver Disease eXcluding INR (MELD XI) Score Predicts Post-Heart Transplant Mortality Among Children with Congenital Heart Disease

Hemodynamic Findings Associated with End-Organ Dysfunction in Children with End-Stage Heart Failure

Pediatric Heart Transplant Donor and Recipient Factors Associated with Death or Re-Transplantation by One Year

The Fontan Liver after Cardiac Transplantation

Expanding the Donor Pool: Regional and Age Variation in Pediatric Organ Donation Rates

Impact of Geographic Distance from Transplant Center on Pediatric Heart Transplant Outcomes

Fontan Patients Have Similar Rates of Development of HLA Antibodies After Heart Transplant Regardless of PLE Status

Optical Coherence Tomography After Pediatric Heart Transplantation – The Experience of 51 Examinations
Relationship between Hemodynamic Variables and NYHA/Ross Functional Capacity in Children with Advanced Heart Failure

Mortality Is Increased in Pediatric Heart Transplant Recipients with a Positive Cross-Match

Pharmacy & Pharmacology

Dabigatran May Have More Significant Drug Interactions with Calcineurin Inhibitors Than Oral Anti-Xa Inhibitors

Does On-Site Analysis of Serum Levels Optimise Management of Patients Taking Voriconazole? A Retrospective Cohort Study

Warfarin, Rifampin and LVADS- OH MY: Effect of Rifampin on INR and Time in the Therapeutic Range in Patients with a Left Ventricular Assist Device

Intra-Patient Variability of Tacrolimus Levels and Cardiac Allograft Outcomes

Concomitant Warfarin and Aspirin Versus Warfarin Alone for the Prevention of Embolic Events in Patients with a Left Ventricular Assist Device [Thoratec HeartMate II®]

Tacrolimus Immunosuppressive Regimens Are Associated with a Mortality Benefit in Lung Transplantation Recipients at a High-Volume Single Center

Use of Pentoxifylline to Mitigate Amphotericin Induced Nephrotoxicity

Medication Regimen Complexity in Older Adults with Heart Failure

Anticoagulation Monitoring in Left Ventricular Assist Device [LVAD] Patients

Pre-Transplant Amiodarone Exposure Increases Mortality in Cardiac Transplant Recipients: A Meta-Analysis

Rituximab for Antibody Mediated Rejection of Uncertain Benefit

Mycophenolate-Based Immunosuppressive Regimens Are Associated with a Mortality Benefit in Lung Transplantation Recipients at a Single High-Volume Center
Thromboelastographic Evidence for Reduced Dose Enoxaparin or Fondaparinux Bridge Therapy in Mechanical Circulatory Support Patients with Sub-Therapeutic INR

Safety and Efficacy of Recombinant Activated Factor VII (Novoseven) Administration in Pediatric ECMO Patients

Mycophenolate Mofetil in Adult Orthotopic Heart Transplant Recipients: How Much Is Too Much?

89 Year Old Donor Heart: Alive and Kicking!

Massive Air Embolism Resulting in Ischemic Stroke After LVAD

Primary Cardiac B-cell Lymphoma Masquerading as Acute Cellular Rejection

Bridge to Diagnosis: Impella Support in a Pediatric Patient with Myocarditis

Plasma Exchange to Remove HIT Antibodies Prior to Left Ventricular Assist Device Implantation and Heart Transplantation

Lung Transplantation after Awake v-v ECMO Treatment with Extended Reconditioning with the Organ Care System -Pushing the Limits-

Long Term Successful Biventricular Assist Device (BIVAD) Use in a Post-Transplant Patient: Lessons Learned

Outcome of Patients with Pulmonary Arteriovenous Malformations After Heart Transplant

Unusual Pattern of Constrictive Pericarditis in the Patient Who Underwent Heart Transplantation

Cryptosporidium-Associated Elevated Tacrolimus Levels and EBV Viremia in a Pediatric Heart Transplant Recipient

Post-Fontan Protein-Losing Enteropathy: A Possible Context for Under-Recognized HLA Antibodies

Bringing Complement Under Control: Atypical Hemolytic-Uremic Syndrome Successfully Treated with Eculizumab
[1197] Successful Durable LVAD Implantation Following Repair of Acute Post-Myocardial Infarction Ventricular Septal Defect

[1198] Safe Utilization of Hydrogen Gas in Clinical Setting after Lung Transplantation

[1199] The Role of Antibody Screening and Cardiac Biopsy in the Management of a Patient with Biventricular Assist Device Support as Bridge to Retransplantation While on Single Immunosuppressive Agent


[1201] Pulmonary Artery Banding as an Alternative to Mechanical Support in an Infant with Severe Left Ventricular Dysfunction and Failure to Wean from Bypass

[1202] Recurrent Left Ventricular Assist Device Thrombosis Successfully Treated with Slow Thrombolytic Infusion Protocol

[1203] Outcomes Following LVAD Exchange from One Device Platform to Another in the Setting of LVAD Thrombosis

[1204] Incidental Finding of Cardiac Sarcoma in a Donor Heart Leading to Abandonment of Transplantation Proceeding

[1205] Catastrophic Antibody-Mediated Rejection in a Lung Recipient Associated with Unplanned Pregnancy

[1206] A Novel Intervention Utilizing Biventricular HVAD Support in Intermacs 1 Patients

[1207] Lung Transplantation to the Cystic Fibrosis Recipient with Asymmetric Native Lungs and Hepatitis C

[1208] Long-Term Use of Intrapericardial Continuous Flow LVADs in Children: 4 1/2; Patient-Years of Follow Up in Three Patients

[1209] Post Centrifugal Plasma Filtration (PCPF) in Acute Antibody Mediated Rejection (AMR) After Heart Transplantation

[1210] Constrictive Pericarditis after Lung Transplantation for Bronchiectasis

[1211] 15 Year Old Female Presenting with Hemiplegia Seven Years After Heart Transplantation

[1212] Development of Allograft Cancer after Lung Transplantation
<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1213</td>
<td>The Impact of Cardiac Resynchronization Therapy on Hemodynamics and Flow Profiles in a Patient with a Continuous Flow Left Ventricular Assist Device: A Case Report</td>
</tr>
<tr>
<td>1214</td>
<td>VT Storm Caused by Mechanical Irritation Due to a Percutaneous Left Ventricular Partitioning Device (PARACHUTE) Improved After Surgical Extraction and Implantation of LVAD</td>
</tr>
<tr>
<td>1215</td>
<td>Graft Versus Host Disease Following Lung Transplantation</td>
</tr>
<tr>
<td>1216</td>
<td>How Bad Is Too Bad? Heart Transplantation Post VAD Related Neurologic Injury</td>
</tr>
<tr>
<td>1217</td>
<td>Successful Long-Term Outcome After Lung Transplantation for Pulmonary Disorder Associated with Erdheim-Chester Disease</td>
</tr>
<tr>
<td>1218</td>
<td>The Use of von Willebrand Factor (vWF) for Management of Recurrent GI Bleeding in Continuous Flow Left Ventricular Assist Device Recipients</td>
</tr>
<tr>
<td>1219</td>
<td>An Unusual Cause of Post-Transplant Lymphadenopathy</td>
</tr>
<tr>
<td>1220</td>
<td>Deleterious Effect of HLA Donor Specific Antibodies Mediated Rejection and Graft Dysfunction Following Lung Transplant Exacerbated by Lung Tissue Specific Autoantibodies</td>
</tr>
<tr>
<td>1221</td>
<td>Pediatric Cardiac Transplantation for Respiratory Insufficiency, Recurrent Chylothorax and Elevated PVR as Leading Problems of a Failing Fontan</td>
</tr>
<tr>
<td>1222</td>
<td>Successfully Treat Pulmonary Hemorrhage by Repeated Therapeutic Bronchoscope and Inhaled Tranexamic Acid on Patient with Pulmonary Hypertension Receiving ECMO Support</td>
</tr>
<tr>
<td>1223</td>
<td>Excessive Hemolysis in a Patient with JAK 2 Mutation After Total Artificial Heart Implantation Resolved by Changing from C2 Driver to Freedom Driver</td>
</tr>
<tr>
<td>1224</td>
<td>Restrictive Cardiomyopathy in Arthrogryposis and Freeman-Sheldon Syndrome: A Novel Association</td>
</tr>
<tr>
<td>1225</td>
<td>ECMO Bridge to Recovery for Antibody Mediated Rejection after Lung Transplantation</td>
</tr>
<tr>
<td>1226</td>
<td>Zygomycetes Myocarditis Early After Cardiac Transplantation</td>
</tr>
<tr>
<td>1227</td>
<td>A Vent for the Heart to Breathe!</td>
</tr>
<tr>
<td>1228</td>
<td>A Case of Accelerated Antibody Mediated Rejection in the Modern Age of Single-Bead HLA Antigen and C1q Assays</td>
</tr>
</tbody>
</table>
[1229] OHT with Immune Accommodation
[1230] Too Much, Too Little, Too Late: Slowing the Runs
[1231] Dramatic Presentation of RV Failure Post Heart Transplantation
[1232] Untreatable Hypertension in a Lung Transplant Recipient: The Role of Non-HLA Antibodies
[1233] Hyperthyroidism after Heart Transplantation
[1234] Please HELP! Successful Use of Mechanical Circulatory Support in a Peripartum Woman with HELLP Syndrome
[1235] Cardiac Hemochromatosis Treated with Prolonged ECMO Support and Chelation Therapy
[1236] Logistic Ex-Vivo Lung Perfusion for Hyperimmunized Patients
[1237] Pulmonary Kaposi’s Sarcoma after Lung Transplantation, with 2-Year Follow-Up
[1238] Late Invasive Scedosporium Sternal Infection Post Bilateral Lung Transplant in a Patient with Cystic Fibrosis
[1239] Mechanical Circulatory Support in a Patient with Cardiomyopathy Due to Kearns-Sayre Syndrome
[1240] Dobutamine Induced Eosinophilic Cardiomyopathy
[1241] The Perfect Storm: Two Forms of Cardiomyopathy Found in a Single Heart
[1242] Use of Eculizumab to Treat Life-Threatening Autoimmune Hemolytic Anemia in a Heart Transplant Recipient
[1243] Use of a Percutaneous Right Ventricular Assist Device for Right Ventricular Failure after LVAD Implant
[1244] SVC Syndrome Following Orthotopic Heart Transplantation Resolved via AngioJet Thrombolysis: A Case Report
[1245] Early Post-Transplant Constrictive Pericarditis in a Patient with Antibody Mediated Rejection
[1246] Case Report: Stage IV Large Cell Neuroendocrine Lung Carcinoma Incidentally Discovered after Lung Transplant
[1247] Pneumatosis Intestinalis Complicating Lung Transplantation after Hematopoietic Stem Cell Transplantation: Report of Two Cases
(1248) Quantiferon-CMV Assay Guided Management of Resistant CMV Infection after Heart Transplantation

(1249) Plasmapheresis Prior to HVAD Implantation in a Patient with Acute Heparin Induced Thrombocytopenia

(1250) Safe and Successful Heart Transplantation Despite Factor Xa Inhibitor Treatment by Measuring Thrombin Generation

(1251) Neurotoxicity of Immunosuppressive Therapies in Heart Transplantation

(1252) Dual Sternotomy and Thoracotomy Implantation of HeartMate II in Patients with Previous CABG

(1253) Sinusitis or Something More Sinister in Disguise: A Lung Transplant Recipient with Cystic Fibrosis, Fever and Sinus Drainage

(1254) A Case of Mediastinitis and Ruptured Aortic Pseudoaneurysm Post Orthotopic Heart Transplantation

(1255) Post Transplant Lymphoproliferative Disorder Presenting as Epstein-Barr Virus Meningoencephalitis

(1256) Heart Transplant Against Cross Match in a Highly Sensitized Congenital Heart Disease Patient and Successful Post-Transplant Management

(1257) A Single Centre’s Lung Transplantation Experience for Pulmonary Graft Versus Host Disease

(1258) Anticoagulation Strategies in a Ventricular Assist Device Patient with Heparin Induced Thrombocytopenia

(1259) Severed HeartWare Left Ventricular Assist Device Driveline with Successful Splicing

(1260) Post-Transplant Lymphoproliferative Disease Affecting the Major Airways in a Lung Transplant Recipient

(1261) Longest Continous Impella 5.0 LVAD Support Via Right Subclavian Artery Approach

(1262) Use of Cardiomems to Detect Abnormal Exercise Response in a Patient with a Left Ventricular Assist Device

(1263) Implantable Pulmonary Artery Pressure Sensor Detects Asymptomatic Atrial Fibrillation in Left Ventricular Assist Device Patient

(1264) Monomorphic Ventricular Tachycardia in a Heart Mate II LVAD Patient; When Do You Consider Ablation Therapy?
(1265) Sympathectomy for Lung Transplant Recipients with Raynaud’s

(1266) Diffuse Alveolar Hemorrhage after Initiation of Extracorporeal Membrane Oxygenation for Refractory Hypoxemia Secondary to Acute Respiratory Distress Syndrome

(1267) A Case of Neonatal Left Ventricular Noncompaction: From Fetus to Transplant

(1268) Occlusive PE to Left Main PA Following Lung Transplant Recannalized Using Directed Thrombolysis

(1269) Resolution of Recurrent Sustained Ventricular Tachycardia in a Patient on Left Ventricular Assist Device Support After Surgical Repositioning of the Inflow Cannula

(1270) Prior Mitral Valve Annuloplasty Could Be a Cause of Left Ventricular Assist Device-Induced Mitral Stenosis?

(1271) Mycobacterium Abscessus Infection in a Patient with a Cardiovascular Implantable Electronic Device and Left Ventricular Assist Device

(1272) Successful Management of a Giant Left Ventricular Assist Device Pocket Abscess in an Elderly Patient
The following approved Corporate Events and Industry Theaters are taking place during the ISHLT Annual Meeting.

The Industry Theaters will take place in the Washington 3 Ballroom.

The entrance is from the Exhibit Hall directly across from Booth 507.
Tuesday • April 26

NOON - 2:00 PM
LUNG BIOENGINEERING: EVLP Site Tours

2:00 PM - 4:00 PM
LUNG BIOENGINEERING: EVLP Site Tours

Wednesday • April 27

10:15 AM - 11:15 AM
ST. JUDE: Industry Theatre
(Washington 3)

12:20 PM - 12:50 PM
UNITED THERAPEUTICS: Industry Theater
(Washington 3)

12:30 PM - 1:30 PM
CAREDX: The Baylor Experience with the Genomic Test, Allomap, in Heart Transplant Patients
(Lebanese Taverna)

3:50 PM - 4:50 PM
HEARTWARE: Industry Theater
(Washington 3)

6:00 PM - 8:00 PM
LUNG BIOENGINEERING: EVLP Site Tours

7:30 PM - 9:30 PM
ACTELION PHARMACEUTICALS/MEDSCAPE: The Evolving Landscape of PAH: 20 Years of Prostanoids and Beyond
(Maryland)
Supported by an educational grant from Actelion Pharmaceuticals, Ltd and accredited by Medscape Education

7:00 PM - 10:00 PM
ST. JUDE: PREVENT Investigator Meeting
(Hoover)

8:00 PM - 10:00 PM
HEARTWARE: Corporate Update Presentation and Dinner
(off-site)
Thursday • April 28

7:00 AM - 8:00 AM
ACTELION PHARMACEUTICALS: Nordic Expert Group Meeting
(Jackson)

HEARTWARE: DT2 Investigator Meeting
(Hoover)

RELIANTHEART VAD Systems
(Washington 5)

ST. JUDE: Japan MCS Update Breakfast
(Park Tower 8206)

NOON - 1:00 PM
ST. JUDE: ELEVATE Registry Publication/ Presentation Committee Meeting
(Park Tower 8206)

NOON - 2:00 PM
LUNG BIOENGINEERING: EVLP Site Tours

12:05 - 1:05 PM
HEARTWARE: Industry Theater
(Washington 3)

12:15 PM - 1:45 PM
TRANSMEDICS: The Organ Care System (OCS™) for Lung and Heart Perfusion – The Future is Near
(Virginia)

12:55 PM - 1:55 PM
HEARTWARE: Industry Theater
(Washington 3)

5:30 PM - 6:30 PM
BAYER: Industry Theater
(Washington 3)

7:00 PM - 9:00 PM
ST. JUDE: MCS Dinner Reception and Tech Fair
(off-site)
Friday • April 29

7:00 AM - 8:00 AM
ACTELION PHARMACEUTICALS: Nordic Expert Group Meeting
(Jackson)

7:00 AM - 8:00 AM
HEARTASSIST 5 User’s Meeting
(Washington 5)

10:05 AM - 10:35 AM
HEARTWARE: Industry Theater
(Washington 3)

NOON - 1:30 PM
ST. JUDE: MOMENTUM 3 Investigator Meeting
(Washington 5)

NOON - 2:00 PM
GILEAD SCIENCES: Controversies in PAH: Experts Explore Combination Therapy
(Maryland)

NOON - 2:00 PM
CAREDX: Detecting Rejection and Surveillance in Cardiac Transplantation: Applications of Genomic Medicine
(Virginia)

NOON - 2:00 PM
LUNG BIOENGINEERING: EVLP Site Tours

1:30 PM - 2:00 PM
ST. JUDE: Industry Theater
(Washington 3)

5:30 PM - 7:00 PM
ST. JUDE: LIS/APICA Project Team Meeting
(Park Tower 8206)

5:30 PM - 7:00 PM
SYNCARDIA SYSTEMS COCKTAIL RECEPTION
(McKinley)

5:30 PM - 7:00 PM
HEARTWARE RECEPTION
(Wilson)
ALPHABETICAL LISTING

Abiomed, Inc. 919
Actelion Pharmaceuticals 607
Alere VADCare Program 408
Bayer Healthcare 813
Berlin Heart, Inc. 305
BiologicTx 1004
Cardiac Assist, Inc. 1036
CareDx, Inc. 911
CARMAT 1018
Centurion Medical Products 309
Corporate and Endowment Solutions 917
Essential Pharmaceuticals, LLC 1030
Evaheart 107
Genentech, A Member of the Roche Group 1008
Gilead Sciences, Inc. 507
HeartWare 413
INTERMACS – Interagency Registry for Mechanically Assisted Circulatory Support 108
ISHLT – Mechanically Assisted Circulatory Support Registry (IMACS) 106
ISHLT – Transplant Registry 1002
Jarvik Heart Inc. 406
Lung Bioengineering 700
Lung Biotechnology 1032
Maquet Medical Systems 908
Millar, Inc. 1014
Minnetronix, Inc. 1028
Novartis Pharmaceuticals Corporation 102
One Lambda, A Thermo Fisher Scientific Brand 1022
Pediatric Heart Transplant Study (PHTS) 1000
ReliantHeart 311
Scanlan International, Inc. 909
Scholten Surgical Instruments, Inc. 1012
St. Jude Medical 706
Sunshine Heart 1010
SynCardia Systems, Inc. 104
Texas Children’s Hospital 1006
TransMedics, Inc. 613
United Therapeutics 407
University of Minnesota Health 307
Vivoline Medical AB 401
XVIVO Perfusion AB 205
<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>102</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>104</td>
<td>SynCardia Systems, Inc.</td>
</tr>
<tr>
<td>106</td>
<td>ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)</td>
</tr>
<tr>
<td>107</td>
<td>Evaheart</td>
</tr>
<tr>
<td>108</td>
<td>INTERMACS – Interagency Registry for Mechanically Assisted Circulatory Support</td>
</tr>
<tr>
<td>205</td>
<td>XVIVO Perfusion AB</td>
</tr>
<tr>
<td>305</td>
<td>Berlin Heart, Inc.</td>
</tr>
<tr>
<td>307</td>
<td>University of Minnesota Health</td>
</tr>
<tr>
<td>309</td>
<td>Centurion Medical Products</td>
</tr>
<tr>
<td>311</td>
<td>ReliantHeart</td>
</tr>
<tr>
<td>401</td>
<td>Vivoline Medical AB</td>
</tr>
<tr>
<td>406</td>
<td>Jarvik Heart Inc.</td>
</tr>
<tr>
<td>407</td>
<td>United Therapeutics</td>
</tr>
<tr>
<td>408</td>
<td>Alere VADCare Program</td>
</tr>
<tr>
<td>413</td>
<td>HeartWare</td>
</tr>
<tr>
<td>507</td>
<td>Gilead Sciences, Inc.</td>
</tr>
<tr>
<td>607</td>
<td>Actelion Pharmaceuticals</td>
</tr>
<tr>
<td>613</td>
<td>TransMedics, Inc.</td>
</tr>
<tr>
<td>700</td>
<td>Lung Bioengineering</td>
</tr>
<tr>
<td>706</td>
<td>St. Jude Medical</td>
</tr>
<tr>
<td>813</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>908</td>
<td>Maquet Medical Systems</td>
</tr>
<tr>
<td>909</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>911</td>
<td>CareDx, Inc.</td>
</tr>
<tr>
<td>917</td>
<td>Corporate and Endowment Solutions</td>
</tr>
<tr>
<td>919</td>
<td>Abiomed, Inc.</td>
</tr>
<tr>
<td>1000</td>
<td>Pediatric Heart Transplant Study (PHTS)</td>
</tr>
<tr>
<td>1002</td>
<td>ISHLT Transplant Registry</td>
</tr>
<tr>
<td>1004</td>
<td>BiologicTx</td>
</tr>
<tr>
<td>1006</td>
<td>Texas Children’s Hospital</td>
</tr>
<tr>
<td>1008</td>
<td>Genentech, A member of the Roche Group</td>
</tr>
<tr>
<td>1010</td>
<td>Sunshine Heart</td>
</tr>
<tr>
<td>1012</td>
<td>Scholten Surgical Instruments, Inc.</td>
</tr>
<tr>
<td>1014</td>
<td>Millar, Inc.</td>
</tr>
<tr>
<td>1018</td>
<td>CARMAT</td>
</tr>
<tr>
<td>1022</td>
<td>One Lambda, a Thermo Fisher Scientific Brand</td>
</tr>
<tr>
<td>1028</td>
<td>Minnetronix, Inc.</td>
</tr>
<tr>
<td>1030</td>
<td>Essential Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>1032</td>
<td>Lung Biotechnology</td>
</tr>
<tr>
<td>1036</td>
<td>Cardiac Assist, Inc.</td>
</tr>
</tbody>
</table>
Abiomed, Inc.
22 Cherry Hill Drive
Danvers, MA 01923
www.abiomed.com

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.

The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

For additional information, please visit: www.abiomed.com.

Actelion Pharmaceuticals
5000 Shoreline Court South
San Francisco, CA 94080
www.actelionus.com

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Alere VADCare Program
30 South Keller Road
Orlando, FL  32810

The comprehensive Alere VADCare® Program helps you carefully and efficiently manage your patients after discharge to reduce the risk of hospital readmission. Alere fully supports the transition of VAD patients from hospital to home. Patients receive all of the necessary equipment and wound care supplies they need to take care of their VAD equipment and driveline exit site. Additional services through the Alere VADWatch® program include home INR monitoring; weight and blood pressure management; and tracking of VAD metrics in the Alere VADWatch® Data Management application, which gives clinicians secure, anytime access to patient data.

Bayer Healthcare
100 Bayer Blvd
Whippany, NJ  07981

Bayer is one of the world’s leading, innovative companies in the healthcare and medical products industry and combines the activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for Cardiopulmonary, Hematology, Neurology, Oncology and Women’s Healthcare.
Berlin Heart, Inc.
200 Valleywood Rd. Suite B100
The Woodlands, TX  77380
www.berlinheart.de

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA.

BiologicTx
40-D Commerce Way
Totowa, NJ  07512
www.BiologicTx.com

BiologicTx is a national specialty pharmacy that joins the administration of therapeutics, research and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services, BiologicTx Clinical Trials,™ BiologicTx Sequence and BiologicTx Paired Donation.™
Cardiac Assist, Inc.
240 Alpha Drive
Pittsburgh, PA  15238
www.cardiacassist.com

CardiacAssist is the inventor of the world’s most versatile temporary cardiopulmonary bypass device on the market, The TandemHeart® pump. Our pump can be used in a variety of configurations (surgical, percutaneous cardiac support, percutaneous respiratory support) when paired with our PROTEK line of cannulae. Visit our booth to learn more about our latest innovations, PROTEK Duo and Voyager Vest.

CareDx, Inc.
3260 Bayshore Blvd.
Brisbane, CA  94005
www.caredx.com

Product Description: AlloMap is a non-invasive blood test for heart transplant patients. AlloMap is the first and only non-invasive test with a rapid turnaround time that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.
CARMAT
36 Avenue de L’Europe
Velizy, 78140  France

CARMAT (the contraction of its founders’ names, Pr Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart, as well as its power supply and remote monitoring systems. The key differentiating features of this project are the use of bovine pericardium for most parts in contact with blood – including the pulsatile internal membrane - and real-time adjustment of flow and rate thanks to embedded sensors and electronics. CARMAT heart is an investigational device only. It started its First-in-Man trial in France in December 2013 and is not approved for clinical use anywhere in the world.

Centurion Medical Products
100 Centurion Way
Williamston, MI  48895
www.centurionmp.com

Centurion Medical Products specializes in creating sterile procedural trays customized to meet your specific requirements. Centurion Driveline Maintenance Bundles are designed to provide optimal protection for LVAD driveline sites to reduce complications for your patients with LVADs. Intuitively designed to encourage best practices, our kits help to reduce the incidence of patient complications, unscheduled nursing visits and hospital readmissions. We offer products that provide bacterial protection and long wear times. Featuring SorbaView SHIELD®, an all-in-one catheter dressing with a built-in stabilization device; and our Foley Anchor, to comfortably keep the driveline securely in place prevent stress at the site.
Corporate and Endowment Solutions
4341 Acer Grove Rd.
Springfield, IL  62711

Essential Pharmaceuticals, LLC
100 Princeton South Corporate Center
Suite 140
Ewing NJ  08628

Essential Pharmaceuticals, LLC is a specialty pharmaceutical company devoted to the development and sales of pharmaceutical and biopharmaceutical products including Custodiol® HTK organ preservation solution. Originally developed for cardiac surgery, Custodiol® HTK offers superior convenience due to its easy handling characteristics, water like viscosity and no need for additives or filters which makes it a preferred solution for many transplant centers. Please visit us at our booth # 1030 or at www.essentialpharma.com or www.custodiol.com
The EVAHEART Left Ventricular Assist System (LVAS)™ is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010 and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is ongoing in the US.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.
Gilead Sciences, Inc.
333 Lakeside Dr
Foster City, CA 94404
www.gilead.com

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

HeartWare
500 Old Connecticut Path
Framingham, MA 01701

At HeartWare, we are focused on enhancing outcomes in the treatment of end-stage heart failure. We believe a commitment to quality and continuous learning, improving and innovating are requirements for a best in class global medical device company. As a leader in VAD support, HeartWare is committed to partnering with clinicians to help patients gain access to our technology. The HVAD® System has quickly become the VAD of choice, demonstrating high survival rates, low complication rates and improved quality of life.

Our goal: To meaningfully extend the lives of the heart failure patients by enhancing their quality of life.
The Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) is a prospective North American registry established in 2005 for patients who are receiving mechanical circulatory support device (MCSD) therapy to treat advanced heart failure. The purpose of the registry is to collect and analyze clinical and laboratory data from patients who are receiving MCSDs for whom discharge from the hospital is feasible. Intermacs® with over 17,000 patients, provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection.

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.
The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

**ISHLT – Transplant Registry**

700 N 4th Street
Richmond, VA  23219
www.ishlt.org

- ISHLT Thoracic Transplant Registry
- ISHLT DCD Registry
- ISHLT Pediatric Heart Failure Registry

**Jarvik Heart Inc.**

333 West 52nd St
New York, NY  10019
www.jarvikheart.com

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.
Lung Bioengineering  
1015 Spring Street  
Silver Spring MD  20910

Lung Bioengineering was born from the difficult experiences of one PAH patient, our founder’s daughter. When she was ten years old, she could barely walk to her school bus without becoming short of breath. Her doctors explained the prognosis of a typical PAH patient at that time. Her mother refused to accept this outcome and instead began looking for solutions to her daughter’s condition. She was the first in an ever-expanding line of patients to inspire Lung Bioengineering to reach farther to develop novel therapies. People with PAH lead us to this path and we forge ahead for them and others with chronic lung diseases.

Lung Bioengineering is conducting a clinical trial dedicated to ex vivo lung perfusion. A successful trial may pave the way towards expanding the supply of available lungs. [www.lungbioengineering.com]

Lung Biotechnology  
1040 Spring Street  
Silver Spring, MD  20910  
lungbiotechnology.com

Lung Biotechnology is building a bridge to the future with its focus on developing innovative therapies for patients with PAH and other chronic, life-threatening pulmonary diseases. Lung Biotechnology currently markets Tyvaso (treprostinil) inhalation solution and Adcirca (tadalafil), an oral medication. Visit lungbiotechnology.com, tyvaso.com and adcirca.com for more information.
MAQUET Medical Systems, USA is a market leader offering a comprehensive portfolio of products utilized in the Hybrid and Traditional OR, ICU, Cath Lab and in patient transport. Our products are designed to meet the needs of clinical professionals in the areas of: advanced hemodynamic monitoring, cardiothoracic and vascular surgery, thoracic drainage, cardiac intervention, perfusion, anesthesia and ventilation. MAQUET is focused on improving patient care and quality of life, providing clinicians with sustainable technologies that fit their daily practice and investing in the development of innovative solutions that will help further advance clinical practice and significantly improve patient outcomes.

Millar clinical products provide cath lab clinicians and cardiovascular researchers with complete insight into cardiovascular function for diagnosis or medical research. Our leading clinical product is the Mikro-Cath™ diagnostic pressure catheter used to obtain clean, blood pressure signals for accurate hemodynamic assessment in the cath lab. For a complete evaluation of cardiac function from a single catheterization, Millar offers the CD Leycom® Inca® Pressure-Volume (PV) Loop System and catheters for real-time pressure and volume data analysis. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial.
Minnetronix, Inc.
1645 Energy Park Drive
Saint Paul, Minnesota  55108
info@minnetronix.com
www.minnetronix.com

Minnetronix is a medical technology and innovation company with deep expertise in electronic and electro-mechanical devices. Founded in 1996, the company creates new technologies and therapies that solve unmet clinical and business needs for patients and medical device companies, including transcutaneous energy transmission systems (TETS) and mechanical circulatory support power and control systems. Minnetronix leverages its broad industry knowledge to provide innovative and strategic partnership options, as well as design, development and manufacturing services. The company offers multiple pathways to create value, including intellectual property generation and new business models. Minnetronix is FDA Registered and ISO 13485 Certified.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ  07936
One Lambda, Inc. is a leader in transplant diagnostics and offers a broad range of products to support clinicians and laboratories in the management of transplant patients. Donor specific antibody (DSA) testing and monitoring are specific tools which support this process. Visit the One Lambda booth to discover how we can help improve your standard of care by reducing the risk of Antibody Mediated Rejection (AMR) with our DSA monitoring products LABScreen™ Single Antigen and non HLA biomarker assays including AT1R and complement binding (C1q) antibodies.

Pediatric Heart Transplant Study (PHTS)

The Pediatric Heart Transplant Study (PHTS) is an international registry established in 1993 for pediatric patients listed for heart transplantation. PHTS is dedicated to the advancement of the science and treatment of children during listing for and following heart transplantation. The purposes of the group are to establish and maintain a prospective, event driven database for heart transplantation, to encourage and stimulate basic and clinical research in the field of pediatric heart transplantation and to promote new therapeutic strategies. The ultimate goal is to improve patient outcomes. The registry resides at the University of Alabama at Birmingham.
ReliantHeart
8965 Interchange Dr.
Houston, TX 77054

Scanlan International, Inc.
One Scanlan Plaza
Saint Paul, Minnesota 55107
info@scanlangroup.com
www.scanlaninternational.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps; Scanlan® SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: Scanlan® VASCU-STAT™ bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.
For more than thirty-five years, SSI has manufactured high quality endomyocardial biopsy forceps. The Scholten disposable Bioptome model is called the Novatome™ and, like its predecessor, is specifically designed to acquire maximum quality specimen size for accurate pathology results. Our device has earned a reputation for its ease of use, heart rhythm feedback and is considered the “gold standard” by many. Our innovative design paired with over three decades of clinical experience makes our device the best choice for safety and performance. With the Novatome,”™ SSI continues to provide reliability, value and forceps of the highest quality to your industry.

St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management and cardiovascular diseases. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
The C-Pulse® Heart Assist System is a counterpulsation technology used to treat patients with moderate to severe heart failure (Class III/Ambulatory Class IV). The implantable device is placed outside the bloodstream and gives patients the ability to disconnect from the system. Preliminary results of the C-Pulse System have indicated relief of heart failure symptoms, improved quality of life and cardiac function and reduced the need for heart failure hospitalization. The C-Pulse implant procedure can be performed minimally invasively.

Texas Children’s Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children’s hospital in Texas and among the top in the nation, Texas Children’s has garnered widespread recognition for its expertise and breakthroughs in pediatric and women’s health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Center for pediatric research; Texas Children’s Pavilion for Women, a com-
prehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children’s Hospital West Campus, a community hospital in suburban West Houston; and Texas Children’s Hospital The Woodlands, a second community hospital planned to open in 2017.

TransMedics, Inc.
200 Minuteman Road, Suite 302
Andover, MA 01810
www.transmedics.com

TransMedics, Inc., based in Andover, MA, is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation and has developed technologies to address the unmet need for more and better organs for transplantation.

The Organ Care System (OCS™) makes it possible to preserve donor lungs, hearts, livers and kidneys in a functioning state from donor to recipient and allows physicians to continuously monitor their quality and function. The OCS™ Heart and OCS™ Lung systems are CE-marked and in use in leading European transplant centers and are currently under investigation in the US.

United Therapeutics
55 T.W. Alexander Drive
Research Triangle Park, NC 27709

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Vivoline Medical’s vision is to increase organ transplantation by developing state-of-the-art products that help to increase the amount of organs available for transplantation. The Vivoline® LS2 is Vivoline Medical’s second generation Ex Vivo Lung Perfusion (EVLP) system and efficient ease of use has been prioritized. It is a compact, CE-Marked system, intended for ex vivo perfusion, evaluation and preservation of Lungs. Vivoline® LS2… Simplifying EVLP.
XVIVO manufactures and markets solutions for transplantation designed to preserve and evaluate organs and tissues prior to transplantation. The XPS™ is a flexible and comprehensive platform for normothermic EVLP empowering the user to remain in control of the entire process. Our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex vivo lung evaluation and assessment. Our products are CE-marked and approved by the FDA.

XVIVO aims to:
- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs.
- extend the safe ex-vivo preservation time for organs prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.
37TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
2017
APRIL 5-8, 2017
SAN DIEGO, CA

38TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
2018
April 11-14, 2018
NICE • FRANCE

39TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
2019
April 3-6, 2019
ORLANDO, FL
A pulmonary embolism may lead to an unfamiliar, serious consequence.\textsuperscript{1,2}

As many as \textbf{1 out of every 25} of your previously treated PE patients (>3 months of anticoagulation\textsuperscript{3}) may develop chronic thromboembolic pulmonary hypertension, or CTEPH.\textsuperscript{1,4,4*}

> A ventilation-perfusion (V/Q) scan can rule out CTEPH in PE patients with chronic symptoms\textsuperscript{5} after >3 months of anticoagulation.\textsuperscript{3}

\textbf{If you know what to look for, a V/Q scan makes it relatively easy to spot.}\textsuperscript{5}

\textsuperscript{*Based on a study with 223 patients in which 3.8\% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism with or without prior deep-vein thrombosis (95\% CI, 1.1 to 6.5). CTEPH did not develop after 2 years in any of the 132 remaining patients with more than 2 years of follow up.}

\textbf{VISIT CTEPH.com}

\textbf{INFORMATION. ANSWERS. SUPPORT.}

References: